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Summary in Norwegian
Klassifikasjon av kreftsmerte 
Kreftsmerte – hva skal et fremtidig klassifikasjonssystem inneholde? 
Smerte er et subjektivt, sammensatt og plagsomt symptom som forekommer hyppig 
hos kreftpasienter. Til tross for eksisterende retningslinjer, er det mange 
kreftpasienter som ikke får god smertebehandling, særlig ved langkommet sykdom. 
En av mange årsaker til dette, er mangelen på et allment akseptert 
klassifiseringssystem for kreftsmerte – et verktøy for å stille en korrekt diagnose.
På bakgrunn av ovennevnte forhold ble den internasjonale EU-finansierte 
forskningsgruppen ‘European Palliative Care Research Collaborative’ (EPCRC) 
dannet. En av gruppens hovedmålsettinger var å utvikle klassifikasjonssystem for tre 
vanlige symptomer hos kreftpasienter med langtkommet sykdom: smerte, depresjon 
og ufrivillig vekttap. Arbeidene i denne avhandlingen har vært utført i nær tilknytning 
til EPCRC. Det overordnete målet med avhandlingen er å bidra i utviklingsprosessen 
av et internasjonalt klassifikasjonssystem for smerte hos kreftpasienter blant annet 
ved å finne frem til noen faktorer som er avgjørende for å kunne beskrive en 
smertetilstand og derved å kunne stille en korrekt smertediagnose.  
Hovedfunnene i avhandlingen er:  
x Det foreligger flere systemer for klassifisering av smerte hos kreftpasienter, 
men ingen av disse er i utstrakt bruk, verken i forskning eller klinisk praksis. 
Smertens intensitet og patofysiologi, forekomst av gjennombruddssmerte, 
psykisk stress og respons på behandling inngår i to eller flere av de seks 
formelle systemene som ble funnet ved systematisk litteraturgjennomgang.
x Pasienter bekreftet i intervju at faktorer påvist å være viktige for kreftsmerte i
tidligere studier, også var relevante for deres smerteopplevelse. De vektla 
fysiske og psykiske aspekter ved det å ha smerte, og søvn ble ansett som en 
viktig faktor.
xv 
x I en europeisk studie hvor mer enn 2000 kreftpasienter som brukte sterke 
smertestillende (opioider) deltok, ble følgende faktorer funnet å ha betydning 
for grad av smerteintensitet og/eller smertelindring: gjennombruddssmerte,
smertens lokalisasjon, opioiddose, bruk av svake smertestillende, søvn, 
psykisk stress, smertens patofysiologi, misbruk av alkohol/narkotika, 
kreftdiagnose og lokalisasjon av spredning av kreftsykdommen.
x I en italiensk studie hvor 1800 kreftpasienter deltok, ble de fem førstnevntes 
relevans bekreftet. Videre ble det i den samme studien påvist at 
smerteintensitet og opplevd smertelindring målt ved studiens oppstart samt 
forekomst av gjennombruddssmerte, smertens lokalisasjon, alder og 
kreftdiagnose var faktorer som kunne predikere smerte etter to uker.
Minst tre hovedutfordringer må løses for å komme nærmere et internasjonalt 
klassifikasjonssystem for kreftsmerte: å velge de mest relevante faktorene for 
inklusjon i systemet, inkludert å velge et tilstrekkelig antall faktorer, å oppnå enighet 
om hvilke endepunkt som skal brukes og til slutt å innføre det fremtidige 
klassifikasjonssystemet i klinisk praksis.  
xvi 
Summary in English 
Cancer pain classification – what should be the content of a future system? 
Pain is a subjective, complex and burdensome symptom which is very common in 
cancer patients. Despite existing treatment guidelines, several cancer patients still do 
not receive optimal pain treatment, in particular patients with advanced disease. The 
lack of a common classification system for cancer pain – a diagnostic tool – has been 
identified as one of several causes for this undertreatment.
Motivated by these considerations, the international EU-funded ‘European Palliative 
Care Research Collaborative’ (EPCRC) was established. One of the main aims was 
to develop a classification system for three common symptoms in cancer patients 
with advanced disease: pain, depression, and cancer related weight loss.
The papers included in this thesis have been performed in close collaboration with 
the EPCRC. The overall aim of the thesis is to contribute in the development process 
of an international classification system for pain in cancer patients by for example to 
identify factors that are important for describing pain and thus improve diagnostics 
and treatment of cancer pain.
The main results in this thesis are:
x There are several systems for pain classification in cancer patients, but none 
of these are widely used in research or in clinical practice. Pain intensity and 
pathophysiology, the presence of breakthrough pain, psychological distress, 
and response to treatment are included in two or more of the six formal 
systems that were identified by systematically reviewing existing literature.
x Patients confirmed in interviews that the factors identified to be important for 
cancer pain in previous studies, were relevant also for their experience of 
pain. They emphasised physical and psychological aspects of being in pain, 
and sleep was considered important.
xvii 
x In an European study where more than 2000 cancer patients using strong pain 
medication (opioids) participated, the following factors were identified to be of 
importance for the degree of pain intensity and pain relief: breakthrough pain, 
localisation of pain, opioid dose, use of weak pain medication, sleep, 
psychological distress, pathophysiology of pain, substance abuse, cancer 
diagnosis, and localisation of metastases.
x In an Italian study where 1800 cancer patients participated, the relevance of 
the five first factors listed above was confirmed. Furthermore, results from the 
same study showed that pain intensity and pain relief measured at study start 
as well as the presence of breakthrough pain, localisation of pain, age, and 
cancer diagnosis were factors that could predict pain after two weeks.
At least three major challenges for the further development a future international 
classification system for cancer pain: to choose the most relevant factors (and how 
many) to include in the system, to achieve agreement on what outcomes to use, and 
finally to start using the classification system in clinical practice.   
xviii 
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11. Background
1.1 Preface 
Pain is one of the most prevalent, burdensome and feared symptoms among cancer 
patients. Despite analgesic pain treatment and tumour directed therapy, as many as 
50% of cancer patients in general and about 70% of patients with incurable disease, 
experience pain (34 ,185). The lack of standardised diagnostic procedures has been 
identified as one important reason for the under treatment of pain (20 ,80 ,106 ,187).
Motivated by multiple problems seen in cancer patients receiving palliative care, 
international palliative care researchers, many of them connected to the European 
Association for Palliative Care (EAPC) Research Network(47), launched the European 
Palliative Care Research Collaborative (EPCRC) (50) in 2006. The EPCRC was 
funded by a three-year grant from the European Union’s 6th framework. EPCRC 
aimed at establishing an international arena for palliative care research. The overall 
aims were to study genetic variations relevant for response to opioid treatment, to 
develop an international and computer based assessment and classification system 
for pain, cachexia, and depression in cancer patients, and to develop evidence based 
guidelines for these symptoms (106). This thesis has been performed as a part of the 
EPCRC. It aims at contributing to the development of an international classification 
system for cancer pain.  
1.2 Cancer 
Worldwide, the incidence of cancer is estimated to increase from 11.3 million cases 
in 2007 to 15.5 million cases in 2030 (191). In Norway, there were in 2009 27 500 new 
cases of cancer, a number that is expected to increase to 30 500 in 2020 (28). Also 
the survival rates for many cancers are increasing. Therefore, in the future, patients 
are expected to live longer with the malignant disease, and even more patients will 
risk experiencing distressing symptoms including pain (46).
21.3 Palliative care 
The World Health Organization (WHO) defines palliative care as follows: «Palliative 
care is an approach that improves the quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the prevention 
and relief of suffering by means of early identification and impeccable assessment 
and treatment of pain and other problems, physical, psychosocial and spiritual. 
[Palliative care] provides relief from pain and other distressing symptoms» (168).
Palliative care is offered to patients with any life-threatening diseases. However, the 
majority of patients receiving specialised palliative care are suffering from a 
malignant disease. The EAPC has defined palliative care as «the active, total care of 
the patient whose disease is not responsive to curative treatment» and points out 
that palliative care is interdisciplinary and that «palliative care affirms life and regards 
dying as a normal process; it neither hastens nor postpones death. It sets out to 
preserve the best possible quality of life until death» (46).
Due to therapeutic refinements the patients receive anti-cancer treatment for a longer 
period of time during the disease trajectory with the intention of life prolongation. 
Furthermore, symptom relief is also an important aspect of the oncological treatment. 
In general oncology, patients with incurable disease are offered both tumour directed 
and symptom specific treatment, and are also often in need of a comprehensive, 
broad and patient-centred multi professional diagnostic and therapeutic approach 
(182). A recent randomised controlled study in patients with metastatic non-small cell 
lung cancer compared standard oncologic care with standard oncologic care plus 
early integrated palliative care. The ‘palliative care’ group had longer survival and 
significantly better quality of life and mood compared to the ‘oncology group’ (177).
Recognising the importance of integrating palliative care into oncology, the WHO 
revised its definition of palliative care by also adding the following: «Palliative care is 
applicable early in the course of illness, in conjunction with other therapies that are 
intended to prolong life, such as chemotherapy or radiation therapy, and includes 
those investigations needed to better understand and manage distressing clinical 
3complications» (168). This approach was also recently supported in a commentary by 
the EAPC (107) and in a review (175).
Despite existing definitions of palliative care, the terminologies used worldwide for 
this medical field are heterogeneous (46).  The descriptions ‘palliative care patients’, 
‘patients with advanced cancer’ and ‘patients with incurable cancer’ have commonly 
been used to describe cancer patients with metastases and a complex disease 
burden. Patients in palliative care often suffer from many symptoms at the same 
time. These symptoms usually are fluctuating in presence and intensity (116). In a 
systematic literature review among patients with incurable cancer, 37 symptoms 
were identified as occurring in more than 10 % of the patients (178). Pain, fatigue, lack 
of energy, weakness, and appetite loss were experienced by > 50% of the patients. 
Similar results were found in an earlier study at our institution (102). Improved 
diagnostics and treatment of these symptoms, including pain, is important.
1.4 Cancer pain
The International Association for the Study of Pain (IASP) defines pain as «an 
unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage» and points out that pain is 
always subjective (94). Pain is a complex and multifactorial symptom which is 
experienced differently due to inter-individual differences. Pain influences most 
aspects of a person’s life and is considered to be a major threat to good function and 
quality of life (62 ,63 ,155 ,159 ,198). Pain due to a malignant disease is common; about 
90% of cancer patients experience pain at some point during the disease trajectory 
(34). Pain in cancer patients may be caused by the cancer disease itself, by the anti-
cancer treatment or may occur due to other conditions (63). The term ‘cancer pain’ 
refers mainly to pain caused directly by the cancer disease. A meta-analysis on 
prevalence of cancer pain reported prevalence rates to be 33% in cancer patients 
after curative treatment and 64% in patients with metastatic disease (185).
4Pain is prevalent even in cancer patients treated with opioids. In a review of 26 
publications on analgesic treatment of cancer pain, nearly half of the patients were 
identified as being undertreated (44). In a pan-European cross-sectional multicentre 
study performed by the EAPC including 3030 patients receiving analgesic pain 
treatment (94% with cancer), 32% reported moderate to severe pain (111). In a 
Norwegian multicentre prevalence study 52% of 857 included hospitalised cancer 
patients receiving anti-cancer treatment reported to have pain, and scored mean pain 
on average the last 24 hours to be 3.99 on an 11-point numerical rating scale ranging 
from 0 to 10 (NRS-11)(90).
1.4.1 Guidelines for treatment of cancer pain  
Opioids are considered the cornerstone of analgesic treatment of cancer pain (155
,159).The WHO three step pain relief ladder was introduced in the 1980’s. These 
guidelines, that are widely accepted and used for treatment of cancer pain, 
recommend that a cancer patient with pain should be offered oral administration of 
analgesic drugs in the following order: step I non-opioids (for example 
paracetamol/non-steroidal anti-inflammatory drugs); step II mild opioids (codeine); 
and step III strong opioids such as morphine, until the patient is free of pain (190).
Figure 1:  World Health Organisation’s (WHO) three step pain relief ladder for 
treatment of cancer pain (195).
5Based upon these treatment principles, the EAPC Research Network in 1996 
published guidelines for the use of opioids in cancer pain (45) which were updated in 
2001 (78). Sixteen new recommendations are given in a review of the evidence base 
for the EAPC guidelines and other aspects of cancer pain treatment which is in the 
process of being published(31). In summary, most of current recommendations for 
cancer pain treatment are based on low levels of formal scientific evidence.
In addition to opioids, several different approaches are applied for the treatment of 
cancer pain (155). Neuroaxial treatment of cancer pain including such as spinal, 
epidural and intrathekal administration of opioids and local anesthetics may be 
necessary to apply in some patients to achieve pain control (133), and tumour directed 
therapy, such as surgery, radiotherapy, and systemic therapy (endocrine treatment, 
chemotherapy and ‘targeted therapy’) should be considered for the treatment of 
cancer pain (175).
1.4.2 Barriers to optimal cancer pain management 
Several barriers to optimal treatment of cancer pain have been identified, and can be 
related to patients, physicians and to the health care system.
Patients’ barriers 
Several patients’ beliefs and misconceptions regarding the use of opioids for cancer 
pain have been identified (73). Patients fear side-effects and development of tolerance 
as well as addiction and are therefore reluctant to take analgesics. Patients’ 
reluctance to report pain was recently stated as one important reason for the under 
treatment of pain (20). There may be several reasons for this. The patients may fear 
that pain represents disease progression; they may be fatalistic thinking that ‘pain is 
an inevitable part of having cancer’; they may think that ‘good patients’ do not 
complain about pain, and they may think that the report of pain would distract the 
physician from treating the cancer disease (73).
6Professionals’ barriers 
Physicians’ and nurses’ insufficient knowledge about the underlying malignant 
disease, the pathophysiology of cancer pain, and principles of pain treatment are 
important barriers to correct pain diagnosis and appropriate pain treatment (146).
Physicians’ reluctance to prescribe opioids was in 1993 described as ‘opiophobia’ 
(199) and is still stated as an important barrier to optimal pain management by medical 
oncologists (20).
Barriers of the health care system 
Accessibility of opioids is limited in many European countries due to excessive 
regulatory barriers which cause poor pain treatment (37). A lack of standardised and 
evidence based education of health care professionals as well as a lack of available 
specialists in pain management and palliative care have also been identified as 
important barriers to optimal pain management (20 ,199).
Finally, the lack of standardised and systematic assessment and classification tools 
for cancer pain has by several authors been stated as an important barrier to optimal 
pain management (20 ,35 ,80 ,106 ,187).
1.4.3 Why is an international cancer pain classification system needed?  
Several arguments for an international consensus on a classification system for 
cancer pain have been proposed. An international cancer pain classification system 
can:
In the clinic (35 ,55 ,64 ,85)
x Improve the management of pain in the individual patient
x Guide the information to assess  
x Guide the use of standardised and efficient assessment methods
x Guide treatment decisions 
x Predict the level of complexity of needed interventions for pain
x Predict response to pain treatment  
7Research (17 ,18 ,55 ,85)
x Guide the inclusion of patients into clinical studies  
x Facilitate comparison of effects between studies 
x Improve the quality of meta-analyses  
x Facilitate the translation of research results into clinical practice 
Health care system / policy making (42 ,148)
x Tool for quality assurance of cancer pain treatment
x Tool for conducting comparisons between institutions 
81.5 What is classification?
1.5.1 Classification in general 
Taxonomy is the science and practice of classification. A classification divides objects 
into subclasses. Each of the subclasses is defined by «certain characteristics 
essential for membership in that subclass» (82). Aristotle (384-322 BC) developed a 
‘classification of living things’, placing plants, animals and humans in a hierarchy 
according to structure, function and skills (11). Carl Linnaeus (1707-1778) established 
conventions for the naming of organisms; the Linnaean taxonomy is a scientific 
hierarchical classification system widely used in biology (164) . In medicine, the 
concept of diagnosis is the assignment of individual cases to particular classes in a 
taxonomic system of diseases and is identical to classification in other areas of 
biological science (82).
1.5.2 Classification in medicine  
A diagnostic procedure is an essential part of clinical practice, and much medical 
research is performed aiming at improving methods of diagnostics. A classification 
system in medicine summarises all relevant information from the patient’s medical 
history, the clinical examination and supplementary examinations into a short and 
useful description and is a guide to which information to assess and how to assess it. 
The diagnosis or the classification of a condition is a summary and a conclusion of 
information gathered from different sources (e.g. the results of x-ray or a biopsy, or 
the presence or absence of a symptom or sign); it constitutes the basis for medical 
treatment decisions and guides prognostic considerations (115). In clinical practice, the 
diagnostic process usually contains the following steps: 
9Figure 2: The diagnostic process 
1.5.3 Examples of classification systems in medicine 
International Classification of Diseases
The International Classification of diseases,10th edition,  the ICD-10, is the 
international standard diagnostic classification for general epidemiological and health 
management purposes as well as clinical use. The first edition of this classification 
system was the International List of Causes of Death from 1893. The WHO has been 
responsible for the ICD since 1948. The ICD is widely used to classify diseases and 
other health problems, it provides the basis for national mortality and morbidity 
statistics, and is an important tool for administrative health care planning (193). The 
field of cancer pain is poorly reflected in the ICD-10 and has been addressed as a 
part of the revision, which is planned to be finalised by 2015 (165).
The patient experiences a
The patient consults a physician 
Medical history + clinical examination + supplementary investigations
Diagnosis/classification of the 
Choice and start of relevant 
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International Classification of Diseases for Oncology 
The international Classification of Diseases for Oncology (ICD-O) is a multi-axial 
classification of the site, morphology, behaviour, and grading of cancer diseases.  
It is used in cancer registries for coding of site (topography) and histology 
(morphology), information usually obtained from a pathology report and is not used 
for cancer pain (193).
Diagnostic and Statistical Manual of Mental Disorders 
The Diagnostic and Statistical Manual of Mental Disorders, 4th edition, the DSM-IV, 
is published by the American Psychiatric Association and is the standard 
classification of mental disorders. It can be used in various clinical settings e.g. for 
inpatients as well as in primary care, it can be used by health care providers of 
different professions and is an important tool for public health statistics. It contains 
five axes: clinical syndromes, developmental disorders and personality disorders, 
physical conditions, severity of psychosocial stressors, and highest level of 
functioning, none of these related to cancer pain (7).
TNM Classification of Malignant Tumours 
The TNM classification of malignant tumours is the gold standard for describing the 
anatomical extent of malignant diseases. It is based on the assessment of three 
components: T: the extent of the primary tumour, N: the absence or presence and 
extent of regional lymph node metastasis, and M: absence or presence of distant 
metastasis. The TNM classification divides the patients into four prognostic stages. 
The TNM system was developed in the 1940s by Prof. Pierre Denoix and first 
published in 1953 (183). In 1987 this and two other approaches to classification 
tumours (from the International Federation of Gynecology and Obstetrics (FIGO) and 
the American Joint Committee for Cancer (AJCC)) were unified as the Union for 
International Cancer Control (UICC) TNM Classification of Malignant Tumours 4th
Edition, which has been revised and developed continuously. For instance in brain 
tumours, testicular cancer and lymphomas other classification systems are applied. 
The TNM system does not address cancer pain.
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1.5.4 Examples of classification systems for cancer pain   
A comprehensive review by Caraceni and Weinstein summarised in 2001 that there 
have been several attempts to define a cancer pain classification system during the 
last decades. For example, cancer patients experience pain with different 
pathophysiological mechanisms in multiple sites and described existing approaches 
to cancer pain classification as temporal, etiologic, anatomic, pathophysiologic, or 
syndromic (35).
International Association for the Study of Pain: Classification of Chronic Pain  
The International Association for the Study of Pain (IASP) Classification of Chronic 
Pain is a descriptive coding system for chronic pain syndromes which was first 
presented in 1986 and later revised in 1994 (135). The included list of pain terms was 
also revised in 2011 (94).  This classification system consists of five axes: I, 
anatomical region or site affected by pain; II, organ systems whose abnormal 
functioning produces pain; III, temporal characteristics of pain; IV, pain intensity and 
time since pain onset; and V, etiology, where cancer is listed among several other 
causes of pain. The patients report intensity and duration of pain. Further 
assessments consisting of medical history, clinical examinations and supplementary 
investigations are performed by a health care provider. A code number is given to 
every clinical pain syndrome.  
Edmonton Classification System for Cancer Pain  
The Edmonton Classification System for Cancer Pain (ECS-CP) is a tool for 
prediction of treatment response and was initially launched in 1989 as the Edmonton 
Staging System for Cancer Pain (ESS) (23). Since then, thorough research has been 
performed and the ECS-CP has been developed and revised (55). The ESS (23)
consisted of seven domains: mechanism of pain (visceral, bone or soft tissue, 
neuropathic, mixed, unknown); incidental pain (presence or absence); daily opioid 
dose; cognitive function (impaired or normal); psychological distress (present or 
absent); tolerance (present according to an average daily increase in opioid 
consumption of more than 5% over the first three weeks of follow-up); and past 
history of drug or alcohol addiction (positive or negative). Depending on the 
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assessment of these domains, the patients were classified as having good, 
intermediate, or poor prognosis for pain control. In 1995 the number of prognostic 
groups were reduced to two (good and poor) and the two domains daily opioid use 
and cognitive function were removed from the system (25).
Due to difficulties with the definitions, its practical use and the relatively poor 
predictive properties of the ESS, a revised version was presented in 2005 (rESS) 
(145). In the rESS the domain cognitive function was reintroduced based upon 
literature review and expert opinion. Tolerance was excluded due to difficulties in 
clinical interpretation and practical implementation of the calculations (55). To classify 
patients into different prognostic groups was left as most patients achieved pain 
control (56). A Delphi process among palliative care and pain experts resulted in: the 
change of the name ‘incidental pain’ to ‘incident pain’; an “unable to classify” 
category was added to all domains; the domains ‘psychological distress’ and 
‘addictive behaviour’ were re-separated into two domains; and the name was 
changed to the Edmonton Classification System for Cancer Pain (145).
At present the ECS-CP consists of five domains: mechanism of pain (mainly 
nociceptive or neuropathic), incident pain (present/absent), psychological distress 
(present/absent), addictive behaviour (present/absent), and cognitive function 
(impaired/normal). A health care provider performs the assessment and summarise it 
into a ‘code’ (52).
In 2010 the results from a prospective international validation study of the ECS-CP 
including 944 cancer patients with pain was published (54). The primary outcome was 
time (in days) to achieve stable pain control, defined as «receiving less than three 
breakthrough analgesic doses per day and a patient self-reported pain score of less 
than or equal to 3/10 for three consecutive days». The final opioid dose and the 
number of adjuvant analgesics use were also outcome measures. In multivariate 
analysis, younger age (< 60 years), neuropathic pain, incident pain, psychological 
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distress, and pain intensity (moderate and severe), were associated with longer time 
to achieve stable pain control (54). Pain intensity has been stated to be an important 
domain to add to the ECS-CP (53). Both the ESS from 1989, the rESS from 2005, and 
the ECS-CP are presented in appendix.
Cancer Pain Prognostic Scale
The Cancer Pain Prognostic Scale (CPPS) is a tool for the prediction of pain relief in 
cancer patients (92). Seventy-four cancer patients were included in a prospective 
study defining pain relief > 80% measured by the Brief Pain Inventory (BPI) (0% no 
relief, 100% complete relief) as the primary endpoint. Worst pain intensity (NRS-11) 
and emotional well-being (the Functional Assessment of Cancer Therapy-general 
(FACT-G)) were identified as predictors at week 1 and daily opioid dose and mixed 
pain mechanism predictors at week 2.
1.5.5 Definitions and understanding of concepts 
To improve cancer pain management, there is a need for a comprehensive, accurate 
and simple diagnostic tool for cancer pain (85). A cancer pain classification system 
should combine a series of information about the patient and the pain to a common 
description, a pain diagnosis. It may be comparable with the use of the term 
‘phenotype’ in genetic studies (68). The standardised and systematic description might 
be used for grouping of patients. Different groups or subclasses in a classification 
system may represent different levels of probability for achieving pain control or may 
give information about the expected level of complexity of offered pain treatment, for 
example as suggested in the first version of the ECS-CP (21 ,23). Prediction of 
expected response to pain therapy is an important aim of a cancer pain classification 
system (35).
Some theoretical terms are useful for the evaluation of a systems’ quality: If ‘positive’ 
and ‘negative’ refer to the presence or absence of the condition of interest ‘sensitivity’ 
is defined as «the proportion of positives that are correctly identified by a test» and 
‘specificity’  as «the proportion of negatives that are correctly identified by a test». 
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‘Positive predictive value’ is the proportion of patients with positive test results who 
are correctly diagnosed with a condition, and ‘negative predictive value’ is the 
proportion of patients with negative test results who are correctly diagnosed (6).
Several terms have  been used to describe symptoms and signs within cancer pain 
classification, for example ‘covariates’/’attributes’ (30), ‘features’ (52), and dimensions 
(88). For the improvement of diagnostic tools, clear definitions of the domains to 
include are necessary (106 ,143). The EPCRC agreed upon a conceptual framework 
using the terms ‘symptom’, ‘domain’, and ‘item’ (85) a framework which has been used 
in this thesis with the following definitions:
Symptom
A ‘symptom’ is defined as «a physical or mental feature which is regarded as 
indicating a condition of disease, particularly such a feature that is apparent to the 
patient» (147). Pain and dyspnoea are examples of symptoms. 
Domain
A ‘domain’ is a word which origins from old French ‘demeine’  meaning «belonging to 
a lord» (147) and is a concept used in every field of human activity. Regarding cancer 
pain, pain localisation and breakthrough pain are examples of domains. A sub-
domain has been used for one of more characteristics of a domain. Sub-domains of 
pain mechanism are for example nociceptive and neuropathic pain.
 Item 
An ‘item’ is «an individual article or unit, especially one that is part of a list, collection, 
or set» (147). Items may be used for more detailed assessment of pain domains. The 
number of pain episodes and their duration are examples of items of the domain 
breakthrough pain.
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1.5.6 Patient reported outcomes 
Patient reported outcomes (PROs) has become a commonly used ‘umbrella’ term for 
the description of patients’ self-report of subjective symptoms, health related quality 
of life (HRQOL) and effect of treatments (189), defined by the U.S. Food and Drug 
Administration (FDA) as «any report coming directly from patients about a health 
condition and its treatment» (184).
1.5.7 Quality of life 
There is no generally agreed definition of quality of life (QOL), however, many agree 
that QOL is a multidimensional construct defining all aspects of a patient’s well-being 
including e.g. physical, psychological, social, spiritual, and economic aspects (57). The 
WHO defines health as follows: «Health is a state of complete physical, mental and 
social well being and not merely the absence of disease or infirmity» (192). The 
general term QOL has been narrowed into ‘health related quality of life’ (HRQOL) for 
use in clinical research, covering the aspects of QOL that are most relevant to 
medicine and health care: physical, psychological, role, cognitive, and social function 
as well as pain and other subjective symptoms (105). HRQOL is widely assessed in 
cancer care by the EORTC-QLQ-C30 (122 ,172). In addition, several other 
questionnaires for the assessment of PROs and HRQOL exist (57).
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1.6 Cancer pain domains 
Pain is a complex and multifactorial symptom. Thus, to be able to classify cancer 
pain properly, several aspects of the pain condition and the patient should be 
considered and assessed. In a systematic literature review on cancer pain 
assessment, the following domains (‘dimensions’) of pain were identified (88): pain 
intensity, breakthrough pain, neuropathic pain, pain localisation, duration, pain 
history, treatment and exacerbating/relieving factors, interference, psychological 
distress/pain affect, and beliefs/coping. Other domains considered relevant for 
cancer pain classification are pain etiology  - as one approach to classification 
presented in a comprehensive review by Caraceni and Weinstein (35) - and cognitive 
function and addiction, which were additional domains included in the ECS-CP (52 ,56).
1.6.1 Pain intensity 
Intensity has in several publications been presented as the clinically most important 
domain of cancer pain (29 ,36 ,53 ,87 ,88 ,98). Pain intensity is essential for describing and 
reporting the subjective pain experience (39), it is an indicator of impact on several 
aspects of life (150) and crucial as a guide for treatment decisions(53). Unidimensional 
scales such as NRS, VRS, and VAS are recommended used for the assessment of 
pain intensity, preferably an 11-point NRS where 0 corresponds to “no pain” and 10 
to “pain as bad as you can imagine” (103). The categorisation of pain intensity is 
commonly used for clinical decision making using the cut-points 0 to 3 for mild, 4 to 6 
for moderate, and 7 to 10 for severe pain (150). More severe pain indicates that the 
patient is undertreated (44) and/or the pain is difficult to treat (53).
1.6.2 Breakthrough pain  
Several terms have been used to describe temporal variations of intensity and quality 
of pain. Haugen et al. conclude in a systematic literature review (81) that the majority 
of authors used the term ‘breakthrough pain’ and thus this term will be used in the 
following, even if other terms has been used in the papers included in this thesis (for 
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example ‘incident pain’ in paper IV). There is no universally accepted definition of 
breakthrough pain (200). Most definitions include that the background or baseline pain 
needs to be adequately treated (81) as Portenoy and Hagen did in 1990: 
«Breakthrough pain is a transitory exacerbation of pain that occurs on a background 
of otherwise stable pain in a patient receiving chronic opioid therapy» (157).
Breakthrough pain is often experienced as recurrent episodes of pain characterised 
by rapid onset and short duration. It varies if it is predictable or not, and if the pain is 
different from the baseline pain. These aspects were considered in the definition by 
Hagen et al. in 2008 (75): «A transitory exacerbation of pain experienced by a patient 
who has relatively stable and adequately controlled baseline pain. Breakthrough pain 
can be an exacerbation of the baseline pain OR it can be a pain with a different 
cause from that of the baseline pain. Breakthrough pain can be evoked, 
spontaneous, predictable, or unpredictable. It is difficult to characterize breakthrough 
pain when baseline pain is not controlled». 
The ECS-CP includes the domain ‘incident pain’, a term mainly used to describe one 
of several subtypes of breakthrough pain (81). In the ECS-CP pain is defined as 
incident when «a patient has background pain of no more than moderate intensity 
with intermittent episodes of moderate to severe pain, usually having a rapid onset 
and often a known trigger» (52).
Ten different assessment tools for breakthrough pain were identified in a systematic 
literature review (81), nine of them for patients’ self-report. The Breakthrough Pain 
Questionnaire (157) has been used in several clinical studies (93 ,202), it contains four 
screening questions to identify the presence of breakthrough pain and 12 questions 
related to characteristics of the breakthrough pain, such as frequency, relation to 
fixed analgesic dose, and precipitating events. The Alberta Breakthrough Pain 
Assessment Tool has been developed for the use in clinical studies. It consists of 15 
questions to the patient, in addition, a health care provider assesses the 
pathophysiology, the etiology, descriptions of the baseline and the breakthrough pain 
as well as current medications(75).
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Depending on the population studied, study methodology, and definition used, the 
prevalence of breakthrough pain varies considerably. Thirty-nine per cent (152), 52% 
(160), 65% (32), and 89% (202) are examples of numbers reported. The lack of a 
common definition and assessment of breakthrough pain, and the lack of a common 
description of the patient populations included in studies, may be reflected in the 
major variability in reported prevalences. Breakthrough pain is a domain shown to be 
associated with more severe pain, an increased risk of pain-related adverse 
outcomes, and greater cost of care (200).
1.6.3 Pain mechanism  
Pathophysiology of cancer pain has been thoroughly studied and different terms are 
in use also for this domain, for example ‘pain mechanism’ and ‘pain quality’ (15).  In 
the original ESS (23), ‘pain mechanism’ was assessed by the following sub-domains: 
‘visceral’, ‘bone-soft tissue’, ‘neuropathic’, ‘mixed’, and ‘unknown’ pain. This was later 
revised in the ECS-CP to mainly distinguish between nociceptive and neuropathic 
pain as it was shown that neuropathic pain was clinically most relevant (56). The 
importance of neuropathic pain in cancer patients has been recognised in several 
publications (15 ,35 ,130 ,154 ,156 ,181). Thus, throughout the text in this thesis mainly the 
term ‘neuropathic pain’ will be used to cover the clinically most important aspect of 
mechanisms and pathophysiology of pain, even if for example ‘pain mechanism’ was 
the term mainly used in paper I, II and III.
The definition of neuropathic pain was in 2008 revised by the Neuropathic Pain 
Special Interest Group (NeuPSIG) of IASP to: «Pain caused by a lesion or disease of 
the somatosensory nervous system». Neuropathic pain can be peripheral or central 
and is usually further classified according to anatomical site and disease (94 ,179).
These studies have mainly focused on non-cancer pain. Cancer patients may 
experience neuropathic pain due to several causes; for example direct infiltration of 
peripheral nerves by the cancer, tumours or metastases in brain or spinal chord,
side-effects after anti-cancer therapy (surgery, chemotherapy and radiotherapy), and 
due to other co morbidities (72 ,154). Neuropathic pain is a burdensome and 
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increasingly common symptom in cancer patients which represents a therapeutic 
challenge (16).
Several screening tools exist for neuropathic pain for use in both non-cancer and 
cancer pain (14), five of them will briefly be presented in the following. The ‘Leeds 
Assessment of Neuropathic Symptoms and Signs’  was the first tool to be developed; 
it contains five items regarding pain for self-report and two clinical examination items 
(13). The ‘Neuropathic Pain Questionnaire’ consists of 10 items related to sensations 
or sensory responses, and two related to affect (113). The ‘Douleur Neuropathique en 
4 questions’ consists of seven items related to symptoms and three related to clinical 
examination (19). ‘painDETECT’ is a questionnaire for patient’s self-report. Seven 
questions address the quality of pain and are scored on a six-point verbal rating 
scale ranging from never to very strongly. Temporal course of the pain and radiated 
pain are addressed with one item each (66). Finally, the ‘ID-Pain’ is also a 
questionnaire not requiring clinical examination, consisting of five sensory descriptor 
items and one item relating to whether pain is located in the joints (153). All of these 
five screening tools for neuropathic pain have been developed in a chronic pain 
population and not in cancer patients. In the new IASP guidelines for neuropathic 
pain it is underlined that the clinical examination, including accurate sensory testing, 
is crucial for neuropathic pain diagnosis (74).
A recent systematic review of 22 studies of neuropathic pain including a total of 
nearly 13700 cancer patients reported a prevalence of neuropathic pain to be 19% 
and a prevalence of 39% if mixed pain also was included (15).
1.6.4 Pain localisation  
The site of pain influences the degree of interference with functions as e.g. pain in a 
finger may cause less practical problems than pain in a leg hampering walking.  
Many cancer pain patients experience pain at more than one site. A study including 
2266 cancer patients reported that 30% had pain at one site, 39% at two sites and 
that 31% had pain at three or more sites (72). A figure representing the body where 
the patient can shade the area corresponding to the localisation of the actual pain, a 
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body map, has been used for the assessment of pain localisation for the last 30-40 
years in both non-cancer (121) and cancer pain patients (43).
1.6.5 Duration 
How long the pain has lasted was identified as one relevant pain domain in a 
combined systematic literature review and expert survey (88). In textbooks pain is 
usually divided into acute and chronic. Acute pain is characterised by a well-defined 
onset whereas chronic pain is defined as pain that persists for more than three 
months, often with a less well-defined temporal onset. Chronic pain may be 
associated with changes in personality, lifestyle, and physical functions (63). In the 
IASP Classification of Chronic Pain, the duration of pain is assessed as time since 
onset ‘less than one month’, ‘one to six months’, and ‘more than six months’ (135).
1.6.6 Pain history 
Previous pain experiences regardless of non-cancer or cancer pain, may influence 
the present pain condition, and how the patient is coping. Information regarding 
previous pain treatments and the response is important to include in general medical 
history (63), however, this domain has not been emphasised in existing approaches to 
cancer pain classification (35).
1.6.7 Etiology  
It has been usual to divide cancer pain into pain caused directly by the cancer 
disease (cancer pain), caused by treatment (for example radiotherapy induced 
osteonecrosis), and pain unrelated to cancer (e.g. arthritis or fractures) (63).
Etiology is included as the fifth axis in the IASP Classification of Chronic Pain, listing 
nine different causes of pain, among these malignant disease, infections, and 
degenerative diseases (135).
1.6.8 Treatment and exacerbating/relieving factors 
As presented in section 1.4.1, the management of cancer pain includes analgesic 
pain treatment with opioids, non-opioids and adjuvant analgesics, as well as tumour 
directed therapy. In addition, other treatment modalities are available such as 
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neuroaxial, anaesthetic, surgical, neurostimulatory, physiatric, and psychological 
interventions  as well as complementary procedures such as acupuncture (155). Other 
exacerbating and relieving factors of pain may be for example movement, 
swallowing, or stretching. This domain was ranked as number three of ten by experts 
in pain and palliative care in two expert surveys (87 ,88). For the use of different opioids 
in different administration forms it is common to calculate the equipotent dose of 
morphine taken orally during the last 24 hours in mg as the ‘total morphine equivalent 
daily dose’ (MEDD), in this thesis mainly referred to as ‘opioid dose’.
1.6.9 Interference 
Interference is one important domain of pain as pain is a complex symptom that 
influences most aspects of a person’s life (87). BPI measures interference by asking to 
what extent pain has interfered with the following seven domains: general activity, 
mood, walking ability, normal work, relations with other people, sleep, and enjoyment 
of life (43). Fayers et al. recently investigated pain intensity and pain interference 
closely in both palliative care cancer patients and patients with chronic pain (59). They 
conclude that intensity and interference should be regarded as two separate 
measures. In general, it may be difficult for patients with a complex pain condition to 
identify if it is their pain or other aspects that are influencing their functions (59 ,112 ,173).
1.6.10 Psychological distress 
Psychological distress is an ‘umbrella’ concept used in different meanings. Originally, 
it was introduced as a term for the stress not buffered by coping (167). No common 
agreed-upon definition exists, and the term is used with quite different meanings in 
clinical practice and in research. The National Comprehensive Cancer Network 
(NCCN) in 1999 introduced the term in relation to oncology in their first published 
guidelines for the management of distress in cancer patients (141). This was done in 
order to gain increased focus on the psychological aspects of patient-care in 
oncology without making the patients psychiatric cases. In these guidelines, distress 
in cancer patients is defined as «a multifactorial unpleasant emotional experience of 
a psychological, social and/or spiritual nature that may interfere with the ability to 
cope effectively with cancer, its physical symptoms, and its treatment. Distress 
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extends along a continuum, ranging from common normal feelings of vulnerability, 
sadness, and fears to problems that can become disabling, such as depression, 
anxiety, panic, social isolation, and existential and spiritual crisis» (141).
In oncology and palliative care, the term ‘psychological distress’ is used in different 
meanings covering a wide range of psychological states from normal stress 
responses to psychiatric disorders like depression and delirium. Different overlapping 
terms are also in use without being clearly defined such as ‘stress’, ‘problems’, and 
‘suffering’ as well as ‘psychological’, ‘psychosocial’, ‘emotional’, and ‘pain affect’.
In the ECS-CP ‘psychological distress’ is defined as «a patient’s inner state of 
suffering resulting from physical, psychological, social, spiritual and/or practical 
factors that may compromise the patient’s coping ability and complicate the 
expression of pain and/or other symptoms» (52). ‘Pain affect’ was identified as one of 
several pain domains related to cancer pain in a systematic literature review (88). It 
was described as an «emotional component of pain, the unpleasantness and 
significance of pain», and has earlier been described to express an affective 
response related to being in pain (2). Several studies have reported a close 
relationship between cancer pain and psychological distress (140 ,198), however, the 
question of causality remains unsolved (114).
The prevalence of psychological distress among cancer patients vary depending on 
definitions, populations studied and assessment method used. In a study including 
nearly 4500 cancer patients the prevalence of psychological distress as measured by 
the ‘Brief Symptom Inventory’ (a measure of distress with nine subscales and three 
global scales) was 35.1% (197) and a recent literature review reported the prevalence 
of distress to be 20-40% (89).
Depression and anxiety  
Cancer patients receiving palliative care being distressed, for example due to pain, 
often suffer both from depression- and anxiety- related symptoms (89). In the DSM-IV, 
the criteria for a depressive disorder are: depressed mood (such as feelings of 
sadness or emptiness), reduced interest in activities that used to be enjoyed, sleep 
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disturbances (either not being able to sleep well or sleeping to much), loss of energy 
or a significant reduction in energy level, difficulty concentrating, holding a 
conversation, paying attention, or making decisions that used to be made fairly 
easily, and suicidal thoughts or intentions (7). These criteria might be problematic in 
patients with advanced cancer because some symptoms, such as tiredness and loss 
of appetite, may be present just due to the cancer disease itself. However, it is 
important to recognise and diagnose major depression in patients in palliative care as 
this is a treatable condition (95). The prevalence of depression in palliative care is 
stated to vary between 3% and 58% (174); a recent study of 300 patients receiving 
care reported a prevalence of depression according to the DSM-IV criteria in 19% of 
the patients (163).
Both depression and anxiety are assessed in Edmonton Symptom Assessment 
System (ESAS) and in the European Organization for Research and Treatment of 
Cancer Core Quality of Life Questionnaire-C30 version 3.0 (EORTC-QLQ-C30): In 
ESAS by use of single items scored on an NRS-11 (22), and in the EORTC-QLQ-C30 
by the emotional functioning scale consisting of the four questions: ‘did you feel 
tense?’, ‘did you worry?’, ‘did you feel irritable?’, and ‘did you feel depressed?’ 
scored on a four point verbal rating scale (VRS-4) and transformed into a 0-100 scale 
where lower scores mean poorer emotional functioning (1).
Taking the prevalence rates, treatments available for depression and the patients’ 
suffering related to psychological distress into consideration, it is of importance to 
cover these emotional aspects in the everyday clinical assessment of cancer pain 
patients.
1.6.11 Pain beliefs 
Patients’ beliefs about causes and consequences of pain, attitudes to living with 
cancer and pain as well as ways of coping were identified as a commonly assessed 
domain in a systematic literature review (88). Beliefs and misconceptions about opioid 
treatment identified as patients’ barrier to optimal pain management are presented in 
section 1.4.2.
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1.6.12 Cognitive function 
Cognitive function is one domain included in the ECS-CP (52). Attention, 
concentration, intelligence, learning, judgment, memory, orientation, perception, 
problem solving, and psychomotor ability are cognitive functions(84). Loss of one or 
more of these functions is often described as cognitive impairment or failure. Several 
reasons for cognitive impairment or failure in advanced cancer patients have been 
identified, for example metabolic disturbances, brain metastases, infections, 
dehydration, and opioid use. According to the DSM-IV Text Revision, cognitive failure 
includes three separate conditions: delirium, dementia, and amnestic disorders (8) (84).
A review of 22 studies concerning cognitive failure in patients receiving palliative care 
summarised the reported prevalence rates to range from 10% to 83% for general 
cognitive impairment, from 20% to 88% for delirium and from 50% to 68% for 
confusion (84). Cognitive failure is observed in the majority of advanced cancer 
patients before death (118 ,151).
Despite the high prevalence rates, health care professionals are often under- or 
misdiagnosing cognitive failure (84 ,151). The MMSE has been identified as the most 
frequent used assessment tool for cognitive function, but several tools exist (84). The 
assessment of pain in the cognitively impaired patients represents an additional 
challenge; in 2002 the EAPC  recommended the use of a VRS-4 (none, mild, 
moderate, severe) (30). For the nonverbal patient the NCCN guidelines recommend a 
combination of direct observation, family/caregiver input, and evaluation of treatment 
responses and list different tools to use (141).
1.6.13 Addiction 
The WHO defines addiction as “repeated use of psychoactive substance(s) to the 
extent that the user is periodically or chronically intoxicated, shows a compulsion to 
take the preferred substance, has great difficulty in voluntarily ceasing or modifying 
substance use, and exhibits determination to obtain psychoactive substances almost 
by any means. Typically, tolerance is prominent and a withdrawal syndrome 
frequently occurs when substance use is interrupted”. The term ‘addiction’ is not 
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included in the ICD-10 and was replaced by the term ‘dependence’ in 1964, however 
still widely used (194).
Both alcohol and drug addiction are relevant to consider in a cancer pain setting.
Three sub-groups of patients with cancer pain and a history of drug addiction have 
been described: 1. patients actively using drugs with a drug-seeking behaviour; 2. 
patients receiving methadone as maintenance; and 3. patients who have not used 
drugs for several years (63). The management of pain in these patients requires 
special attention as a drug-seeking behaviour may interfere with pain related 
symptoms and as patients in group 2 and 3 may be at risk for relapse when 
experiencing cancer pain (63). Case reports have exemplified the complexity of opioid 
treatment in patients with addiction (117 ,139).
Among patients admitted to acute care hospitals an overall prevalence of alcoholism 
has been reported between 12% and 30% (138). In a retrospective study of 100 
advanced cancer patients 28% were diagnosed with alcoholism (24). The CAGE 
questionnaire was used in that study as a simple tool for screening of alcoholism; it 
includes the following four questions, where a score of two of four was defined as 
alcoholism: (24):
1. Have you ever felt you should cut down on your drinking? 
2. Have people annoyed you by criticizing your drinking? 
3. Have you ever felt bad or guilty about your drinking? 
4. Have you ever had a drink first thing in the morning or to get rid of a hangover 
(eye-opener)?
1.7 Assessment 
Assessment constitutes the basis for correct classification of a phenomenon. To 
assess is to evaluate or estimate the nature, ability, or quality of a certain 
phenomenon (147). Assessment can be described as the process of collecting and 
documenting relevant information which may be relied upon for decision making.  
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In medicine, accurate, appropriate and standardised assessment is crucial for 
classifying the condition or the patient; that is making a diagnosis. Assessment in 
medicine may include medical history, clinical examinations, x-rays, other 
supplementary investigations, and patients’ self-report of symptoms. For subjective 
symptoms, the use of patients’ self-report has been recommended as gold-standard 
(61 ,105) and the assessment should ideally be brief, precise, multi-dimensional and 
specifically targeted to the patient population (85).
In a recent survey among palliative care professionals more than 100 different tools 
for assessment of health related quality of life (HRQOL) and symptoms were 
identified used in clinical practice and in research (80). A systematic literature review 
covering 1966 to 2003 identified 80 different assessment tools for cancer pain in 
palliative care (88), and in a new search from 2003 to 2008 11 new cancer pain 
assessment tools were identified (87). What tools that are used differ across studies 
and there is no consensus on which background information and which symptom 
specific domains to include in different tools (85 ,103). Some of the most commonly 
used assessment tools in oncology and palliative care will be presented in the 
following and in the appendix, all of these have been applied in the papers included 
in this thesis.
1.7.1 Visual analogue, verbal rating, and numerical rating scales 
Visual analogue scales (VAS), categorical verbal rating scales (VRS), and categorical 
numerical rating scales (NRS) are commonly used and well validated unidimensional 
measurement tools for intensity of symptoms in cancer patients (30 ,86). An 11-point 
NRS (NRS-11) with ‘no pain’ and ‘pain as bad as you can imagine’ as anchor words 
for the extreme values was recently recommended used for assessment of cancer 
pain intensity by an international group of pain and palliative care experts (103).
1.7.2 Edmonton Symptom Assessment System 
The ESAS was first presented in 1991 (22) and is a well validated and widely used tool 
for patient’s self-report of subjective symptoms (188). Ten NRS-11 are included; eight 
for assessment of common symptoms (including pain), one for general well-being 
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and one for a patient-specific symptom. ESAS was recently revised, among the 
suggested changes were: change of order of items, using the time frame ‘now’, and 
inclusion of short definitions of the symptoms (188).
1.7.3 Brief Pain Inventory and McGill Pain Questionnaire 
As cancer pain is a multi-dimensional and complex symptom, the EAPC Expert 
Working Group in 2002 (30) recommended the use of the following two multi-
dimensional assessment tools: Short Form of the Brief Pain Inventory (BPI) (43) or the 
McGill Pain Questionnaire (MPQ) (126). The BPI is a tool for self-report of pain that is 
easy to administer and to understand (30)  which has gained widespread recognition 
and that has been translated and validated in many different languages, for example 
in Italian (33) and Norwegian (112). It records information about medical history, pain 
and interference.  Pain intensity is measured by an NRS-11 for each of the following 
items: ‘right now’, ‘on average’, ‘at its worst’, and ‘at its least’. ‘Pain relief provided by 
pain treatments’ is recorded on an NRS-11 from 0% (no relief) to 100% (complete 
relief). Pain’s interference with functions is assessed by seven items by using NRS-
11: general activity, mood, walking ability, normal work, relations with other people, 
sleep, and enjoyment of life. The time frames ‘the last month’ (43), ‘the last week’ (30)
and ‘the last 24 hours’ (30 ,112) have been used. The MPQ is widely used tool for self-
report that has been validated in cancer patients (71) assessing localisation, quality, 
temporal pattern, and intensity of pain (126). A list of pain descriptors is provided and 
the patients are asked to mark the words that best describe their pain and its 
temporal pattern, the patients are asked to list exacerbating and relieving factors, and 
intensity is assessed by a VRS-5 using the words mild, discomforting, distressing, 
horrible, and excruciating.
A body map is included both in the BPI and in the MPQ.
1.7.4 European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire-C30 
The EORTC-QLQ-C30 version 3.0 is a multidimensional instrument for self-reported 
assessment of function, symptoms and quality of life (QOL) in cancer patients (1). The 
questionnaire consists of 30 items incorporated in five functional scales (physical, 
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role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and 
nausea and vomiting), a global health/QOL scale, five singe items regarding common 
symptoms (dyspnoea, loss of appetite, insomnia, constipation, and diarrhoea) as well 
as one item regarding financial difficulties. Except for the items ‘overall physical 
condition’ and ‘overall QOL’ that are scored by seven-point scales (from ‘very poor’ to 
‘excellent’), all items have four level response categories (from ‘not at all’ to ‘very 
much’). Using standardised scoring methods, the measures are transferred into a 0 
to 100 scale. A high score for a functional scale represents a high level of 
functioning, whereas a high score for a symptom scale/item means more 
symptoms/more problems (58). The EORTC QLQ-C30 has been translated into 
several languages (48), is widely used in clinical trials, and has been shown to be 
sensitive to differences between patients, treatment effects and changes over time (57
,101).
1.7.5 Therapy Impact Questionnaire 
The Therapy Impact Questionnaire (TIQ) is a quality-of-life questionnaire developed 
for advanced cancer patients measuring common symptoms and side effects of 
medications, consisting of 36 items rated on a VRS-4 from 1 = absent to 4 = very 
much referring to the previous week (176). In more details the following is assessed: 
common physical symptoms (24 items: pain is one and headache is one), functional 
status (3), emotional and cognitive factors (6), social interaction (2), and one global 
item worded as ‘have you been feeling ill?’. 
1.7.6 Performance Status 
Patients’ performance status is commonly assessed within oncology and palliative 
care as a measure of the patients’ well-being and daily life activities. The Karnofsky 
Performance Status score (KPS) was published in 1948, an 11-point 0% to 100% 
scale where 0% corresponds to death and 100% to a normal situation with «no 
complaints and no evidence of disease» (108). The KPS has been recognised as a 
negative prognostic factor for survival in cancer patients (51) and it has been 
demonstrated that patients with a lower KPS (< 80) have more symptoms and more 
severe pain than patients with higher KPS (158).
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1.7.7 Mini Mental State Exam 
The Mini Mental State Exam (MMSE) from 1975 is a valid and reliable tool that has 
proven to record changes in cognitive function (65). It consists of 20 items and has a 
total score of 30 points, with higher scores representing higher levels of cognitive 
functioning. A score of less than 23-24 of 30 is a commonly used as cut-off to 
indicate cognitive impairment (136). A set of four items from the MMSE (current year, 
date, backward spelling, and copy of a design; with a total score of five) has been 
identified as an appropriate screening tool for cognitive impairment and delirium in 
palliative care patients (60).
30
2. Aims of the thesis  
The overall aim of this thesis is to contribute to the development of an international 
classification system for cancer pain. 
Paper I  
The overall aim of paper I was to identify existing approaches to cancer pain 
classification, thus the following research questions were raised:
x Which classification systems for pain in cancer patients exist in the 
published literature? 
x How are the classification systems developed and validated? 
x Which domains and items are included and what assessment methods are 
used in cancer pain classification systems?
x Are the classification systems used in clinical studies?
Paper II
In paper II the overall aim was to gain detailed knowledge about advanced cancer 
patients’ experiences of pain. The following research questions were asked: 
x Can patients verify the relevance of cancer pain domains identified in 
previous studies? 
x Can patients identify additional domains relevant for cancer pain 
classification?
x How do patients describe their experience of cancer pain?  
Paper III and IV  
For both paper III and IV the overall aims were to verify known domains and to 
explore new domains for cancer pain classification.  
In paper III the research question were: 
x To what extent are the ‘established’ candidate domains breakthrough pain, 
neuropathic pain, and psychological distress associated with pain intensity 
and/or pain relief?
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x To what extent are cancer pain domains identified in the literature, by 
patients, and by experts associated with pain intensity and/or pain relief?
The research questions in paper IV were: 
x Can the associations with pain intensity and/or pain relief of domains 
previously identified in a cross-sectional study be confirmed in another 
patient population?
x Can previously identified domains relevant for cancer pain and/or new 
candidate domains be identified as predictors of pain intensity and/or pain 
relief in a population of cancer patients followed prospectively? 
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3. Materials and methods 
In 2008 a systematic and stepwise research strategy to be used by the European 
Palliative Care Research Collaborative (EPCRC), consisting of systematic literature 
reviews, expert evaluations, patients’ involvement, and empirical data collections was 
presented (106). The designs of the four papers in this thesis have been guided by this 
stepwise research strategy which is summarised in nine steps described in table 1. 
The papers in this thesis have contributed in step 1, 5, and 8.
Step Description 
1
Definition of content and selection of items based on systematic 
literature review. 
Determine the content of the measure based on the literature, the 
content of widely used forms, the clinical expert experience, and advice 
from an expert panel. 
Generate an item pool for pain assessment, primarily based on existing 
pain assessment tools and reflecting the recommended dimensions 
2 Data collection I 
3 Analyses of data leading to functional specification of a computerized 
pain assessment tool 
4 International expert evaluation II 
5 Patient involvement, qualitative interview, and focus groups to 
document qualitative evidence of content and face validity 
6 Development of a computerized analyses model (software based on 
collected data) 
7 International data collection II 
8 Data analysis  
9 Programming of first version of the computer-based pain assessment 
tool
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Table 1: The stepwise research approach of the European Palliative Care Research 
Collaborative (106).
3.1 Systematic literature review 
A systematic literature review aims at identifying, evaluate and interpret all available 
knowledge of a certain topic. It differs from a traditional review as systematic 
procedures for searching and selection of papers and information to include are 
used, and thus being repeatable and transparent research methodology (70 ,137).
Aiming at the development of an international assessment and classification system 
for cancer pain, the identification of existing approaches to cancer pain classification 
was considered an important first step.
3.1.1 Systematic literature search 
The design of the systematic literature review (paper I) was based upon the present 
knowledge in the study group as well as on findings from hand search of textbooks 
and relevant peer reviewed journals. The search strategy was to reflect the aim of 
identifying all existing approaches to cancer pain classification, in all stages of a 
malignant disease. The searches were performed in MEDLINE and Embase using 
OVID as search engine. Both free text and MeSH/EMTREE search terms were used. 
The following terms were covered: ‘classification’, ‘categorisation’, ‘characterisation’, 
‘staging’ and ‘grading’ in studies of cancer patients in general. The initial searches 
resulted in more than 7000 hits that mainly included clinical studies of effectiveness 
of anti-tumour treatment. To narrow the search, we defined that it should be a 
maximum of five words between the word ‘pain’ and for example ‘classification’. The 
search string used in MEDLINE is presented in the appendix.  
3.1.2 Selection of relevant papers 
The titles and abstracts of all hits were screened by four of the authors, 
independently. When at least two of the authors identified a hit as relevant, it was 
included for further evaluation. If only one author recognised a hit as relevant, it was 
discussed in the group to achieve consensus whether to include or exclude. For all 
hits identified as relevant, the full-text papers were retrieved and reviewed by three of 
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the authors. Papers of all methodological categories were included. Exclusion criteria 
were: Papers published before 1986, non-English papers, papers on non-malignant 
pain, papers addressing children or adolescents, and papers exclusively addressing 
development or validation of pain scoring instruments.
3.1.2. Contents and quality 
For each paper the following information was recorded:  
x All details of a classification system if used
x Domains and items of cancer pain applied in the papers (for example pain 
intensity, pain mechanism, temporal variations, localisation of pain, etiology, 
pain syndromes and pain treatment) – based upon knowledge presented in 
section 1.6.
x Other subjective symptoms and signs (for example psychological distress, 
physical functioning and interference)
x Patient related information: patients’ demographics, primary cancer disease, 
stage and localisation of disease and tumour directed treatment.
x Study design and methodology, country of origin of the study, and assessment 
methods.
After systematically extraction of information from the papers, the main findings were 
categorised and synthesised by the authors as  
1) Formal classification systems; systematically developed and partially validated, or 
not validated, and
2) Characteristics not formally described as part of a classification system (‘informal 
approaches’).
3.2 Patients 
Paper II, III, and IV in this thesis are based upon data from three cohorts of mainly 
advanced cancer patients (an overview of the samples are presented in table 2 in 
this section).  Patients were included for qualitative interviews at the cancer 
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department in Trondheim, Norway and Graz, Austria (paper II). The second cohort 
consists of patients included in the European Pharmacogenetic Opioid Study (EPOS) 
(paper III), and the third cohort consists of patients included in the Cancer Pain 
Outcome Research Study Group (CPOR) study (paper IV).
3.2.1 Interview sample  
Patients with advanced cancer, with a pain history, and receiving treatment with 
opioids at the Department of Oncology, St. Olav’s Hospital, University Hospital in 
Trondheim, Norway and at the Division of Oncology, Medical University of Graz, 
Austria were approached. Cognitive status was examined by a short version of the 
Mini Mental Status Exam (MMSE) (60). Only cognitively intact patients (defined as 
score = 5) were included. All patients completed the ESAS. (22). Information regarding 
socio-demographic data and medical history was obtained from the medical records. 
3.2.2 European Pharmacogenetic Opioid Study 
The European Pharmacogenetic Opioid Study (EPOS) was an international,
multicentre, cross-sectional, observational study of cancer patients treated with 
opioids for moderate to severe pain from 2004 to 2008 (110). Patients > 18 years with 
verified malignant disease and on regularly scheduled opioid treatment (step III at the 
WHO pain ladder) for at least three days were included.
The following information was assessed by a health care provider: Medical history 
and consumption of opioids and other medication, functional status assessed by the 
KPS (108) and cognitive function by the MMSE (65). Breakthrough pain was evaluated 
as a dichotomised yes/no- question focusing on pain with a known trigger. Pain 
mechanism was categorised according to the Edmonton Staging System (25):
visceral, bone / soft tissue, neuropathic, mixed, and unknown pain. Addiction was 
evaluated by answering yes or no to the question of previous or present known 
abuse of either alcohol or drugs. The patients completed the BPI (43) and EORTC-
QLQ-C30 version 3.0 (1). The following items from the BPI were included as 
outcomes: ‘pain on the average’, ‘pain at its worst’, and ‘pain relief’, all referring to the 
last 24 hours and measured by an NRS-11. Additionally, pain localisation was 
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recorded by using a body map. The following scales and items from the EORTC-
QLQ-C30 were included in the analyses: emotional functioning (measuring 
psychological distress), physical functioning, social functioning, sleep disturbances, 
nausea/vomiting, and constipation.
3.2.3 Cancer Pain Outcome Research Study Group  
The Italian Cancer Pain Outcome Research (CPOR) Study Group performed a 
multicentre, prospective, non-randomised observational study during 2006 and 2007 
(9 ,10). The CPOR study was initiated motivated by undertreatment of pain (44). It aimed 
at gathering data on the epidemiology of cancer pain and of its treatments, to assess 
the efficacy of pain treatment measured by patient reported outcomes, and to 
evaluate safety profile of the treatments. Patients with advanced cancer, persistent 
pain of any intensity, requiring or already on analgesic treatment, age > 18 years, 
with a life expectancy longer than one month, and able to provide informed consent 
to participate were included. Patients with impaired cognitive function or substance 
abuse were excluded.  
Two samples from these data were used for study IV: sample A consisted of cross-
sectional data from cancer patients using opioids at the day of inclusion and sample 
B consisted of longitudinal data from cancer patients newly referred to palliative care. 
Reasons for this were for sample A to replicate the design of EPOS and for sample B 
to achieve a homogenous sample as possible for the longitudinal analyses.
After inclusion, the patients were examined weekly for four weeks as well as at week 
12. Only data from study entry and day 14 were analysed in paper IV. At each visit a 
health care provider registered: medical history including cancer history, physical 
examination data, medications and recent therapies including analgesic 
consumption, and functional status assessed by the KPS (108). Furthermore, a health 
care provider completed the ECS-CP (version rESS from 2005) (56) assessing 
neuropathic pain, breakthrough pain, psychological distress and/or addiction, and 
cognitive function (appendix).
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The patients completed a questionnaire assessing pain, other symptoms, and 
common side effects of opioids at each visit. Pain was measured by an Italian 
version of the BPI (33). Symptoms and side effects of medications were evaluated 
using a list of 23 items from the TIQ (176). Each item was rated on a four-point verbal 
rating scale (VRS) from 1 = absent to 4 = very much. The previous week was used 
as time frame for all questions (appendix).
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3.3 Patients’ involvement 
The involvement of patients in the process of development of clinical instruments (for 
example questionnaires evaluating symptoms and clinical guidelines) has been 
recommended by the European Organisation for Research and Treatment of Cancer 
(EORTC) (172), the National Institute for Health and Clinical Excellence (NICE)(142),
and the U.S. Food and Drug Administration (FDA) (184). Thus, the EPCRC also 
involved patients in the develpoment process of the new classification system for 
cancer pain (106); this was done in paper II.
3.3.1 Semi-structured interviews  
The aims of paper II were to gain more in-depth understanding of pain domains 
according to patients’ self report and to explore if any domains were missing among 
the previously identified. Thus, qualitative semi-structured interviews guided by a 
general method first presented by Giorgi (69), and later modified and applied by 
Malterud (120),  using phenomenology as the theoretical framework, i.e. focusing on 
how phenomena are experienced, was considered as the appropriate methodology.
The interview guide (appendix) consisted of one open-ended introductory question 
asking ‘Can you please describe what it is like to have pain?’ with clarification probes 
like ‘how is it?’ and ‘what do you think about having pain?’ as well as general open-
ended questions about the 12 predefined candidate pain domains. If needed, follow-
up questions were used in order to reveal the patients’ thoughts, experiences and 
opinions about cancer pain (149). The patients were then asked if they could think of 
other domains relevant for their pain experience. At both sites one researcher 
performed all interviews, respectively. The complete interviews were audio-recorded 
and transcribed word-by-word by one person at each site. The analyses of the 
interviews started during data collection, and were analysed according to the below 
presented procedure by two of the authors. Comments deepening the quantitative 
scoring were transcribed as part of the interview and included in the qualitative 
analyses. Patient quotations relevant for publication were translated into English by 
the authors.
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The Giorgi/Malterud method (for analysis) consists of four steps:
1. «Getting a total impression of the data»; the transcribed interviews were read 
several times to identify relevant descriptions of cancer pain reported by the patients. 
2. «Identifying ‘meaning units’ in each interview»; sentences and paragraphs from 
each interview were collected as meaning units in a dialogue excerpt for each 
interview. 
3. «Abstracting the content of individual meaning units across all interviews»; the 
meaning units were labelled and grouped together with similar descriptions across all 
interviews. 
4. «Summarising their importance»; summarising of the findings (Paper II).  
3.3.2 Patients’ ranking of domains 
A mixed method approach was chosen as the use of diverse methods may enrich the 
understanding of a complex phenomenon such as cancer pain (41 ,120). In the 
quantitative part, the patients were asked to score the relevance of the 12 previously 
identified pain domains by using a 0 to 10 Numerical Rating Scale (NRS-11); 0 = not 
important, 10 = very important, similar to a ranking previously done by experts (87 ,88).
3.4 Expert survey 
An expert survey was performed per e-mailing in January 2009 aiming at gathering 
advice on which domains to choose as the dependent variables (paper III and IV). 
Thirty experts within oncology, pain and palliative care were asked to rank the clinical 
relevance of five variables from the BPI on an NRS-11 (0= not relevant, 10 = highly 
relevant): ‘pain relief provided by pain treatments or medications’; ‘pain at its worst’; 
‘pain at its least’; ‘pain on the average’ (all in the last 24 hours); and ‘pain right now’ 
(43).
3.5 Assessment tools used in paper II-IV
Patients’ performance status was assessed by the KPS in paper II, III and IV. ESAS 
was used in paper II (German and Norwegian versions, appendix). An NRS-11 was 
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used in paper II for the patients’ scoring of the relevance of each domain, where 0 
referred to ‘not important’ and 10 to ‘very important’. Cognitive function was assessed 
by the MMSE in paper III and by the short version of the MMSE in paper II. BPI was 
used in paper III and in paper IV with the time frame ‘last 24 hours’ and ‘last week’, 
respectively. EORTC-QLQ-C30 and 23 items from TIQ were completed in paper III 
and IV, respectively.
3.6 Statistics 
The statistical software SPSS (Statistical Package for Social Science) for Windows 
version 16.0 was used for the analyses in paper II and for the descriptive analyses in 
paper III. For the bivariate and multiple regression analyses in paper III, and for all 
analyses in paper IV, the statistical software STATA (StataCorp. STATA Statistical 
Software: Release 11. College Station, TX: StataCorp LP 2009) version 11.0 was 
used.
3.6.1 Bivariate analysis 
Bivariate analyses were performed in paper III and IV to investigate possible 
associations between a series of candidate domains (independent variables) and the 
outcomes. In paper III the Spearman’s rank correlation was used for continuous 
variables. This is a non-parametric measure of statistical dependence between two 
variables, resulting in values from -1 to +1 (4). For the categorical variables, the 
Kruskall-Wallis test was used which is a non-parametric method for comparison of 
more than two independent samples (3). In paper IV, the Pearson correlation 
coefficient (r) ranging from -1 to +1 was used for all variables. For both paper III and 
IV all correlation coefficients and the belonging p-values were calculated; the p-
values were reported in paper III and the correlation coefficients reported in paper IV. 
In paper III the correlations were presented as p-values; the cut-off for inclusion was 
defined as p-value < 0.001, and in paper IV the correlation coefficients were reported 
and the cut-off for inclusion was defined as Pearson correlation coefficient > 0.1.
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3.6.2 Multivariate regression analysis 
As one aim of a cancer pain classification system is to predict response to treatment 
and the course of pain, we aimed at investigating possible relationships between 
different domains and the pain measured as pain intensity and pain relief. In both 
paper III and IV, regression analysis was chosen as the most appropriate and 
feasible method. Regression analysis is a method for describing the relation between 
the values of two or more variables allowing for to see how much of the variability in 
the dependent variable (outcome) can be attributed to different values of the 
independent variables (predictors) (5). The explained variance is expressed as ‘R 
square’ (R2) and is ranging from 0 to 1. Standardised betas obtained as results in a 
regression analysis allow for comparison of the impact of the independent variables 
on the outcomes regardless of assessment scales used.  
In paper III a linear regression model was used due to continuous outcomes, in paper 
IV both linear and non-linear relationships (by using fractional polynomials) were 
investigated. A backward stepwise model was used both in paper III and IV. The cut-
off p-value for removing domains/variables was 0.01 and 0.05 in paper III and IV, 
respectively. Reasons for having a higher p-value in the longitudinal sample were the 
smaller sample size and the explorative aim of the study in paper IV. Standard 
diagnostics on for example residuals and interactions of the models were tested.
3.7 Ethics 
All studies used in this thesis were performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki (196). All patients in all studies 
used in this thesis gave written informed consent prior to study participation.
In paper II the study protocol and interview guide was approved by the Regional 
committee for medical research ethics at each site and by the Norwegian Data 
Inspectorate. The transcripts contained no person-identifiable information. 
The EPOS protocol (paper III) was approved by the committee for medical research 
ethics of each study centre and the CPOR study (paper IV) complied with Italian 
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requirements for observational studies. The protocol was approved by each Local 
Research Ethics Committee of participating centres.  
45
4. Results and summary of papers 
4.1 Paper I 
«Classification of pain in cancer patients - a systematic literature review» 
Despite several efforts to develop common criteria for the diagnosis and classfication 
of cancer pain, no internationally widely accepted cancer pain classification system 
exists. Standardised assessment and classification would improve cancer pain 
management. As a starting point for the development process of an international, 
robust, and clinically useful assessment and classification system for cancer pain, a 
systematic literature review was performed. The aims were to identify and describe 
existing systems; their development, the included domians/items, assessment 
methods used, and impact on clinical studies.
A systematic literature search in the MEDLINE and Embase databases was 
performed using ‘pain’, ‘cancer’ and classification’/‘characterisation’/’categorisation’/ 
‘staging’/ ‘grading’ as search terms for the time period 1986 to 2006. Titles, abstracts, 
and fulltext articles in English concerning pain classificaiton in adult patients were 
reviewed sytematically by in total four of the authors. The main findings were divided 
into two main categories: 1. formal classification systems (either systematically 
developed and partially validated, or not validated), and 2. characteristics not formally 
described as part of a classifcation system.
The search yielded 692 hits, of these were 92 full text papers included for further 
reading. 55 were clinical studies and 37 were defined as educational papers. Three 
formal, systematically developed and partially validated systems were identifed: the 
International Association for the Study of Pain (IASP) Classification of Chronic Pain, 
the Edmonton Classification System for Cancer Pain (ESC-CP), and the Cancer Pain 
Prognostic Scale (CPPS). None were widely applied in the clinic or in research. 
Another three formal, however not validated systems, were also identified: the Opioid 
Escalation Index (OEI), a prognostic tool for pain treatment, and the Pain 
Management Index (PMI), mainly tools for prognostication and evaluation of pain 
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treatment. Fourty-three clinical studies applied common characteristics of pain and 
patients not formally desrcibed as part of a classification system. Five domains were 
identified in two or more of the formal systems: pain intensity, breakthrough pain, 
neuropathic pain,  psychological distress, and treatment response. The assessment 
of these and other domains varied across studies.
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4.2 Paper II
«Interviews with patients with advanced cancer - another step towards an 
international cancer pain classification system» 
About 50 % of cancer patients in general and about 70 % of the advanced cancer 
patients experience pain during their disease trajectory. Pain is a highly subjective 
and complex experience influencing several aspects of a patient’s life.
Patients’ self report is the gold standard for reporting subjective symptoms. For the 
development of assessment tools regarding subjective symptoms, the involvement of 
patients has been recommended. Thus, the present study was performed to 
investigate if patients in palliative care could verify the relevance of selected pain 
domains and to explore if any domains were missing. 
Results from systematic literature reviews, experts’ opinion, as well as the content of 
the ECS-CP were used as basis for which domains to include in the interview guide 
and for the quantitative ranking of domains, which were the following 12: pain 
intensity, duration, etiology, pain localisation, previous pain experience, interference 
(with function), coping,  breakthrough pain, neuropathic pain, psychological distress, 
cognitive function, and addiction. In the quantitative part of the study, the patients 
were asked to score the relevance of the 12 predefined pain domains on an NRS-11. 
In the qualitative part, semi-structured interviews were performed and analysed word-
by-word. The interview guide is included in appendix 2 of paper II.
Thirty-three Norwegian and Austrian patients were interviewed, 16 females and 17 
males. All were advanced cancer patients using opioids for pain; their mean age was 
63 and the mean Karnofsky performance score was 65. The patients ranked the 
domains according to their relevance as follows: 1. etiology (most relevant), 2. 
duration, 3. intensity, 4. coping, 5. localisation, 6. physical functioning, 7. 
psychological distress, 8. breakthrough pain, 9. cognitive function, 10. neuropathic 
pain, 11. previous pain experience, and 12. addiction. The patients emphasised 
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aspects related to having pain such as poor physical functioning and psychological 
distress. Sleep was identified as a new domain to consider for inclusion in a future 
cancer pain classification system.
In summary, based upon the patients’ descriptions of their pain experiences, the 
relevance of previously identified pain domains was confirmed, however, the ranking 
of their importance differed from experts’ ranking in a previous study. Except for 
sleep, no new domains relevant for cancer pain classifcation were identifed. 
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4.3 Paper III 
«Which variables are associated with pain intensity and treatment response in 
advanced cancer patients? - Implications for a future classification system for cancer 
pain»
A lack of a shared language and a diagnostic tool for cancer pain has been 
recognised by several authors as one barrier to improved cancer pain management. 
Using existing knowledge from systematic literature reviews, view of experts in pain 
and palliative care as well as patients’ opinion, consensus has been reached on 
some of the content of an international cancer pain classification system. However, 
this knowledge has not been widely empirically tested. The aim of the present study 
was thus to apply empirical data from a large European cohort of cancer patients 
treated with opioids to investigate which domains to include in such a system.
EPOS is a cross-sectional study recruiting 2294 cancer patients treated with opioids 
from 17 centres in 11 European countries. Clinical data from EPOS were used in 
paper III. ‘Pain on average’, ‘pain at its worst’, and ‘pain relief’, all from the BPI 
measured on an NRS-11 and referrring to the last 24 hours, were chosen as 
outcomes based upon resuts from an expert survey and findings in the literature.
Data from 2278 patients were used in the present analysis; 52 % males, mean age 
62 years, mean Karnofsky Performance status 59 %, mean opioid dose (MEDD) 341 
mg. The mean pain scores were: average pain 3.5, worst pain 5.3, and pain relief 
74%. Breakthrough pain was present in 58%. Fourty-six candidate domains were 
identified through previous studies. Of these, 21 domains were shown to be 
associated with at least one of the outcomes, and thus included in multivariate linear 
regression analyses.
The domains breakthrough pain, neuropathic pain, localisation of pain, opioid dose, 
use of non-opioids, psychological distress, sleep, addiction, cancer diagnosis, and 
localisation of metastases were results in the final regression models. Breakthrough 
pain and psychological distress were the most important domains as they they 
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contributed significantly to all three final regression models and showed the highest 
standardised betas. The identifed domains explained 12% to 19% of the variablility of 
the pain outcomes.
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4.4 Paper IV 
«Which domains should be included in a cancer pain classification system?
- Analyses of longitudinal data» 
To ensure that a cancer pain classification system groups the patients correctly and 
predicts the course of pain properly, such a system should be evaluated in 
longitudinal studies. Thus, aiming at deciding upon which domains to include in a 
cancer pain classification system, data from the longitudinal CPOR study were used 
to verify the relevance of previously identified domains relevant for cancer pain 
classification, and to explore the value of other domains.
Data from a multicentre, observational longitudinal study of 1801 Italian cancer 
patients were analysed. Analyses were carried out in two samples. A: cross-sectional 
data from patients on opioids at inclusion, and B: longitudinal data from patients just 
admitted to palliative care. Outcome measures in the investigated models were: ‘pain 
on average’, ‘worst pain’, and ‘pain relief’ at study entry, and at day 14, respectively, 
all measured on an NRS-11. Uni- and multivariate regression models were applied to 
test the explicative power on pain outcomes of a series of known pain domains, 
among which breakthrough pain, neuropathic pain, pain localisation, opioid dose, 
psychological distress, sleep disturbances, and cancer diagnosis. 
In the two analyses, 1529 (sample A) and 352 (sample B) patients were included, 
respectively. The sample characteristics were: males 53% in A and 61% in B, 
respectively, mean age 64/65 years, mean Karnofsky performance status 65%/63%. 
Mean pain scores were: average pain 4.4/5.0, worst pain 6.8/7.5, and pain relief 
58%/43%. Mean opioid dose (MEDD) was 87/66 mg. Breakthrough pain was present 
in 52%/57% of the patients, and 26%/25% of the patients had neuropathic pain.
In the cross-sectional analysis (A), the domains breakthrough pain, localisation of 
pain, opioid dose, use of non-opioids, and sleep were associated with one or more of 
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the pain outcomes. In the longitudinal analyses (B), pain intensity at study entry, pain 
relief at study entry, breakthrough pain, localisation of pain, age, and cancer 
diagnosis were predictors. Identified domains explained 16 to 24 % of the variability 
of the pain outcomes.
In summary, the following nine domains were identified to be of significance from the 
CPOR analyses: Pain intensity, pain relief, breakthrough pain, pain localisation, 
opioid dose, use of non-opioids, sleep disturbances, age, and cancer diagnosis. Pain 
intensity at study entry emerged as the strongest predictor of the pain outcomes after 
two weeks.
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5. Discussion 
5.1 Discussion of main findings 
The principle idea of this thesis was to contribute to the process of improvement of 
cancer pain classification and thereby improve treatment of pain for the large number 
of cancer patients experiencing pain. A stepwise approach was applied, based upon 
recommendations given in the EU-funded research collaborative EPCRC(50),
including one systematic literature review, one study of mainly qualitative design, and 
two studies applying empirical data, of cross-sectional and longitudinal design, 
respectively. This thesis is to be considered as an integrated part of the research 
planned and conducted in this community of researchers at eight European centres 
as well as from Canada and Australia, with the European Palliative Care Research 
Centre (PRC)(49) at the Norwegian University of Science and Technology (NTNU) in a 
leading position.  
5.1.1 Paper I 
The first step of this approach was to get an overview of the field of cancer pain 
classification. The systematic literature review identified a lack of international 
consensus regarding cancer pain classification, but also several attempts to classify 
cancer pain were identified. Of these were three defined as formal and formally 
validated classification systems: the IASP Classification for Chronic Pain, the ECS-
CP, and the CPPS. Furthermore three formal, however not systematically validated, 
were identified: the PMI, the OEI and a prognostic tool for pain treatment. Several 
other ‘informal’ approaches were also identified. The ECS-CP was identified as the 
most comprehensive cancer pain classification system, also due to a long lasting 
validation and development process. Five domains were in paper I identified in two or 
more of the six formal systems: pain intensity, breakthrough pain, neuropathic pain, 
psychological distress, and treatment response.
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International Association for the Study of Pain Classification of Chronic Pain
When evaluating the IASP Classification of Chronic Pain in relation to cancer pain, 
two aspects seem to be relevant: it does not aim at providing prognostic information, 
and it was mainly developed for non-cancer pain. Pain due to malignant diseases is 
included only as one of several etiologies. Details about the cancer diagnosis are not 
included neither in this system nor in the ECS-CP or in the CPPS, this will be further 
discussed in section 5.1.4.11.
Edmonton Classification System for Cancer Pain 
At expert meetings in Lofoten (76), Milan (103) and Edmonton (27), one of the 
conclusions was that the Edmonton Classification System for Cancer Pain (ECS-CP) 
is to be regarded as a template and starting point for further development of a cancer 
pain classification system. However, the system has limitations. First, some important 
information is not included, such as pain intensity and cancer disease, however, pain 
intensity is now considered for inclusion (53). Second, even if the ECS-CP has 
performed a thorough work to develop a manual with definitions and instructions for 
use (52), the definitions may be subject to discussion. For example, the definition of 
psychological distress is limited to patients experiencing psychological distress only 
in relation to pain. However, distress of other causes is also of importance for the 
pain experience as distress in general may increase the level of reported pain 
intensity (and vice versa) (198). Furthermore, the definition suggests that psychological 
distress may impair a patients’ coping ability, however, a more commonly accepted 
view is that psychological distress occurs  when the coping abilities are exceeded 
(167).
Third, all assessments are provided by a health care provider and not by patients’ 
self-report which is the recommended method for the assessment of PROs (61 ,105).
Finally, the inclusion of a category of ‘unknown’/’insufficient information to classify’ for 
each domain represents a challenge when analysing data statistically. When allowing 
researchers and clinicians to not to decide upon a category/domain/diagnose, this 
will be similar to a problem of handling missing data.
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Cancer Pain Prognostic Scale 
The Cancer Pain Prognostic Scale (CPPS) is in opposite to the IASP system a 
prognostic tool and it was developed in a population of advanced cancer patients. 
However, different domains were identified as predictors of pain relief at different 
points in time. Furthermore, the CPPS was only identified used in the development 
study (92) and to our knowledge it has not been used in later publications.  
Systems for prognostication and evaluation of treatment response 
The three other formal systems identified in paper I are mainly tools for 
prognostication and/or evaluation of pain treatment. The ‘Pain Management Index’ 
(PMI) (40) assesses the adequacy of pain treatment by combining the potency of the 
prescribed analgesic drug and the level of worst pain intensity (assessed by NRS-
11); the ‘Opioid Escalation Index’ (OEI) evaluates opioid responsiveness based upon 
the patient’s opioid requirement and the level of pain intensity (assessed by VAS) 
(128); and a tool predicting the effect of pharmacological pain treatment based upon 
time to achieve pain relief, breakthrough pain (‘incident’) and opioid dose (132). The 
latter has not been identified used in other studies, but studies applying the PMI (10)
and the OEI (134) have been identified.
5.1.2 Paper II
Paper II represents an additional input to the experts’ opinions and the findings from 
the literature. The semi-structured interviews gave in-depth insight into the patients’ 
experiences of having cancer pain and revealed that the patients emphasise the 
consequences of being in pain such as poor physical functioning and psychological 
distress, and that poor sleep was closely connected to pain. Etiology, duration, and 
intensity of pain were in the quantitative part of paper II ranked as the most important 
domains to the patients. Of importance for the development process of the 
classification system was that we, except for sleep, did not reveal further new 
domains – this was interpreted as a confirmation that we were ‘on the right track’. 
The value of including patients in this process was questioned; this issue will be 
further discussed in section 5.2.2.
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5.1.3 Paper III and IV
In this thesis, and in the stepwise research procedure within the EPCRC, several 
cancer pain domains have been investigated and some have been eliminated. The 
findings from paper I and II and from further publications on cancer pain assessment 
and classification, for example (56 ,76 ,87 ,88), as well as clinical patient-, disease-, and 
treatment related information (for example age, cancer diagnosis, and common side 
effects) guided which domains to include in the analyses performed in paper III and 
IV. We applied large cohorts of advanced cancer patients with pain to empirically 
investigate the content of the classification system. In both papers we chose an 
explorative approach in the sense that we started with a broad perspective, that is 
several pain domains, and then eliminated domains in order to end up with a smaller 
set of domains highly relevant for cancer pain classification. Also the findings from 
paper III contributed to conclusions drawn at the expert meeting in Milan (103).
Considering the results from paper III and IV together, the following domains have 
been identified as relevant for cancer pain classification: pain intensity, pain relief, 
breakthrough pain, neuropathic pain, localisation of pain, opioid dose, use of non-
opioids, psychological distress, sleep disturbances, addiction, age, cancer diagnosis, 
and localisation of metastases, and all of these domains will be discussed in the 
following.
5.1.4 Cancer pain domains 
5.1.4.1 Pain intensity
Pain intensity has a key role in cancer pain management guiding clinical decision 
making (29 ,53). Paper I demonstrated that pain intensity was included as a domain in 
the IASP Classification of Chronic Pain (135), in the CPPS (92) and in the three tools for 
prognostication/evaluation of pain treatment (40 ,128 ,132)  and that it was the most 
frequently applied domain in the clinical studies reviewed. Pain intensity has until 
now not been a part of the ECS-CP (55). However, the Edmonton group has identified 
moderate and severe pain intensity to be a predictor of length of time to achieve 
stable pain control, the need for higher final opioid doses and more complex 
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analgesic treatments in two large study samples (54 ,56), and thus considers to include 
this important domain in a future revision of the ECS-CP. In paper II the advanced 
cancer patients first described the intensity of pain when asked about what it was like 
to have pain and they ranked pain intensity as the third most important domain. In the 
cross-sectional analyses in paper III and IV, pain intensity was used as outcome, 
measured both as ‘pain on average’ and ‘pain at its worst’ (NRS-11). In the 
longitudinal part of paper IV, the pain intensity at study entry was identified as the 
most important predictor of pain intensity after two weeks. The Milan 2009 consensus 
meeting regarded pain intensity to be one of four ‘core domains’ to be included in a 
classification system for cancer pain as well as among the three domains most 
relevant as outcomes in clinical practice and in research. Additionally, it was reached 
consensus to recommend to assess pain intensity on an 11-point NRS with the 
following anchoring points: ‘no pain’ and ‘pain as bad as you can imagine’ (103).
5.1.4.2 Pain relief 
The CPPS was developed as a prognostic tool for pain relief, using pain relief > 80% 
measured on an NRS-11 as the outcome. None of the remaining formal classification 
systems reviewed in paper I included pain relief. In the systematic literature review 
twelve studies focused on treatment response, which mainly was assessed as a 
decrease in self-reported pain intensity. In paper II, the patients described pain relief 
as «getting a new life» and they reported considerable improvement of physical and 
psychological functioning after analgesic treatment. Pain relief was used as one of 
the outcomes in both paper III and IV. Pain relief at study entry was identified as the 
most important predictor of pain relief after two weeks in paper IV. At the Milan 2009 
consensus meeting pain relief was among the three most relevant domains 
considered used as outcomes in clinical pain management and in cancer pain 
research (103).
In the two large multicenter studies validating the ECS-CP (54 ,56), time to achieve 
stable pain control was used as main outcome. Stable pain control was defined as 
«receiving less than three breakthrough analgesic doses per day and a patient self-
reported pain score less than or equal to 3/10 for three consecutive days» (54).
58
The use of pain relief as an outcome measure in patients with both non-cancer and 
cancer pain has a longstanding tradition (91). Pain relief has been shown to be related 
to pain intensity, but also to be different from a change in pain intensity, in pain 
studies with cancer (98) and non-cancer (99) patients. Pain relief is considered as a 
concept that can offer additional information to change in pain intensity, such as 
psychological aspects (99). Pain relief is one of the items included in the BPI, asking 
the question: «In the last week / in the last 24 hours, how much pain relief have pain 
treatments or medications provided?». It is measured on a 0 % to 100 % NRS where 
0% corresponds to no relief and 100% complete relief. Thus, pain relief is assessed 
by asking the patients to in retrospect evaluate an eventual relief of a subjective 
symptom. In general, it has been argued that patients should be followed 
prospectively since a retrospective report may be influenced by recall bias (119).
5.1.4.3 Breakthrough pain 
In paper I, breakthrough pain was identified as a domain in three of the formal 
systems, however all used different terminologies: ‘temporal characteristics’ (135),
‘incident pain’ (54), and ‘incidental pain’ (132). The terminologies used, the assessed 
information, and assessment tools used, varied across the investigated studies; a 
finding consistent with a systematic literature review on breakthrough pain (81). The 
patients in paper II were able to identify and describe breakthrough pain episodes 
different from their baseline pain; however, they did not regard breakthrough pain as 
an important domain.
In paper III, the patients with and without breakthrough pain scored pain intensity on 
average (mean NRS-11) as 3.9 versus 2.9, respectively, and breakthrough pain was 
the domain most strongly associated with pain intensity and pain relief. In paper IV, 
breakthrough pain was the domain most strongly associated with pain intensity in the 
cross-sectional analyses, and was identified as one of four predictors of pain intensity 
in the longitudinal sample. In paper III and IV the presence of breakthrough pain was 
assessed by a health care provider using the definition from the rESS (56): «pain 
aggravated suddenly because of movements, swallowing, defecation, or urination». 
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Despite this ‘narrow’ definition, breakthrough pain was among the main findings in 
these papers, demonstrating its robustness and underlining its relevance for cancer 
pain classification.  
Also in the ECS-CP multicentre studies, breakthrough pain (‘incident pain’) has been 
identified as an important domain by being a predictor of time to achieve pain control, 
the need for higher opioid doses and adjuvant analgesics (54 ,56). Several further 
studies have demonstrated breakthrough pain as a common and significant domain 
in cancer patients and that breakthrough pain is a predictor of more complex pain (32
,129 ,160 ,201).
5.1.4.4 Neuropathic pain 
Paper I revealed that pathophysiology of pain was included in the ECS-CP (‘pain 
mechanism’, mainly distinguishing between nociceptive and neuropathic pain) (52)
and in the CPPS (‘mixed pain’, meaning patients having some element of 
neuropathic pain) (92). Among the characteristics not formally described as part of a 
classification system, pathophysiology/pain mechanism was described in several 
studies, often using the sub-domains nociceptive, somatic, visceral, neuropathic, 
psychogenic, and mixed pain. In paper II, pain mechanism was scored as one of the 
three less important domains to the patients, and was, as expected, one of few 
domains that the patients had little to tell about during the interviews. In EPOS (paper 
III), ‘mixed pain’ was among the final results, interpreted to represent  neuropathic 
pain due to the assessment method (rESS) (25) and because of the medications used 
by the patients classified to have mixed pain (gabapentin/pregabalin). Unexpectedly, 
neuropathic pain was not among the results in paper IV despite that pain mechanism 
was assessed by the rESS from 2005 mainly distinguishing nociceptive from 
neuropathic pain (56), and despite that about 25% of the included patients had 
neuropathic pain.
In the 2010 multicentre study of the ECS-CP neuropathic pain was a predictor of time 
to achieve stable pain control and patients with neuropathic pain used higher doses 
of opioids and needed more adjuvant pain treatments (54), confirming the findings 
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from the 2005-study (56). A prospective study of 167 cancer patients in palliative care 
reported similar results; patients defined as having ‘definite neuropathic pain’ had 
higher pain intensity and required higher doses of opioids than patients without a 
neuropathic pain component (130).
To recognise and diagnose a neuropathic pain condition is important as this may 
have therapeutic consequences (15). One recent attempt to further investigate 
different assessment methods of neuropathic pain in cancer patients by comparing 
four different assessment tools reported that the ‘Leeds Assessment of Neuropathic 
Symptoms and Signs’ (LANSS) showed the highest specificity (130). The IASP 
Neuropathic Pain Special Interest Group has proposed a grading system for the 
diagnosis of non-cancer neuropathic pain (179). The four criteria of this system are: 1. 
Pain with a distinct neuroanatomically plausible distribution; 2. A history suggestive of 
a relevant lesion or disease affecting the peripheral or central somatosensory 
system; 3. Demonstration of the distinct neuroanatonically plausible distribution by at 
least one confirmatory test (as part of the neurologic examination); and 4. 
Demonstration of the relevant lesion or disease by at least one confirmatory test (as 
part of the neurologic examination). If the patient satisfies the first two criteria, the 
presence of neuropathic pain is ‘possible’. To confirm the diagnosis of neuropathic 
pain, confirmatory testing is necessary; if either criteria three or four are satisfied, the 
diagnosis of neuropathic pain is ‘probable’, and if all four are satisfied, the diagnosis 
is ‘definite’ (179). Only eight of 22 studies in a systematic literature review of studies of 
neuropathic pain in cancer patients met at least three of the NeuPSIG criteria (15).
Thus, the NeuPSIG system needs to be validated in large unselected cohorts of 
cancer patients, the four criteria need to be further developed, and an international 
agreement on the assessment methods of neuropathic pain in cancer patients needs 
to be achieved (15).
5.1.4.5 Pain localisation 
Pain localisation is included in the IASP Classification of Chronic pain, however 
neither in the ECS-CP nor in the CPPS (paper I). In paper II the patients reported 
changes in pain sites during the disease trajectory, but did not emphasise the 
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localisation. Pain localisation was among the results in both paper III and IV, however 
with variable sites. The repeated finding of the relevance of pain localisation in this 
thesis, suggests that the assessment, for example by a pain body map, should be 
included in a cancer pain classification system. Within the EPCRC, a computerised 
version of a pain body map has been developed allowing also for indication of pain 
intensity in the marked painful area, a tool which has been shown to be feasible and 
well accepted by patients receiving palliative care (67) and research is on-going to 
further develop and validate this tool (96).
5.1.4.6 Pain treatment 
Paper I identified that the CPPS (92) includes opioid dose as one of four domains. 
Opioid dose (‘previous narcotic exposure’) was included in the original ESS (23),
however later excluded as it was not found to be associated with the probability of 
obtaining good pain control (25). In later validation studies of the ECS-CP, opioid dose 
has been used as an outcome measure (54 ,56). The three formal, although not 
validated classification systems identified in paper I are mainly to consider as tools 
for prognostication and/or evaluation of pain treatment and are not really 
classification systems. Both the ‘Pain management Index’ (PMI) and the ‘Opioid 
Escalation Index’ (OEI) were identified as dynamic tools useful for assessing 
response to opioid treatment in paper I, and were also recently applied in clinical 
studies (10 ,131).
The patients in paper II emphasised mainly the positive effect of pain treatment, but 
also mentioned to have common side-effects. The patients reported to initially have 
fears of dependency and tolerance. These were eliminated after experiencing the 
treatment effect and after repeatedly getting relevant information about the 
medication. Even if clinically useful, these results, however, do not contribute to the 
decision on the content of a future classification system. Opioid dose and the use of 
non-opioids were associated with the pain outcomes in paper III and in the cross-
sectional part of paper IV, confirming previous findings and the clinical experience 
that patients with more complex pain conditions often require higher opioid doses,
adjuvant analgesics as well as other treatment approaches (54 ,56 ,127 ,155).
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5.1.4.7 Psychological distress 
Psychological distress was one of five domains identified in two or more of the formal 
cancer pain classification systems identified in paper I, however differently defined 
and assessed. In the semi-structured interviews (paper II), the patients reported 
different aspects of being psychological distressed influencing their lives significantly, 
but did not rank it higher than number seven. In paper III, psychological distress was 
assessed by patients’ self-report using the emotional functioning scale of the 
EORCT-QLQ-C30. It was among the domains associated with all three outcomes 
and next after breakthrough pain the one contributing mostly to the explained 
variance. These findings confirm the results from the ESC-CP validation studies (54
,56) and other studies showing that pain and psychological distress are closely related 
(114 ,140 ,198). In contrast, psychological distress was not among the significant domains 
in paper IV. One reason for this may be that psychological distress was measured by 
a health care provider using the rESS (56) and not by the patients, and that training in 
the use of this tool was not given in CPOR. The experts at the Milan meeting 2009 
regarded psychological distress as one of the four core domains to be included in a 
cancer pain classification system for cancer pain (103).
5.1.4.8 Sleep disturbances 
Disturbed sleep was not among the identified domains/items in paper I, however 
emphasised by the patients in paper II and thus included for further investigation in 
paper III and IV. Both in paper III and the cross-sectional part of paper IV, sleep 
disturbances was a domain being associated with all three outcomes and contributed 
significantly to changes in the outcomes. This is in concordance with findings of 
sleeping problems being associated with pain in more than 2800 cancer patients (169)
and observations that poor sleep may cause more pain (166). Sleep was assessed by 
patients’ self-report in both studies; in paper III with the question ‘have you had 
trouble sleeping?’ from the EORTC-QLQ-C30, and in paper IV with the question 
‘have you had problems sleeping?’ from the TIQ (176), which could be simple to 
implement in a classification system without being a burden to the patients. More 
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detailed information about sleep quality can be obtained by using sleep 
questionnaires such as the Pittsburgh Sleep Quality Index (26), however such a tool 
would probably be too comprehensive to include in a cancer pain classification 
system for clinical use.  
5.1.4.9 Addiction 
Addiction (‘addictive behaviour’) is included in the ECS-CP, but was not identified in 
any of the other formal classification systems nor among the ‘informal’ approaches 
(paper I). Only two of the patients in paper II reported to have any experience with 
addiction, and these two did not regard this as relevant for their pain experience. In 
paper III, addiction was assessed by a simple question if alcohol and/or drug abuse 
was present or not. Addiction was only included in the regression model for pain 
relief, and its impact on the outcome was limited. In paper IV, substance abuse was 
among the exclusion criteria and thus not available for investigation. In the last 
multicentre validation study of the ECS-CP, addiction was not among the domains 
associated with longer time to achieve pain control in the multivariate analysis (54). It 
may therefore be questionable if addiction is a relevant domain to include in a 
general diagnostic tool; even it is an important condition to be aware of in clinical 
practice.
5.1.4.10 Age 
In paper I patients’ demographics such as age, gender, and performance status were 
identified as investigated and commonly reported domains in the field of cancer pain. 
Age was not among the results in paper II or III, but was one of six domains identified 
as predictors of pain in the longitudinal part of paper IV; indicating that younger 
patients may have more complex pain conditions than older patients. Similar results 
were reported for the ECS-CP (54) and have been reported earlier as well (124). On the 
other hand, another study by Hill et al. reported that age did not influence level of 
reported pain intensity, but that older patients seemed to require lower opioid doses 
(186). It seems reasonable to include a number of patients’ demographics in the further 
development process of a cancer pain classification system (as usual in clinical 
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practice). However, the predictive value of these domains and thus their role in a 
future cancer pain classification system is still unclear.  
5.1.4.11 Cancer diagnosis and localisation of metastases 
Tumour biology plays an important role in pain pathophysiology (12 ,100 ,162). For 
example prostate, breast and lung cancer often cause bone metastases, whereas 
head and neck cancer seldom results in distant metastases, but often leads to 
complex and burdensome local pain conditions (109) Pain caused by tumour directed 
treatments such as surgery, radiotherapy and chemotherapy is also common. 
Furthermore, radiotherapy for painful bone metastases has been shown to cause 
pain relief even with one single fraction (104). Considering these facts, information 
about the cancer disease, the pattern of metastases and the anti-cancer treatments 
given should be mandatory also when classifying or diagnosing cancer pain, and 
cancer disease and oncologic treatments should be an integrated part of the 
management of cancer pain. In paper I, cancer diagnosis and stage of disease were 
reported in the majority if the included clinical studies, but cancer diagnosis was not a 
part of any of the formal classification systems. Based upon the considerations 
above, this may be considered as a major limitation. The patients in paper II were not 
asked about this issue as we regarded this to be too ‘medical’. However, the patients’ 
experiences of pain were closely related to the fact that they were suffering from an 
incurable disease. These patients as well as patients in other studies often believe 
that pain is a sign of disease progression (125). Cancer diagnosis was confirmed to be 
of importance in paper III and in the longitudinal part of paper IV.
5.1.5 Do the models explain the variation in pain? 
Multivariate regression analysis was chosen as analytical method in both paper III 
and IV, giving an explained variance (R square/R2) as one important indicator of 
comprehensiveness (5). The R square was moderate to low in both papers (12-19% in 
paper III and 16-26% in paper IV), meaning that the independent domains included in 
the models, explained only a minor part of the variability of the pain outcomes. This 
may have several reasons such as: 1. Lack of accurate assessment methods as well 
65
as the use of crude methods to assess complex pain domains (for example 
breakthrough pain, neuropathic pain and psychological distress were all assessed 
dichotomously in paper IV), and 2. The low explained variance indicate that several 
other aspects than the investigated ones may influence cancer pain. By including for 
example genetic variability, differences in tumour biology, and variability in patients’ 
pain perception and susceptibility into a future system, the explained variance may 
be increased. Similar results for explained variance (14%-35%) (83), but also higher 
(39%-48%) (97) have been reported by others. In the last validation study of the ECS-
CP (54) multivariate Cox regression analysis was applied. The Nagelkerke pseudo-R 
square (123) for their final model was 21%, which also was low, however not directly 
comparable with our results (144).
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Figure 3: Summary of the results obtained in this thesis
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5.2 Methodological considerations  
In general, awareness of the methodological limitations is necessary to evaluate for 
example internal and external validity of scientific studies. Internal validity refers to 
whether the results are representative for the cohort studied and external validity 
concerns if the results are applicable in other populations (generalisability) (180).
Limitations related to the papers included in this thesis will be discussed in the 
following.
5.2.1 Paper I 
The PRISMA Statement (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) (137 ,161) was published in 2009 to guide researchers in planning, 
completing, and reporting systematic literature reviews. According to these new 
guidelines our search could have been improved. We chose to use only MEDLINE 
and Embase databases, but could have expanded the search in other databases, for 
example the Cochrane library, the date of the searches should have been reported, 
and the eligibility criteria and the detailed checklist for data extraction could have 
been reported.
In the final searches we ended up with 692 hits, a low number when considering the 
number of studies published on cancer pain in general. A relevant question is 
whether we identified all relevant domains/items and classification systems in the 
systematic literature review. It would, however, be a ‘too big task’ to explore all 
existing papers on cancer pain to address the question about its classification and 
the achieved results were regarded sufficient to conclude. 
5.2.2 Paper II 
To involve the patients in the process of deciding upon the content of a cancer pain 
classification system was planned as a part of the stepwise research strategy of the 
EPCRC (106) and based upon recommendations regarding assessment tool 
development from the FDA (184), NICE(142) and EORTC (172). Patients’ experience of 
disease and symptoms in paper II, however, contributed marginally with new 
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information in the development process of a classification system. Considering this, 
one may question the appropriateness of using recommendations developed for 
symptom assessment also for symptom classification. In order to achieve 
completeness of a comprehensive symptom assessment for example in cancer 
survivors, it is intuitively understandable that various methodologies, including in-
depth interviews, should be applied in order to include all relevant domains. 
However, a diagnostic procedure (that is classification) is basically different from 
assessment of symptoms or patient reported outcomes. The content of a 
classification system is a combination of domains related to pathophysiology, clinical 
examination, imaging, laboratory tests, and PROs and thus a complex task for 
patients to evaluate. For the future it may therefore be questioned whether patients’ 
perspectives need to be recommended included in a development process of a 
classification system for symptoms in palliative care specifically and in cancer care in 
general.
We may not have explored all possible domains due to the methodology applied in 
paper II. With another approach for example by more open patients’ interviews or by 
using focus groups interviews including both experts and patients and hereby 
opening for an interaction between health care providers and patients, we might have 
obtained more relevant and comprehensive information.  
The qualitative analyses were performed according to a general method by Giorgi (69)
and Malterud (120). From the presentation of the results it might be claimed that the 
analysis is more reflective of a content analysis. Content analysis has been 
presented as one method of text analysis with two different approaches: a) a 
quantitative approach counting the frequency distribution of words/codes identified in 
the text, and b) a qualitative approach in which extracts from the text are reported to 
illustrate particular themes or categories, referred to as ‘thematic analysis’ (171). The 
analysis we performed may be reflective to a thematic content analysis as in (b), 
however to avoid confusion regarding terminologies and as we did not apply the 
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quantitative approach described as (a), we did not use the term ‘content analysis’ in 
the paper.
The population studied was narrow, as intended, including patients with advanced 
cancer and pain. However, this may hamper the generalisability of the findings into 
general oncology as other aspects of pain may be regarded as more relevant to for 
example long-term survivors or patients receiving curative treatment.  
5.2.3 Paper III and IV 
The empirical studies are both large multicentre studies consisting of data from rather 
heterogeneous patients populations. The heterogeneity may be considered as a 
strength with regard to generalizability of the findings. It may however also be a 
limitation since small effect sizes may be diluted in such heterogeneous samples. 
Considering this, we chose in paper IV to analyse data only from patients recently 
admitted to palliative care in the longitudinal part and thus achieved a more 
homogenous sample. 
The cross-sectional design (paper III) has limitations. Such a study design allows 
only for the study of associations/correlations between the dependent and 
independent variables and thus does not allow for any answers regarding prediction 
or causality. An ideal cancer pain classification system should guide treatment by 
classifying patients into subgroups of patients with different needs for treatment 
and/or different chance for effect of various treatments. To show such a clinical 
validity, a prospective intervention study is needed. The strength of paper IV was the 
prospective design, however, this is also only an observational study. Furthermore, 
paper III and IV were not planned and designed for the development and validation of 
a cancer pain classification system, which limits their value in this development 
process.
Another limitation is the outcomes applied. Pain intensity and pain relief can be 
considered as not representative for the patients’ global pain experience. We aimed 
at studying a complex phenomenon, but had to choose outcomes applicable for 
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research purposes. To minimalise this limitation, the choice of outcome was guided 
by findings in the literature and by an expert survey (paper III), and three outcome 
measures were used.
Regression analysis was chosen as the most appropriate method to study which and 
to what extent a series of domains were influencing or were related to pain intensity 
and/or pain relief. Taking the complexity of pain and all aspects influencing cancer 
pain, and also the need for investigating causality into consideration, it could be 
claimed that the use of a more complex method such as structural equation 
modelling would provide additional and important insights. The explained variance 
(R2) was low in both paper III and IV indicating that several other aspect than those 
investigated contribute to cancer pain. This aspect has been discussed in section 
5.1.5.
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6. Conclusions 
Pain is a common and often undertreated symptom in cancer patients. The lack of an 
international cancer pain classification system has been identified as one reason for 
this. This thesis has contributed with four studies to the on-going development 
process of a cancer pain classification system; one systematic literature review, one 
qualitative study, and two studies of empirical data from large cohorts of cancer 
patients with cross-sectional and longitudinal design, respectively. The four papers 
demonstrate that several aspects are contributing to the complexity of pain in 
patients with advanced cancer; both pain-, patient- and cancer related information.
The following conclusions indicate the answers to the research questions raised in 
this thesis:
Paper I 
Six formal classification systems for cancer pain were identified:  
x Three were systematically developed and partially validated: the International 
Association for the Study of Pain Classification of Chronic Pain, the Cancer 
Pain Prognostic Scale, and the Edmonton Classification System for Cancer 
Pain.
x Three further formal systems were identified as mainly being tools for 
prognostication and evaluation of pain treatment, namely: the Opioid 
Escalation Index, a prognostic tool for pain treatment, and the Pain 
Management Index. 
x In addition, several other domains/items not formally described as part of a 
classification system were identifed.  
The domains pain intensity, breakthrough pain, neuropathic pain, psychological 
distress, and treatment response were included in two or more of the formal systems, 
and the assessment methods used differed across studies.  None of the approaches 
were widely applied in research or in clinical practice. 
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Paper II 
Previously identified domains relevant for cancer pain classification were confirmed 
to be relevant to the patients. These were (ordered due to the patients’ scoring of 
their importance): Etiology, duration of pain, pain intensity, coping, localisation of 
pain, physical functioning, psychological distress, breakthrough pain, cognitive 
function, neuropathic pain, previous pain experience, and addiction. Except for sleep 
disturbances, no new domains were identified. In semi-structured interviews the 
patients emphasised aspects related to being in pain, such as poorer emotional and 
physical functioning. 
Paper III and IV 
In paper III, breakthrough pain and psychological distress were confirmed as 
important domains of a cancer pain classification system. Neuropathic pain, pain 
localisation, opioid dose, use of non-opioids, sleep, addiction, cancer diagnosis, and 
localisation of metastases were identified as candidate domains.
In the cross-sectional analysis in paper IV, breakthrough pain, pain localisation, 
opioid dose, use of non-opioids, and sleep were associated with one or more of the 
pain outcomes. Furthermore, in the longitudinal analysis of paper IV, the domains 
pain intensity and pain relief at study entry, breakthrough pain, localisation of pain, 
age, and cancer diagnosis were identified as predictors. Identified domains/items 
explained from 12% to 26% of the variability of the pain outcomes.
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7. Future directions 
An international cancer pain classification system is needed to improve cancer pain 
management. At the expert meeting in Milan in 2009 it was proposed to name an 
upcoming classification system the ‘Cancer Pain Assessment and Classification 
System’ (CPACS) (103). The major future challenges are to choose the most 
appropriate and the optimal number of domains for inclusion, to reach a consensus 
on how to assess these domains, to reach consensus on the appropriate outcomes, 
and to implement the future CPACS into research and clinical practice. 
At the Milan meeting it was recommended to include the following domains as ‘core 
domains’ in the future CPACS: pain intensity, breakthrough pain, neuropathic pain, 
and psychological distress (103). The results obtained in this thesis suggest to also 
considering the following domains for inclusion: pain relief, localisation of pain, 
analgesic pain treatment, sleep disturbances, and cancer diagnosis.
For assessment consensus has been reached to use a 0 to10 numerical rating scale 
for pain intensity (NRS-11) (103). Which assessment methods and tools to use for 
other domains are not decided, and need to be clarified through further research and 
collaboration.
Efforts have been made to standardise what information to assess in clinical studies 
in palliative care research. The EU-funded ‘PRISMA project’ initiated by the EAPC 
Research Network has completed a systematic literature review and a collected 
experts’ opinions regarding what is the appropriate information needed for describing 
a palliative care population (38 ,79). A publication proposing a general ‘basic data set’ 
to include in all palliative care studies that can be expanded with symptom specific 
assessment appropriate for different studies is in preparation (170).
Finally, large studies are required to investigate the feasibility and effectiveness of a 
future cancer pain assessment and classification system. Studies can investigate the 
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clinical benefit of using a cancer pain classification system for categorising patients 
according to their pain condition and for guiding treatment decisions in individual 
patients. The performance of such studies is facilitated by international collaboration 
(77). The international network of palliative care researchers within the EPCRC is now 
continued within the EAPC Research Network (47) and the European Palliative Care  
Research Centre (PRC) (49).
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Background: This study is part of a research program to reach consensus on an international cancer pain
classiﬁcation system. A conﬁrmative and explorative approach was applied to investigate which of the
variables identiﬁed in the literature, by experts and patients that are associated with pain.
Methods: Data from an international, multicentre, cross-sectional study of cancer patients treated with
opioids were investigated. Dependent variables were: average pain, worst pain, and pain relief (11-point
Numerical Rating Scales). Forty-six independent variables were chosen based upon previous studies.
Bivariate analyses identiﬁed independent variables associated with at least one of the dependent ones;
21 were included in multivariate linear regression analyses.
Results: Two thousand two hundred and seventy-eight patients were investigated; 52% males, mean age
62 years, mean Karnofsky Performance Status 59%, mean daily opioid oral equivalent dose 341 mg. Fifty-
eight percent had breakthrough pain. Mean pain scores were: average pain 3.5, worst pain 5.3 and pain
relief 74%. Variables most strongly associated with these three dependent variables were: breakthrough
pain, psychological distress, sleep, and opioid dose.
Conclusions: Breakthrough pain and psychological distress were conﬁrmed as key variables of a future
classiﬁcation system. Candidate variables were: sleep, opioid dose, pain mechanism, use of non-opioids,
pain localisation, cancer diagnosis, location of metastases, and addiction.
 2010 European Federation of International Association for the Study of Pain Chapters. Published by
Elsevier Ltd. All rights reserved.
1. Introduction
There is no agreement on which cancer pain classiﬁcation
system that should be used in research and clinical practice (Carac-
eni and Weinstein, 2001; Fainsinger and Nekolaichuk, 2008). Con-
sensus on a shared language for cancer pain would facilitate the
translation of results from research into clinical practice, make
comparison between studies possible (Borgsteede et al., 2006),
and be a tool for quality assurance of cancer pain treatment
(Pasman et al., 2009). A cancer pain classiﬁcation system can im-
prove treatment of cancer pain (Fainsinger and Nekolaichuk, 2008).
The European Palliative Care Research Collaborative (EPCRC)
was funded by the EU’s 6th framework program to develop an
international, consensus based and feasible classiﬁcation system
for prevalent symptoms in patients with advanced cancer. The re-
search strategy is a stepwise process including literature reviews,
input from experts, input from patients and empirical studies
(Kaasa et al., 2008).
A systematic literature review identiﬁed six existing formal
classiﬁcation systems for cancer pain (Knudsen et al., 2009). Three
1090-3801/$36.00  2010 European Federation of International Association for the Study of Pain Chapters. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejpain.2010.08.001
⇑ Corresponding author. Address: Dept. of Cancer Research and Molecular
Medicine, Faculty of Medicine, NTNU, 3. Floor Bevegelse, Trondheim University
Hospital, NO-7006 Trondheim, Norway. Tel.: +47 72 82 62 96/+47 92 28 03 64; fax:
+47 72 82 60 28.
E-mail address: anne.k.knudsen@ntnu.no (A.K. Knudsen).
1 Please see Appendix A for details.
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were systematically developed and partially validated; the Classi-
ﬁcation of Chronic Pain of the International Association for the
Study of Pain (Merskey and Bogduk, 1994), the Edmonton Classiﬁ-
cation System for Cancer Pain (ECS-CP) (Fainsinger and
Nekolaichuk, 2008) and the Cancer Pain Prognostic Scale (CPPS)
(Hwang et al., 2002). Except for the ECS-CP, none of the systems
have been widely used. Five variables were common: pain inten-
sity, breakthrough pain (BTP), pain mechanism, response to treat-
ment, and psychological distress (PD) (Knudsen et al., 2009).
Experts in pain and palliative care recommended additionally the
variables pain localisation, interference, duration, previous pain
experience, and pain beliefs for inclusion in a future assessment
and classiﬁcation system for cancer pain (Hjermstad et al., 2008).
A qualitative study on advanced cancer patients’ experiences with
pain and their opinion of its assessment and classiﬁcation pro-
posed to add sleep and social functioning (Knudsen et al., 2010).
The process of development and validation of a clinically useful
cancer pain classiﬁcation system requires deﬁnition of which var-
iable to be the dependent one. A series of dependent variables have
been applied in previous cancer pain studies such as pain intensity
(Caraceni et al., 1999), opioid dose (Mercadante et al., 2000), treat-
ment response (Cleeland et al., 1994), and time to achieve pain
control (Fainsinger et al., 2005). Pain intensity is by many clinicians
regarded as a key variable since it guides treatment decisions and
inﬂuences pain experience (Chow et al., 2006; Hjermstad et al.,
2008).
The overall aim of the present study was to apply empirical data
to investigate which variables to include in an international cancer
pain classiﬁcation system. Data from the European Pharmacoge-
netic Opioid Study (EPOS) (Klepstad et al., 2010) was applied in a
conﬁrmative and explorative approach to answer the following re-
search questions:
1. To what extent are the variables pain mechanism, breakthrough
pain (BTP) and psychological distress (PD) associated with pain
intensity and/or response to pain treatment?
2. Are other previously identiﬁed variables relevant for cancer
pain classiﬁcation associated with pain intensity and/or
response to pain treatment?
2. Methods
2.1. Patients
EPOS is an international, multicentre, cross-sectional, observa-
tional study of cancer patients treated with opioids for moderate
to severe pain (Klepstad et al., 2010). PatientsP18 years with ver-
iﬁed malignant disease and on regularly scheduled opioid treat-
ment for at least three days were included.
2.2. Assessment
The following information was assessed by a health care pro-
vider: Medical history and consumption of opioids and other med-
ication, functional status assessed by the Karnofsky Performance
Status (KPS) (Karnofsky et al., 1948) and cognitive function by
the Mini Mental Status Exam (MMSE) (Folstein et al., 1975). BTP
was evaluated as a dichotomised yes/no-question focusing on pain
with a known trigger. This was similar to the question of incident
pain in an early version of the Edmonton Classiﬁcation System for
Cancer Pain and the only question addressing this domain in EPOS
(Bruera et al., 1989, 1995b). Pain mechanism was categorised as
follows: visceral, bone/soft tissue, neuropathic, mixed, and un-
known pain; not further deﬁned in EPOS (Bruera et al., 1995b).
Addiction was evaluated by answering yes or no to the question
of previous or present known abuse of either alcohol or drugs.
The patients completed the Brief Pain Inventory (BPI) (Daut
et al., 1983) and the European Organisation for Research and Treat-
ment of Cancer quality-of-life core questionnaire (EORTC-QLQ-
C30) version 3.0 (Aaronson et al., 1993). Variables included in the
present analyses were from BPI: pain localisation (body map), ‘pain
on the average’, ‘pain at its worst’ and ‘pain relief’; all referring to
the last 24 h (11-point Numerical Rating Scales (NRS-11)), and
from EORTC-QLQ-C30: the physical, emotional and social function-
ing scales, and the symptom scales/items for nausea and vomiting,
constipation and insomnia (‘have you had trouble sleeping?’).
Hence, PD was assessed by use of the emotional functioning scale
in the EORTC-QLQ-C30 questionnaire, consisting of the four ques-
tions: ‘did you feel tense?’, ‘did you worry?’, ‘did you feel irrita-
ble?’, and ‘did you feel depressed?’. All scales and single-item
measures were calculated following the EORTC guidelines into a
score ranging from 0 to 100. A high score for a functional scale rep-
resents a high level of functioning whereas a high score for a symp-
tom scale/item represents a high level of symptomatology
(Aaronson et al., 1993).
2.3. Stepwise analytical process
The analytical approach in this paper consists of four steps
(Fig. 1).
Step 1 was performed as an expert survey with the aim to ad-
vise on dependent variables to be applied. In January 2009, 30 ex-
perts within oncology, pain and palliative care were asked to rank
the clinical relevance of ﬁve variables from the BPI on an NRS-11
(0 = not relevant, 10 = highly relevant). The variables chosen for
ranking were: Pain relief provided by pain treatments or medica-
tions; pain at its worst; pain at its least; pain on the average (all
in the last 24 h); and pain right now.
Step 2 was conducted in order to decide upon which variables
to include as dependent ones in the analyses. These were deﬁned
based upon results from: (1) a systematic literature review on can-
cer pain classiﬁcation (Knudsen et al., 2009); (2) a combined sys-
tematic literature review and expert survey on cancer pain
assessment (Hjermstad et al., 2008); and (3) data from a qualitative
study on 33 advanced cancer patients exploring the patients’ expe-
riences and view upon variables identiﬁed in (1) and (2) (Knudsen
et al., 2010). Additionally, the common opioid side effects nausea/
vomiting and constipation were included.
In step 3 bivariate analyses were performed in order to decide
which of the examined variables to include in the multivariate
analyses. For each of the dependent variables, the Kruskal–Wallis
test was used for the categorical independent variables and the
Spearman’s correlation coefﬁcient for the continuous ones. All vari-
ables from step 2, showing a statistically relevant association with
at least one of the dependent variables were included in the mul-
tivariate analyses.
In step 4 multivariate regression analyses were conducted.
Backward elimination was chosen for selecting the relevant vari-
ables, as a lack of high correlations between independent and
dependent variables is one of the assumptions under which this
is considered a good method (Sauerbrei et al., 2007). A p-va-
lue = 0.01 was applied for removing variables. As the data showed
between country differences in mean pain intensity and pain relief
scores, country was used as an adjustment factor in all the regres-
sion analyses, choosing Norway as reference country. The adjust-
ment was performed forcing nine dichotomous variables in each
model, one for each of the remaining countries. Due to collinearity
between physical functioning and Karnofsky Performance Status,
only the latter was included in the model. Common assumptions
in regression analysis were investigated without identifying condi-
tions weakening the models.
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2.4. Ethics
The protocol was approved by the committee for medical re-
search ethics of each study centre. All patients gave written in-
formed consent to participate in the study.
3. Results
Two thousand two hundred and ninety-four patients were in-
cluded in the present analyses; the patients were recruited from
17 centres in 11 European countries from February 2004 to April
2008 (Klepstad et al., 2010). Greek patients were not included
due to a low number of patients. Eleven patients withdrew from
the study. Hence, the ﬁnal study sample included 2278 patients.
As shown in Table 1, 1193 were male and 1085 female, mean
age was 62 years, and mean KPS was 59. The majority was inpa-
tients (81%). The most common cancer diagnoses were gastrointes-
tinal, lung, breast and prostate cancer, and 45% of the patients had
bone metastases. The characteristics of pain and other symptoms
are presented in Table 2. Average pain was 3.5 and pain at its worst
was 5.3. Pain relief was 74%, and 58% of the patients had BTP. The
most common pain mechanism was ‘bone/soft-tissue pain’. The
average oral morphine daily equivalent dose was 341 mg.
Sixteen experts (53%) responded and scored the items from the
BPI in the following order of importance: ‘pain right now’ (median
score 9), ‘pain at its worst’ (9), ‘pain on the average’ (8.5), ’pain re-
lief’ (8) and ‘pain at its least’ (4). Three dependent variables were
chosen for the present study: ‘pain on the average’, ‘pain at its
worst’ and ‘pain relief’.
Based upon the studies in step 2, 46 independent variables were
included in the present analyses (Table 3). Bivariate analyses
showed that six variables were signiﬁcantly associated with all
three dependent variables: BTP, pain localisation (lower extremi-
ties), opioid dose, physical functioning, PD and sleep. Eight vari-
ables showed signiﬁcant association with two of the dependent
ones: pain mechanism (bone/soft-tissue and mixed pain), pain
localisation (upper extremities), the use of non-opioids, the use
of gabapentin/pregabalin, KPS, social functioning, and constipation.
Seven variables (back pain, use of corticosteroids, cognitive func-
tioning, addictive behaviour, nausea/vomiting, prostate cancer, li-
ver metastases and gender) were signiﬁcantly associated with
only one of the dependent variables (Table 3).
In Fig. 2 box plots for the dependent variable ‘pain on the aver-
age’ and the three hypothesised key variables are presented. Pa-
tients with and without BTP reported average pain as 3.9 vs. 2.9.
Patients with PD had average pain of 4; patients without scored
3.2. With visceral pain the average pain was 3.1, with bone/soft-
tissue pain 3.3, with neuropathic pain 3.8, with mixed pain 3.9
and with unknown pain, the average pain score was 2.5. Similar re-
sults were observed for the two other dependent variables ‘pain at
its worst’ and ‘pain relief’.
The regression analyses included 21 variables (Table 3), of
which 13 variables constituted the ﬁnal models (Table 4). Two of
the three hypothesised variables, BTP and PD, were conﬁrmed to
be associated with pain. In addition, sleep disturbances and the
use of non-opioids were included in all three models. The third
hypothesised variable, pain mechanism, was included in two of
the models, so were also opioid dose, cancer diagnosis and location
of metastases. Pain localisation was included in all three models,
however with different sites for each model. BTP, PD, sleep and
opioid dose showed the highest standardised betas among the in-
cluded (Table 4). The adjusted explained variance (R2) for the
regression models varied from 0.12 to 0.19.
Outcomes: 
1. Pain on the average the last 24 h (NRS-11) 
2. Pain at its worst the last 24 h (NRS-11) 
3. Pain relief the last 24 h (0%-100%-NRS-11) 
Brief Pain Inventory 
Step 4:  
Multivariate regression analyses  
Variables significantly 
associated with one of the 
dependent variables selected 
for step 4, (p < 0.001)  
Step 1:  
Choice of dependent variables 
Survey among 30 experts in oncology, 
pain and palliative care 
Step 2: 
Choice of independent variables 
2.1. Systematic literature review  
on cancer pain classification 
2.2. Systematic literature review + expert survey  
on cancer pain assessment 
2.3 Patient interviews 
Step 3: 
Bivariate analyses 
Fig. 1. Flowchart of the stepwise analytic process of the EPOS data described in the methods part.
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4. Discussion and conclusions
The present study aimed at verifying three key variables and at
exploring other variables relevant for cancer pain classiﬁcation in a
cohort of cancer patients on opioids. BTP and PD were conﬁrmed to
be relevant as they contributed signiﬁcantly to all three ﬁnal
regression models and showed the highest standardised betas.
Sleep disturbances and opioid dose were important as well, con-
tributing signiﬁcantly to three and two of the ﬁnal regression mod-
els, respectively. Pain mechanism was included in two of the ﬁnal
models. Identiﬁed candidate variables were: The use of non-opi-
oids, which was included in all three models; pain localisation,
cancer diagnosis and location of metastases, all included in two
of the ﬁnal models; and ﬁnally addiction, only included in one
model.
In a treatment decision making process, one important step is to
group or classify the patients according to expected treatment ef-
fects. This may also provide a better understanding of patient co-
horts in clinical studies. A classiﬁcation system should be based
upon simple, but robust variables. Our primary hypothesis was
based upon a systematic literature review where BTP, PD and pain
mechanism were identiﬁed as key variables (Knudsen et al., 2009).
Interestingly, BTP and PD were conﬁrmed to also be important in
this large sample of cancer patients recruited from 11 countries
and 17 institutions across Europe. This strengthens the value of
these variables for inclusion in a future cancer pain classiﬁcation
system. Similar variables have been shown to be important in
the validation studies of the Edmonton Classiﬁcation System for
Cancer Pain (ECS-CP) (Fainsinger et al., 2005, 2010); a system con-
sisting of the ﬁve variables: incident pain or BTP, pain mechanism,
PD, addiction and cognitive function, and which is regarded as a
template and a starting point for further development of an inter-
national pain classiﬁcation system (Hagen et al., 2008; Kaasa et al.,
2010).
In the ECS-CP all variables are assessed by a health care provider
using deﬁnitions and guidelines developed through an interna-
tional construct validation study (Nekolaichuk et al., 2005). In
EPOS, BTP and pain mechanism was assessed similarly as in the
ECS-CP. Despite the narrow deﬁnition of BTP used in EPOS
Table 1
Patient characteristics.
Patient characteristics N (%) Mean (range) S.d.a
Age 62.2 (18–96) 12.3
Gender
Male 1193 (52.4)
Female 1085 (47.6)
Country
Norway 565
Italy 462
Germany 452
United Kingdom 295
Iceland 150
Sweden 135
Switzerland 115
Lithuania 54
Denmark 31
Finland 30
Greece 5
Karnofsky Performance Status 59.2 (10–100) 17.2
Time since diagnosis (months) 31.5 (0–401) 45.5
Cancer diagnosis
Gastro intestinal 523 (23.0)
Lung 418 (18.3)
Breast 303 (13.3)
Prostate 264 (11.6)
Gyneacological 173 (7.6)
Urological 166 (7.3)
Hematological 133 (5.8)
Head and neck 125 (5.5)
Unknown origin 62 (2.7)
Sarcoma 58 (2.5)
Skin 50 (2.2)
Location of metastasesb
Bone 1020 (44.8)
Liver 562 (24.7)
Lung 502 (22.0)
CNS 132 (5.8)
Other 911 (40.0)
None 370 (16.2)
Treatment setting
Inpatients 1850 (81.2)
Outpatients 428 (18.8)
a S.d. = standard deviation.
b Patients may have more than one site of metastases.
Table 2
Characteristics of pain and other symptoms.
Pain and other symptoms N (%) Mean (range) S.d.a
Pain intensity
Pain on the average last 24 hb 3.50 (0–10) 2.2
Pain at its worst last 24 hc 5.25 (0–10) 2.8
Pain relief
Pain relief provided by pain
treatments last 24 hd
74 (0–100) 22.3
Breakthrough pain
Present 1322 (58.0)
Absent 947 (41.6)
Pain mechanism
Bone/soft-tissue pain 1011 (44.4)
Mixed pain 778 (34.2)
Visceral pain 358 (15.7)
Neuropathic pain 110 (4.8)
Unknown 18 (0.8)
Localisation of paine
Back 868 (38.1)
Pelvic front 835 (36.7)
Thorax front/abdomen 700 (30.7)
Lower extremities 535 (23.5)
Upper extremities 300 (13.2)
Head 193 (8.5)
Pharmacological pain treatment
Total oral morphine equivalent
opioid dose (mg)
341 (0–9090) 550.2
Time on opioids (months) 4.9 (0–132) 10.9
Previously treated with another
opioid
761 (33.4)
Systemic corticosteroids 1107 (48.6)
Non-opioids (NSAIDs, paracetamol) 1212 (53.2)
Gabapentin, pregabalin 399 (17.5)
Other subjective symptoms
Physical functioningf 40.3 25.8
Psychological distressf 64.5 26.4
Social functioningf 46.0 33.2
Sleepg 35.0 33.8
Nausea/vomitingg 23.7 28.2
Constipationg 45.0 37.1
Cognitive functioningh 26.9 (9–30) 3.4
Addictive behaviour present 142 (6.2)
a S.d. = standard deviation.
b 11-point Numerical Rating Scale (NRS-11 from 0 to 10).
c NRS-11.
d NRS-11 0–100%: 0% = no relief, 100% = complete relief.
e Patients may have more than one localisation of pain.
f EORTC functioning scale 0–100; high scores represents a high level of
functioning.
g EORTC symptom scale/single item 0–100; high score represents a high level of
symptomatology or problems.
h Mini Mental Status Exam (MMSE): score range 0–30; higher scores mean better
cognitive function.
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(presence of a known trigger), this was the variable most strongly
associated with pain. The assessment of pain mechanism in EPOS
was based on the revised Edmonton Staging System (rESS) from
1995 (Bruera et al., 1995b); an assessment later revised in the
Table 3
Bivariate analyses: overview independent and dependent variables.
Dependent variables ‘Pain on the average’ ‘Pain at its worst’ ‘Pain relief’
Mean complete sample = 3.5 (NRS 0–10) Mean complete sample = 5.3 (NRS 0–10) Mean complete sample = 74% (0% = no relief,
100% complete relief)
Independent variables Kruskal–Wallis Spearman’s coefﬁcient Kruskal–Wallis Spearman’s coefﬁcient Kruskal–Wallis Spearman’s coefﬁcient
p-Value p-Value p-Value p-Value p-Value p-Value
Breakthrough pain <0.001 – <0.001 – <0.001 –
Pain mechanism
Visceral pain 0.002 – 0.501 – 0.018 –
Bone/soft-tissue pain 0.001 – <0.001 – 0.337 –
Neuropathic pain 0.209 – 0.618 – 0.332 –
Mixed pain <0.001 – <0.001 – 0.012 –
Localisation of pain
Head 0.002 – 0.402 – 0.007 –
Thorax front/abdomen 0.002 – 0.003 – 0.628 –
Pelvic front 0.005 – 0.006 – 0.016 –
Back 0.011 – 0.003 – <0.001 –
Upper extremities <0.001 – <0.001 – 0.003 –
Lower extremities <0.001 – <0.001 – <0.001 –
Opioid dosea – <0.001 – <0.001 – <0.001
Time on opioidsb – 0.870 – 0.906 – 0.162
Previous opioid treatmentc 0.030 – 0.212 – 0.091 –
Adjuvant analgesics
Steroids 0.024 – 0.721 – <0.001 –
Non-opioidsd 0.001 – 0.023 – <0.001 –
Gabapentin/pregabalin <0.001 – <0.001 – 0.009 –
Karnofsky Performance Status – <0.001 – <0.001 – 0.386
Physical functioning – <0.001 – <0.001 – <0.001
Psychological distress – <0.001 – <0.001 – <0.001
Social functioning – 0.016 – 0.001 – <0.001
Sleep – <0.001 – <0.001 – <0.001
Nausea/vomiting – 0.007 – 0.294 – <0.001
Constipation – <0.001 – <0.001 – 0.005
Body mass index – 0.495 – 0.284 – 0.332
Cognitive functioning – 0.002 – <0.001 – 0.180
Addictive behaviour 0.183 – 0.051 – <0.001 –
Cancer diagnosis
Gastro intestinal 0.093 – 0.161 – 0.169 –
Lung 0.112 – 0.475 – 0.268 –
Breast 0.738 – 0.513 – 0.195 –
Prostate 0.003 – <0.001 – 0.649 –
Gyneacological 0.018 – 0.315 – 0.356 –
Urological 0.529 – 0.168 – 0.049 –
Hematological 0.624 – 0.917 – 0.812 –
Head and neck 0.036 – 0.188 – 0.293 –
Unknown origin 0.167 – 0.108 – 0.674 –
Sarcoma 0.380 – 0.154 – 0.251 –
Skin 0.659 – 0.922 – 0.750 –
Time since diagnosisb – 0.316 – 0.245 – 0.919
Location of metastases
Bone 0.998 – 0.196 – 0.239 –
Liver <0.001 – 0.003 – 0.019 –
Lung 0.226 – 0.198 – 0.392 –
CNS 0.355 – 0.271 – 0.584 –
Other 0.750 – 0.573 – 0.016 –
Age – 0.105 – 0.005 – 0.495
Gender <0.001 – 0.026 – 0.019 –
Variables in bold print were included in the regression analyses (step 4).
a Daily oral morphine equivalent dose in mg.
b In months.
c Number of previous opioids used.
d Paracetamol and NSAIDs.
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ECS-CP as the distinction between nociceptive and neuropathic
pain has been shown to be the clinically most relevant (Fainsinger
et al., 2005). The different pain mechanisms were not deﬁned in
EPOS. Only 110 patients were categorised to have neuropathic pain
and 788 to have mixed pain. Four hundred and two patients used
gabapentin/pregabalin, medication often used for treatment of
neuropathic pain. This indicates that more than 110 patients had
neuropathic pain; most probably categorised as having mixed pain.
As mixed pain was included in the ﬁnal regression model (for
‘average pain’ as dependent variable), this may still be regarded
as a conﬁrmation of previous ﬁndings deﬁning neuropathic pain
as a key variable for cancer pain classiﬁcation (Caraceni et al.,
1999; Fainsinger et al., 2005).
Our results show that more PD is associated with more severe
pain, conﬁrming previous results (Wilson et al., 2007). PD was as-
sessed by the patients, applying one of the most widely used health
related quality of life instruments, the EORTC QLQ-C30 (emotional
functioning scale) (Aaronson et al., 1993). Such a rater-indepen-
dent conﬁrmation of a key variable may be regarded as a further
strengthening of its importance.
In the present study, addiction was only included in the regres-
sion model with ‘pain relief’ as a dependent variable. This may be
explained by the fact that pain relief is a concept covering other
and more complex aspects of pain than the measurement of pain
intensity (Jensen, 2003). In EPOS, only 142 patients (6.2%) with
addiction were recognised. In ECS-CP the screening tool
Breakthrough pain Psychological distress
EORTC score 0-50 51-100No BTP                BTP present 
Pain mechanism
V B N M U
BTP:  Breakthrough pain  
V:  Visceral pain 
B:  Bone / soft-tissue pain 
N:  Neuropathic pain 
M:  Mixed pain 
U:  Unknown pain 
EORTC: European Organisation for Research and Treatment 
of Cancer quality-of-lifecore questionnaire (EORTC- 
QLQ-C30) version 3.0 
Fig. 2. Box plots of the hypothesised key variables with ‘pain on the average’ as the dependent variable.
Table 4
Multivariate regression analyses: the ﬁnal models for all three dependent variables.
Independent variables Dependent variables ‘Pain on the average’ ‘Pain at its worst’ ‘Pain relief’
N = 1870 N = 1883 N = 1843
R2 adj. = 0.17 R2 adj. = 0.19 R2 adj. = 0.12
ba CIb Stand. bc b CI Stand. b b CI Stand. b
Const. 2.22 1.63, 2.80 – 2.72 1.96, 3.50 – 76.1 71.9, 80.4 –
Breakthrough pain 0.87 0.68, 1.06 0.20 1.29 1.04, 1.53 0.23 6.1 8.1, 4.0 0.13
Psychological distress 0.01 0.01, 0.006 0.12 0.01 0.02, 0.007 0.11 0.1 0.05, 0.14 0.11
Pain mechanism Mixed 0.34 0.14, 0.54 0.07 – – – – – –
Bone soft-tissue – – – 0.47 0.72, 0.22 0.08 – – –
Sleep 0.47 0.27, 0.68 0.10 0.58 0.31, 0.84 0.10 4.0 6.3, 1.8 0.08
Non-opioids 0.32 0.14, 0.51 0.07 0.42 0.18, 0.66 0.07 3.1 5.1, 1.1 0.07
Pain localisation Upper extremities 0.42 0.17, 0.68 0.07 – – – – – –
Lower extremities – – – 0.44 0.18, 0.71 0.07 – – –
Back – – – 0.38 0.15, 0.62 0.07 3.0 4.9, 1.0 0.07
Opioid dose (lg) 0.23 0.14, 0.31 0.12 0.34 0.23, 0.44 0.14 – – –
Cancer diagnosis Prostate cancer 0.44 0.72, 0.16 0.07 0.51 0.88, 0.14 0.06 – – –
Location of metastases Liver metastases 0.39 0.61, 0.18 0.08 0.54 0.81, 0.27 0.08 – – –
Addictive behaviour – – – – – – 6.8 11.0, 2.6 0.07
a Regression coefﬁcient.
b 95% conﬁdence interval.
c Standardised beta.
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‘CAGE’-questionnaire (Fainsinger et al., 2005) can be applied; re-
cently identifying addiction in 11% of the patients (Fainsinger
et al., 2010). This may suggest that a more comprehensive assess-
ment is needed to recognise patients with addiction, e.g. by use of
the ‘CAGE’-questionnaire (Bruera et al., 1995a).
The ﬁfth variable of the ECS-CP, cognitive functioning, was not
included in the present regression models. However, pain manage-
ment and research in cognitively impaired patients requires atten-
tion in the further development of a classiﬁcation system.
Sleep disturbances were identiﬁed as associated with pain and
may reﬂect some of the underlying complexity of a pain patient
(Knudsen et al., 2010). Sleep, therefore, may be an important and
feasible candidate variable for identifying patients with poorly
controlled pain. In the present study sleep was assessed by one
simple question from the EORTC QLQ-C30 (‘have you had trouble
sleeping?’) (Aaronson et al., 1993). Perhaps more detailed informa-
tion about sleep quality such as in designated sleep questionnaires
(e.g. Pittsburgh Sleep Quality Index) (Buysse et al., 1989) could add
further information; however, these instruments are too compre-
hensive to be used for general assessment of sleep in a pain classi-
ﬁcation system.
Different variables have been applied as the dependent ones in
different cancer pain studies. Pain intensity may be the most cru-
cial variable for classiﬁcation and treatment decisions (Fainsinger
et al., 2009) and therefore chosen as dependent variable in the
present study. Two different measures of pain intensity from the
BPI were applied; ‘pain on the average’ and ‘pain at its worst’
The experts ranked ‘pain right now’ and ‘pain at its worst’ to be
the most relevant items followed by ‘pain on the average’, ’pain re-
lief’ and ‘pain at its least’. In order to keep the number of depen-
dent variables low, only ‘pain on the average’ and ‘pain at its
worst’ were chosen by the authors for the assessment of pain
intensity; a choice guided by ﬁndings in previous studies and by
experts’ opinions. As ‘pain on the average’ is more adequate for
guidance of long term pain treatment this was chosen in prefer-
ence to ‘pain right now’; the latter regarded as more useful for
assessment of acute pain or by i.v. titration of opioids (Elsner
et al., 2005). ‘Pain at its worst’ may reﬂect the presence of ﬂuctuat-
ing pain and to be more associated with interference (Paul et al.,
2005). The third dependent variable, response to pain treatment
measured as ‘pain relief’, was chosen to strengthen the analysis.
The use of multiple dependent variables for our analyses and the
fact that many variables showed a signiﬁcant association with
more than one of them, strengthens the face validity of our results.
However, an international pain classiﬁcation system should use
one standardised clinically relevant dependent variable.
The independent variables investigated explain up to 19% of the
variation of the dependent ones. This indicates that several other
factors inﬂuence the level of pain intensity and the experience of
treatment response; e.g. genetic variation, differences in tumour
biology and differences in the patients’ perception. Similar results
have been published in previous cancer pain studies. The differ-
ences in the scores between categories on an NRS, e.g. with or
without BTP or history of addiction, were all below 1, which is be-
low what is usually considered as clinically signiﬁcant (Sloan et al.,
2003). However, the differences in the EPOS data were shown in a
population of more than 2000 patients, which make the ﬁndings
interesting. In comparison, meta-analysis of more than 30,000 pa-
tients with hypertension have shown that a reduction of blood
pressure of 5–6 mm Hg, i.e. not relevant on an individual level, sig-
niﬁcantly reduce the risk of stroke and coronary heart disease at a
group level (Collins et al., 1990).
The most important limitation of EPOS is the cross-sectional de-
sign. In the cross-sectional sample, only possible associations be-
tween independent and dependent variables can be described.
The associations shown in the present study do not explain how
the variables are related, e.g. if PD causes more severe pain or vice
versa, and the ﬁndings do not equals causality. New studies should
be conducted with a longitudinal design in order to ﬁnd which
variables that predict pain complexity and variability in response
to treatment.
The present study emphasises the importance of well-deﬁned
and standardised assessment and classiﬁcation tools. However,
complex time consuming assessments may limit the user friendli-
ness of a classiﬁcation system. This suggests the need to consider
combinations of the classiﬁcation system; one basic to be used as
core questions in all studies and in clinical practice and one spec-
ialised for symptoms or variables to be used in clinical research.
Based upon the ﬁndings of the present study, the previous
EPCRC studies, the ECS-CP as well as the consensus achieved
among experts, pain intensity, treatment response, breakthrough
pain and psychological distress are key variables to be included
in a future classiﬁcation system for cancer pain. Several other can-
didate variables have been identiﬁed and need further
investigation.
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a b s t r a c t
The overall aim of the present study was to further develop an evidence-based platform for the content of
an international cancer pain classiﬁcation system. Data from a multicentre, observational longitudinal
study of cancer patients were analysed. Analyses were carried out in 2 samples: (A) Cross-sectional data
of patients on opioids at inclusion, and (B) patients just admitted to palliative care. Outcome measures in
the models we investigated were pain on average, worst pain, and pain relief at inclusion, and at day 14,
respectively. Uni- and multivariate regression models were applied to test the explicative power on pain
outcomes of a series of known pain domains, including incident pain, psychological distress, neuropathic
pain, pain localisation, sleep disturbances, total morphine equivalent daily dose (MEDD), and cancer diag-
nosis. In the 2 analyses, 1529 (A) and 352 (B) patients were included, respectively. Incident pain, pain
localisation, MEDD, use of nonsteroidal antiinﬂammatory drugs, and sleep were associated with one or
more of the pain outcomes in analysis A, while initial pain intensity, initial pain relief, incident pain, local-
isation of pain, cancer diagnosis, and age were predictors in the longitudinal analysis. Identiﬁed domains
explained 16% to 24% of the variability of the pain outcome. Initial pain intensity emerged as the stron-
gest predictor of pain outcome after 2 weeks, and incident pain was conﬁrmed to be a relevant domain.
The regression models explained only a minor part of the variability of pain outcomes.
 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
1. Introduction
In order to choose the optimal treatment of a symptom such as
cancer pain, knowledge of expected treatment response is funda-
mental. Most medical classiﬁcation systems are grouping patients
based upon a prediction of treatment response and/or the natural
course of the disease. A diagnostic tool for cancer pain may consist
of host factors (e.g., age, gender, genetics), disease factors (e.g., can-
cer diagnosis), pain factors (e.g., intensity), comorbidities, and sus-
ceptibility (e.g., previous psychological/somatic experiences). For
optimal management of cancer pain and for comparison of re-
search results, standardised approaches for assessment and classi-
ﬁcation are needed [5,14], but there is no international consensus
on the content of a cancer pain classiﬁcation system [22,33].
The Edmonton Classiﬁcation System for Cancer Pain (ECS-CP) is
extensively studied [33]. It includes the following domains: inci-
dent pain, neuropathic pain, psychological distress, addiction,
and cognitive function [14,15,35], and has been recommended as
a starting point for the development of an international system
for cancer pain classiﬁcation [29]. In the cross-sectional European
0304-3959/$36.00  2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.pain.2011.12.005
DOI of original article: 10.1016/j.pain.2011.12.016
⇑ Corresponding author. Address: European Palliative Care Research Centre,
Faculty of Medicine, Norwegian University of Science and Technology (NTNU), 3.
Floor Bevegelse, Trondheim University Hospital, Trondheim NO-7006, Norway. Tel.:
+47 72 82 62 96; fax: +47 72 82 60 28.
E-mail address: anne.k.knudsen@ntnu.no (A.K. Knudsen).
1 On behalf of the European Palliative Care Research Collaborative (EPCRC,
Appendix A) and the Cancer Pain Outcome Research Study Group (CPOR-SG).
www.e l sev ie r . com/ loca te /pa in
PAIN

153 (2012) 696–703
Pharmacogenetic Opioid Study (EPOS) including 2278 cancer pa-
tients, incident pain, psychological distress, neuropathic pain, pain
localisation, sleep disturbances, opioid dose, the use of nonsteroi-
dal antiinﬂammatory drugs (NSAIDs), cancer diagnosis, localisation
of metastases, and addiction were considered potential domains in
a new system [32]. Pain intensity is also recognised as a key do-
main for prognostication and management of cancer pain [13,29]
and is a predictor of time needed to achieve stable pain control
in cancer patients [14].
Standardised assessment of key domains is crucial for the cor-
rect classiﬁcation of cancer pain. However, assessment methods
used in clinical practice and in research vary considerably [23].
Haugen et al. recently addressed this for incident pain [20]. For
neuropathic pain, the International Association for the Study of
Pain (IASP) recently published assessment recommendations aim-
ing at standardisation [19]. To agree upon who is to assess which
domain is also important. Patients’ self report is recommended
for pain intensity and other subjective pain domains [16,45],
whereas clinical examination is stated to be a crucial part of the
diagnostic process of neuropathic pain [19].
A system’s ability to predict the course of pain should be eval-
uated prospectively. In 2006 the Italian Cancer Pain Outcome Re-
search Study Group (CPOR) initiated a longitudinal observational
study of cancer pain patients [3]. Aiming at deciding upon which
domains to include in a ﬁrst version of an international cancer pain
classiﬁcation system, data from the CPOR study are used to answer
the following research questions:
1. Can the domains/items associated with cancer pain in the cross-
sectional EPOS study [32] be conﬁrmed in an independent
patient population?
2. Can previously identiﬁed domains relevant for cancer pain clas-
siﬁcation and/or new candidate domains be identiﬁed as pre-
dictors of pain intensity and/or pain relief in a population of
cancer patients followed prospectively?
2. Material and methods
2.1. Patients
During 2006 to 2007, the CPOR Study Group performed an
Italian multicentre, open-label, prospective, nonrandomised
observational study [2,3]. Patients with advanced cancer, persis-
tent pain of any intensity, requiring or already on analgesic treat-
ment, age P 18 years, with a life expectancy longer than
1 month, and able to provide informed consent to participate, were
included. Patients with impaired cognitive function or substance
abuse were excluded. Two samples from these data were used
for the present study:
– Sample A: cross-sectional data from patients using opioids at
the day of inclusion.
– Sample B: longitudinal data from patients newly referred to pal-
liative care.
2.2. Assessment
After inclusion, the patients were examined weekly for 4 weeks
as well as at week 12. Only data from inclusion and day 14 were
analysed in the present study. At each visit a health care provider
registered: medical history including cancer history, physical
examination data, medications and recent therapies including
analgesic consumption, and functional status assessed by the Kar-
nofsky Performance Status (KPS) [30]. Furthermore, a health care
provider completed the ECS-CP (version rESS from 2005) [15]
assessing pain mechanism, incident pain, psychological distress
and/or addictive behaviour, and cognitive function.
The patients completed a questionnaire assessing pain, other
symptoms, and common side effects of opioids at each visit. Pain
was measured using 5 questions from the Italian version of the
Brief Pain Inventory [7,10], assessing intensity of worst, actual,
least, and average pain, and pain relief, all referring to the previous
week (11-point numerical rating scales [NRS-11]). Symptoms and
side effects of medications were evaluated using a list of 23 items
from the Therapy Impact Questionnaire, a quality-of-life question-
naire developed for advanced cancer patients [46]. Each item was
rated on a 4-point verbal rating scale from 1 = absent to 4 = very
much. The previous week was used as time frame for all questions.
2.3. Analysis design – part A
Part A of the present study was a cross-sectional analysis aim-
ing at verifying the ﬁndings from the EPOS [32] in an independent
population of advanced cancer patients included in the CPOR study
Fig. 1. Flow chart presenting the analysis plan.
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[2,3]. Only patients on opioid treatment were considered in order
to replicate the design of EPOS. The following domains/items were
included as independent variables: incident pain, psychological
distress, neuropathic pain, pain localisation (back, upper and lower
extremities), sleep disturbances, total morphine equivalent daily
dose (MEDD), use of NSAIDs, addiction, cancer diagnosis (prostate
cancer), and localisation of metastases (liver), as these were the re-
sults from EPOS [32]. The following domains/items were added: 3
other prevalent cancer diagnoses (breast, lung, and gastrointestinal
cancer), bone metastases as this most often causes pain, and fur-
ther localisations of pain.
The choice of outcomes was based upon the results from an ex-
pert survey [32] and from other previous studies and included pain
intensity assessed as ‘‘pain on average’’ (NRS-11) and ‘‘pain at its
worst’’ (NRS-11) as well as ‘‘pain relief’’ (0% = no relief to
100% = complete relief), all referring to the previous week. Pain
intensity is regarded as a key domain for pain classiﬁcation and
for clinical decision-making [13]. Assessment of pain relief might
reﬂect further information about the pain and the patient’s experi-
ence [28] and was therefore added as a third outcome to strength-
en the analysis. Multivariate linear regression analysis adjusted by
centre was carried out. Backward elimination was chosen for
selecting domains/items, as a lack of high correlations between
independent and dependent domains/items is one of the assump-
tions under which this is considered a good method [43]. A P-va-
lue = 0.01 was applied for removing domains/items.
2.4. Analysis design – part B
Part B of the present study aimed at identifying predictors of
pain intensity and/or pain relief 2 weeks after initial assessment.
Both previously identiﬁed and new candidate domains/items were
explored in a population of patients admitted to palliative care
within 4 days before inclusion in the CPOR study.
Pain on average (NRS-11), pain at its worst (NRS-11), and pain
relief (0% = no relief to 100% = complete relief), all at day 14, were
deﬁned as outcomes. Titration of opioids is expected to be ﬁnalised
within 2 weeks and new major symptoms might not occur [31,47].
Table 1
Patient characteristics.
Patient characteristics Assessments at study entry
Sample A
Cross-sectional
analysis
n = 1529
Sample B
Longitudinal
analysis
n = 352
Age: mean (range)/SD 63.8 (22-92)/12.2 64.8 (26-88)/
11.9
Gender: n (%)
Male 808 (52.8) 216 (61.4)
Female 721 (47.2) 136 (38.6)
Karnofsky performance status: mean
(range)/SD
64.5 (20–100)/
16.3
62.8 (20–100)/
17.1
Time since diagnosis:a mean
(range)/SD
33.6 (0–42.6)/
47.2
n = 1517
23.7 (0–30.6)/
34.2
n = 350
Cancer diagnosis:b n (%)
Gastrointestinal 430 (28.1) 95 (27.1)
Lung 342 (22.4) 97 (27.6)
Breast 254 (16.6) 32 (9.1)
Prostate 119 (7.8) 22 (6.3)
Gyneacological 83 (5.4) 13 (3.7)
Urological 93 (6.1) 31 (8.8)
Head and neck 84 (5.5) 28 (8.0)
Unknown origin 21 (1.4) 6 (1.7)
Sarcoma 9 (0.6) 2 (0.6)
Skin 14 (0.9) 3 (0.9)
Other 79 (5.2) 22 (6.3)
Location of metastases:c n (%)
Bone 728 (47.6) 157 (44.6)
Liver 423 (27.7) 79 (22.4)
Lung 431 (28.2) 85 (24.2)
CNS 80 (5.2) 19 (5.4)
Abdominal 240 (15.7) 43 (12.2)
Lymph node 635 (41.5) 135 (38.4)
Other 271 (17.7) 57 (16.2)
None 103 (6.7) 37 (10.5)
Type of recruiting centre
Oncology centre 911 (59.6) 95 (27)
Palliative care centre 605 (39.6) 256 (72.7)
a Months.
b For sample A cancer diagnosis is not recorded in 1 patient.
c Patients may have more than one site of metastases.
Table 2
Characteristics of pain, pain treatment, and other symptoms.
Domains/items Assessments at study entry
Sample A
Cross-sectional
analysis
n = 1529
Sample B
Longitudinal
analysis
n = 352
Pain intensity on the average:a mean
(range)/SD
4.4 (0–10)/2.0 5.0 (0–9)/1.9
Pain intensity at its worst:a mean
(range)/SD
6.8 (0–10)/2.3 7.5 (0–10)/2.0
Pain relief:b mean (range)/SD 57.5 (0–100)/25.4 43.0 (0–100)/
26.6
Incident pain: c n (%)
Present 803 (52.5) 201 (57.1)
Absent 726 (47.5) 151 (42.9)
Pain mechanism:c n (%)
Neuropathic pain 388 (25.9) 86 (24.7)
Nociceptive pain 1108 (74.1) 262 (75.3)
Localisation of pain:d n (%)
Back 492 (32.2) 109 (31.0)
Pelvis 82 (5.4) 21 (6.0)
Thorax front/abdomen 785 (51.5) 171 (48.6)
Lower extremities 236 (15.5) 55 (15.6)
Upper extremities 143 (9.4) 36 (10.2)
Head 107 (7.0) 29 (8.2)
Psychological distress present:c n (%) 550 (36.0) 131 (40.2)
Cognitive function limited:c n (%) 72 (4.7) 16 (4.6)
Addictive behaviour present:c n (%) 14 (0.9) 5 (1.4)
Sleep disturbances present:e n (%) 308 (20.2) 110 (31.4)
Pharmacological pain treatment: n
(%)
Patients on opioids 1529 (100) 271 (77)
MEDD: mg (range)/SD 86.7 (1.5–1050)/
94.5
66.1 (0–1050)/
110.7
Systemic corticosteroids 661 (43.2) 124 (35.2)
NSAIDs 592 (38.7) 156 (44.3)
Anticonvulsants 257 (16.8) 38 (10.8)
Antidepressants 183 (12.0) 27 (7.7)
Anticancer treatment: n (%)
Ongoing radiotherapy 100 (6.5) 31 (8.8)
Ongoing chemotherapy 754 (49.3) 112 (31.8)
Ongoing hormone therapy 157 (10.3) 16 (4.6)
Other subjective symptoms:e n (%)
Nausea 161 (10.5) 29 (8.2)
Vomiting 91 (6.0) 11 (3,1)
Constipation 439 (28.5) 84 (24.1)
Somnolence 295 (19.3) 65 (18.5)
Vertigo 53 (3.5) 19 (5.4)
Difﬁculties swallowing 138 (9.0) 34 (15.0)
Sweating 233 (15.2) 40 (11.4)
MEDD, total oral morphine equivalent daily dose; NSAIDs, nonsteroidal antiin-
ﬂammatory drugs.
a Brief Pain Inventory: 11-point numerical rating scale (NRS).
b NRS-11 0–100%: 0% = no relief, 100% = complete relief.
c Edmonton Classiﬁcation System for Cancer Pain (ECS-CP).
d Patients may have more than one localisation of pain.
e Therapy Impact Questionnaire (TIQ): assessment on a 4-point verbal rating
scale (VRS) from 1 = absent to 4 = very much. Results refer to patients who score 3
or 4 on the VRS-4.
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The choice of which domains and items to include as candidate
predictors was based upon ﬁndings from previous studies and pro-
posed classiﬁcation systems [15,23,24,29,32,33]. A bivariate corre-
lation analysis (Pearson correlation coefﬁcientP 0.1) was used to
decide upon which domains to enter into multivariate linear
regression models. Fractional polynomials [42] were applied to
investigate possible nonlinear functional relationships for continu-
ous domains/items in the models; the combination of linear and
nonlinear domains/items was tested through backward elimina-
tion. A P-value = 0.05 was applied for removing domains/items,
which is different from the P-value used in the cross-sectional
analysis. Reasons for this were the smaller sample size and the
explorative aim of the study. For both parts A and B, standardised
regression coefﬁcients from the ﬁnal regression models were pre-
sented with 95% conﬁdence intervals, and adjusted R2 was used
as indicator of the amount of variance in the outcome explained
by the included domains/items.
2.5. Ethics
The study complied with Italian requirements for observational
studies. The protocol was approved by each Local Research Ethics
Committee of participating centres. All patients gave written in-
formed consent to participate in the study.
3. Results
There were 1801 patients from 110 Italian centres included in
the CPOR. The samples for the cross-sectional and the longitudinal
analyses included 1529 patients on opioids, and 352 patients new-
ly admitted to palliative care, respectively. Flow charts explaining
eligibility criteria are shown in Fig. 1. Patients’ characteristics are
shown in Table 1 and characteristics of pain and other symptoms
are shown in Table 2. In both samples the most common cancer
diagnoses were gastrointestinal, lung, and breast cancer.
3.1. Sample A
Among the 1529 patients on opioids included in the cross-sec-
tional analysis, 53% were male and 47% female, their mean age was
64 years, and mean KPS was 64.5. Forty-eight percent had bone
metastases (Table 1). Pain intensity measured on average was
4.4, pain at its worst was 6.8, and pain relief was 57.5%. Fifty-
two percent of the patients had incident pain, and 26% had
neuropathic pain. The average oral MEDD was 87 mg. Sixty percent
were treated in an oncology department and 40% in a palliative
care centre. About 2/3 received tumour-directed treatment
(Table 2).
3.1.1. Part A – Cross-sectional analyses
Table 3 shows the results from the cross-sectional multivariate
analyses. The domains incident pain, pain localisation (upper
extremities and head), MEDD, the use of NSAIDs, and sleep distur-
bances were statistically signiﬁcantly associated with one or more
of the outcomes. If incident pain was present, pain intensity on
average would increase with 0.64 (beta) on an NRS-11, and pain
at its worst would increase with 0.87 compared with patients
without incident pain. The standardised betas allow for compari-
son of the impact of the included domains/items on the outcomes
regardless of scales used. Incident pain and sleep showed the high-
est standardised betas (0.16/0.20 and 0.16/0.14/-0.15, respec-
tively), which indicates the highest relevance among the
examined domains. The explained variance for the regression mod-
els (adjusted R2) varied from 0.21 to 0.26.
3.2. Sample B
Among the 352 patients on their ﬁrst visit to palliative care in-
cluded in the longitudinal analyses, 61% were male and 39% fe-
male, the mean age was 65 years, mean KPS was 62.8, and 45%
had bone metastases (Table 1). Table 2 shows that pain intensity
measured on average was 5.0, worst pain was 7.5, and pain relief
43%. Fifty-seven percent of these patients had incident pain, and
25% had neuropathic pain. The average MEDD was 66 mg. The per-
centage of patients on opioids at inclusion was 77% and at day 14 it
was 94%. In 300 patients (85.2%), a change in the pharmacological
treatment was recorded during the ﬁrst 2 weeks. At day 14 the
pain scores were as follows: average pain 3.5, worst pain 5.3, and
pain relief 63%. The majority were treated in a palliative care centre
(73%). About 45% received tumour-directed treatment.
3.2.1. Part B – Longitudinal analyses – step 1
In the bivariate analysis (Table 4), the domains initial pain
intensity, initial pain relief, incident pain, neuropathic pain, pain
localisation (thorax/abdomen), sleep disturbances, and ongoing
radiotherapy showed a correlationP 0.1 with all 3 outcomes. Lung
cancer, abdominal metastases, constipation, and sweating showed
a signiﬁcant correlation with 2 of the outcomes. The following 9
Table 3
Results from cross-sectional analyses (part A).
Domains Outcomes
Pain on average last week NRS-11 (BPI)
n = 1520
Pain at its worst last week NRS-11 (BPI)
n = 1480
Pain relief last week NRS-11 (BPI)
n = 1480
Beta a CI Stand. beta Beta CI Stand. beta Beta CI Stand. beta
Const. 1.73⁄⁄⁄ 1.04–2.41 – 5.39⁄⁄⁄ 4.38–6.41 – 58.1⁄⁄⁄ 48.0–68.2 –
Incident pain 0.64⁄⁄⁄ 0.44–0.84 0.16⁄⁄⁄ 0.87⁄⁄⁄ 0.63–1.11 0.20⁄⁄⁄ – – –
Sleep 0.39⁄⁄⁄ 0.28–0.50 0.16⁄⁄⁄ 0.38⁄⁄⁄ 0.24–0.51 0.14⁄⁄⁄ 4.7⁄⁄⁄ 6.2–3.2 0.15⁄⁄⁄
Pain localisation:
Upper extremities 0.53⁄⁄ 0.21–0.84 0.08⁄⁄ – – –
Head – – – – – – 6.1⁄⁄ 10.6–1.5 0.06⁄⁄
MEDD at inclusion (mg) – – – 0.17⁄⁄ 0.07–0.27 0.08⁄⁄ – – –
Use of NSAIDs – – – 0.36⁄⁄ 0.12–0.60 0.08⁄⁄ – – –
Adjusted R2 0.26 0.21 0.22
NRS-11, 11-point numerical rating scale; BPI, Brief Pain Inventory; CI, 95% conﬁdence interval; Stand. beta, Standardised beta (ranging from 1 to +1); MEDD, total morphine
equivalent daily dose; NSAIDs, nonsteroidal antiinﬂammatory drugs.
Table 3 shows the results from the multivariate linear regression analysis of the cross-sectional Cancer Pain Outcome Research Study Group data on advanced cancer patients
on opioids, n = 1529. It was adjusted by study centre. The P-value used for removing domains in the backward procedure was 0.01. R2 is the variance explained by the
domains included in each of the models.
⁄P < 0.05; ⁄⁄P < 0.01; ⁄⁄⁄P < 0.001.
a Regression coefﬁcient.
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domains/items showed signiﬁcant correlation with only one of the
3 outcomes: psychological distress, MEDD, use of anticonvulsants,
age, time since cancer diagnosis, gastrointestinal cancer, nausea,
vertigo, and difﬁculties swallowing. In total, 21 domains/items
showed a correlationP 0.1 with one or more of the outcomes.
The correlation between initial pain intensity measured as ‘‘pain
on average’’ and as ‘‘pain at its worst’’ was 0.72. To avoid multicol-
linearity, only ‘‘pain on average’’ was used, thus 20 domains/items
were included for further investigation.
3.2.2. Part B – Longitudinal analyses – step 2
Table 5 shows the results from the multivariate regression anal-
ysis of the longitudinal CPOR data. Six domains were shown to be
predictors in one or more of the ﬁnal regression models: initial
pain intensity (on average), initial pain relief, incident pain, locali-
sation of pain (thorax/abdomen), cancer diagnosis (lung cancer),
and age (younger). If incident pain was present, pain intensity on
average at day 14 would increase with 0.44 (beta) on an NRS-11
compared with patients without incident pain, and patients with
Table 4
Results from bivariate analysis of longitudinal data (part B).
Outcomes Pain on average a at day 14
n = 352
Pain at its worst a at day 14
n = 352
Pain relief b at day 14
n = 352
Pain scores at day 14: Mean (range)/SD 3.5 (0–9)/1.9 5.3 (0–10)/2.2 63 (0–100)/24.3
Candidate domains/items
Pain intensity on average a at inclusion 0.45 c 0.36 0.32
Pain intensity at its worst a at inclusion 0.26 0.33 0.22
Pain relief at inclusion b 0.22 0.16 0.36
Incident pain 0.19 0.16 0.15
Neuropathic pain 0.18 0.12 0.18
Localisation of pain
Head 0.07 0.07 0.07
Thorax/abdomen 0.15 0.17 0.20
Pelvic 0.006 0.04 0.02
Back 0.06 0.08 0.09
Upper extremities 0.08 0.04 0.05
Lower extremities 0.07 0.09 0.05
Age 0.06 0.12 0.09
Gender 0.06 0.02 0.07
Karnofsky performance status 0.03 0.0006 0.03
Physical functioning d 0.03 0.009 0.03
Psychological distress 0.07 0.11 0.03
Cognitive functioning 0.02 0.03 0.02
Addictive behaviour 0.03 0.008 0.01
Sleep disturbances 0.15 0.14 0.12
Time since diagnosis 0.08 0.12 0.07
Cancer diagnosis
Gastrointestinal 0.11 0.09 0.06
Lung 0.11 0.11 0.10
Breast 0.03 0.02 0.02
Prostate 0.004 0.03 0.01
Metastases
Bone 0.07 0.06 0.04
Liver 0.07 0.001 0.02
Lung 0.05 0.06 0.03
CNS 0.006 0.02 0.08
Abdominal 0.11 0.12 0.06
Lymph nodes 0.03 0.04 0.09
Treatment
MEDD 0.09 0.10 0.03
Steroids 0.07 0.05 0.08
NSAIDs 0.05 0.05 0.07
Anticonvulsants 0.09 0.08 0.11
Antidepressants 0.02 0.04 0.01
Ongoing chemotherapy 0.02 0.004 0.09
Ongoing radiotherapy 0.13 0.10 0.11
Ongoing hormone therapy 0.01 0.4 0.009
Other symptoms (TIQ) e
Nausea 0.03 0.11 0.06
Vomiting 0.03 0.09 0.05
Constipation 0.08 0.12 0.04
Somnolence 0.06 0.07 0.02
Vertigo 0.07 0.09 0.10
Difﬁculties swallowing 0.11 0.09 0.09
Sweating 0.11 0.11 0.08
CNS, central nervous system; MEDD, total morphine equivalent daily dose; NSAIDs, nonsteroidal antiinﬂammatory drugs.
Table 4 shows the results from the bivariate correlation analysis of the longitudinal Cancer Pain Outcome Research Study Group data on advanced cancer patients just
admitted to palliative care; n = 352. The Pearson coefﬁcient > 0.1 was used to decide upon which domains to enter into multivariate linear regression models.
a From Brief Pain Inventory, assessed on an 11-point numerical rating scale (NRS-11).
b From Brief Pain Inventory, assessed on an NRS-11: 0% no relief, 100% complete relief.
c Pearson correlation coefﬁcient (r).
d Assessed as total score of basic activities of daily living (B-ADL).
e Therapy Impact Questionnaire, assessment on a 4-point verbal rating scale (VRS) from 1 = absent to 4 = very much.
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lung cancer scored pain intensity on average 0.59 (NRS-11) higher
than patients without lung cancer. A 1-year increase in age re-
sulted in a reduction of pain intensity (pain at its worst) of 0.02
on an NRS-11, that is, younger age implied higher pain scores.
The standardised betas for the longitudinal regression models
showed the domains’ impact on the outcomes in the following or-
der: initial pain intensity, initial pain relief, pain localisation, can-
cer diagnosis (lung), incident pain, and age. The explained
variance for the regression models (adjusted R2) varied from 0.16
to 0.24. No evidence of nonlinearity was identiﬁed.
4. Discussion
The present study aimed at contributing to the development of
an international cancer pain classiﬁcation system. In the cross-sec-
tional analysis, 5 domains (incident pain, pain localisation, sleep
disturbances, initial MEDD, and the use of NSAIDs) were associated
with pain in a large population of Italian advanced cancer patients
on opioids. Incident pain, sleep disturbances, and pain localisation
were associated with 2 or 3 of the outcomes and showed the high-
est standardised betas. In the longitudinal analysis, 6 domains
were identiﬁed as predictors of pain intensity and/or pain relief
at day 14. Initial pain intensity was the most important domain,
contributing signiﬁcantly to all 3 ﬁnal models and showing the
highest standardised betas. The other domains were initial pain re-
lief, incident pain, pain localisation, cancer diagnosis (lung), and
younger age. For all pain outcomes, the identiﬁed predictors ex-
plained only a minor part of the variability.
Fainsinger et al. [14] recently published an international multi-
centre study showing that initial pain intensity, psychological dis-
tress, incident pain, neuropathic pain, and younger age were
associated with longer time to achieve stable pain control. The
importance of 3 of these domains was conﬁrmed in the longitudi-
nal part of the present study. Pain intensity has a key role in the
management of cancer pain guiding clinical decision-making
[12,13]. More severe pain mainly indicates that the patient is
undertreated and/or that the pain condition is difﬁcult to treat.
Incident pain is a common and problematic domain in cancer pa-
tients that also has been shown to predict more complex pain
[6,34,40]. To be aware that a patient at younger age may have a
more complex pain condition than older patients is of clinical
relevance; this may be due to differences in physiology [11] or
more difﬁculties in coping with pain [18].
Initial pain relief was identiﬁed as a predictor of improved pain
relief after 2 weeks. This domain may contain more information
than pure pain, for example, coping ability, and may therefore
add relevant information for diagnosing a complex pain condition.
Pain localisation was also among the results in both the cross-sec-
tional and the longitudinal analyses of the present study and in the
EPOS study [32], however, the sites varied. The repeated ﬁnding of
the relevance of pain localisation suggests that its assessment, for
example, by a body map, should be a part of a cancer pain classiﬁ-
cation system. Lung cancer was identiﬁed as a negative predictor in
all 3 longitudinal regression models of CPOR, indicating that differ-
ent cancer diagnoses may cause different pain features. The ability
to associate different pain conditions to different tumour lesions
may improve clinical pain diagnosis [4,17]. Poor sleep was associ-
ated with all 3 outcomes in the cross-sectional analysis, conﬁrming
that sleep disturbances may indicate a poorly controlled pain situ-
ation [32] or that poor sleep itself may cause more pain [44]. A
higher prevalence of trouble sleeping in cancer patients than in
the general population has been reported [37]. This underlines
the relevance of assessing sleep disturbances as one aspect of
interference in cancer pain patients. Cognitive function and addic-
tive behaviour are 2 of the 5 domains included in the ECS-CP, but
because these were related to the exclusion criteria in the CPOR
study, further investigation of these domains was not possible.
Unexpectedly, neither neuropathic pain nor psychological dis-
tress predicted pain outcomes in this study. Neuropathic pain is
considered to be a problematic pain situation needing speciﬁc
therapeutic strategies [8,19]. For the assessment of neuropathic
pain, the previous version of the ECS-CP (rESS) [15] was used, ask-
ing the health care provider to state if neuropathic pain was pres-
ent or not. IASP recently published revised guidelines on
neuropathic pain assessment [19] recommending the combination
of neuropathic pain screening tools, clinical interview, and clinical
examination including sensory examination. To follow the IASP
recommendations may have given other results regarding neuro-
pathic pain. Several previous studies have shown a signiﬁcant
association between cancer pain and psychological distress
[36,48], and in the last validation study of the ECS-CP, psychologi-
cal distress was associated with longer time to achieve pain control
[14]. Differences in assessment may be one explanation for not
Table 5
Results from multivariate analysis of longitudinal data CPOR (part B).
Domains Outcomes
Pain on average last week NRS-11 (BPI)
n = 348
Pain at its worst last week NRS-11 (BPI)
n = 351
Pain relief last week NRS-11 (BPI)
n = 348
Beta a CI Stand. beta Beta CI Stand. beta Beta CI Stand. beta
Const. 0.81 0.28–1.34 – 4.53 3.19–5.87 – 62.1 50.1–73.2 –
Initial pain intensity b 0.44⁄⁄⁄ 0.35–0.54 0.45⁄⁄⁄ 0.44⁄⁄⁄ 0.33–0.55 0.38⁄⁄⁄ 2.1⁄ 3.5 to 6.1 0.16⁄⁄
Initial pain relief c – – – – – – 2.4⁄⁄⁄ 1.4–3.4 0.26⁄⁄⁄
Incident pain 0.44⁄ 0.08–0.80 0.14⁄⁄ – – – – – –
Localisation of pain: thorax/abdomen – – – – – – 7.2⁄⁄ 2.4–11.9 0.15⁄⁄
Cancer diagnosis: lung cancer 0.59⁄⁄ 0.20–0.99 0.14⁄⁄ 0.61⁄ 0.13–1.09 0.12⁄ 7.5⁄⁄ 12.7 to 2.3 0.14⁄⁄
Age – – – 0.02⁄⁄ 0.04 to 0.01 0.13⁄⁄ – – –
Adjusted R2 0.24 0.16 0.18
CPOR, Cancer Pain Outcome Research Study Group; NRS-11 = 11-point numerical rating scale; BPI, Brief Pain Inventory; CI, 95% conﬁdence interval; Stand. beta, Standardised
beta (ranging from 1 to +1).
Table 5 shows the results from the multivariate linear regression analysis of the longitudinal CPOR data on advanced cancer patients recently admitted to palliative care;
n = 352. The P-value used or removing domains in the backward procedure was 0.05. No adjustment was performed. R2 is the variance explained by the domains included in
each of the models.
⁄P < 0.05, ⁄⁄P < 0.01, ⁄⁄⁄P < 0.001.
a Regression coefﬁcient.
b 11-point NRS.
c NRS-11: 0% = no relief, 100% = complete relief.
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conﬁrming this in the CPOR population. Psychological distress was
measured by a health care provider by recording if psychological
distress was present or not using the 2005 version of the ECS-CP
[15]. However, the researchers in the ECS-CP validation study were
systematically trained in the use of the ECS-CP, a training not given
in the CPOR study.
Instead of educating the clinicians in measurement of subjective
symptoms, the patients can be asked directly. The use of patients’
self-report of subjective symptoms may be more reliable and has
been recommended as the gold standard [16]. In the EPOS study
[32], psychological distress was measured by using the emotional
functioning scale of the European Organization for Research and
Treatment of Cancer QLQ-C30 questionnaire [1], that is, patients’
self-report, and was one of the identiﬁed key domains. The assess-
ment of incident pain also varies considerably [20]. In CPOR it was
evaluated as a dichotomised yes/no-question focusing on pain with
a known trigger, as in a previous version of the ECS-CP; the rESS [15].
Even with such a narrow deﬁnition and assessment performed by a
health care provider, itwas shown tobe a robust domain for the clas-
siﬁcation and prognostication of difﬁcult pain conditions.
An important strengthof thepresent study is the longitudinal de-
sign of CPOR. Instead of only describing possible associations in
cross-sectional data, the longitudinal design allows for analysis of
whether domains can predict pain outcomes after a period of time,
that is, prognostication, which is the actual purpose of a cancer pain
classiﬁcation system. There are important limitations of the present
study. CPOR was initially designed for another purpose, and cancer
patients in Italy use less opioids than inmany other European coun-
tries [9]. There were considerable between-centre differences with
regard to pain scores and treatments offered, which may be ex-
plained by the fact that more than 100 centres participated in the
study. The CPOR patients had higher pain scores and used consider-
ably lower daily oral morphine equivalent doses as compared with
the EPOS population. Despite the heterogeneity, 5 of 10 domains
fromEPOSwere conﬁrmed tobeof importance in the cross-sectional
CPOR population, and 2 of these were also among the longitudinal
results, indicating their robustness. Different outcomes are used
across cancer pain studies, for example, time to achieve pain control,
ﬁnal opioid dose, number of other modalities to achieve stable pain
control [14], pain relief [25], andpain intensity [39],whichmaybean
important reason for differences in domains demonstrating rele-
vance. A recent expert conference recommended the use of pain
intensity, pain relief, and temporal pattern of pain as outcomes in
clinical practice and research [29].
Our models explained 16% to 26% of the variability of the pain
outcomes. This may be explained either by the lack of accurate
assessment or by the incomplete relevance of the clinical domains
included. The use of crude assessment methods of ﬂuctuating and
complex domains in patients with advanced disease is common,
for example, incident pain, neuropathic pain, and psychological
distress were measured dichotomously. By applying a continuous
measure such as a NRS-11, it might have been possible to explain
more of the variability. Furthermore, the low explained variance
indicates that aspects other than the investigated ones, such as ge-
netic variability or variability in pain perception and susceptibility,
may inﬂuence cancer pain. Other pain studies have reported simi-
lar (14%–35%) [21], but also higher explained variance: 39% to 48%,
and 67%, respectively [27,41].
Current knowledge does not result in a diagnostic tool that canbe
used to precisely predict future outcomes in cancer pain, but points
towards some domains that increase the risk for the patients to
experience more severe cancer pain in the future. At present, 4 do-
mains are considered core domains of a cancer pain classiﬁcation
system: pain intensity, pain mechanism, incident pain, and psycho-
logical distress [29]. The results from the present study suggest that
the following further domains may be considered for inclusion in a
cancerpain classiﬁcationsystem:pain relief, pain localisation, initial
MEDD, use of adjuvants, sleep disturbances, age, and cancer diagno-
sis. One example of clinical utility of such knowledge is: a young pa-
tient having severe pain, incident pain, and lung cancer is
challenging to treat, and special attention should be given to pain
treatment and treatment response. A classiﬁcation or prognostic
systemmust be considered dynamic. Analogue to the development
of the TNM (tumor-nodes-metastasis) system [26,38], newdomains
should be added when new evidence identiﬁes domains that im-
prove the predictive ability of the cancer pain classiﬁcation system
[29]. Prospective international studies designed for the purpose of
pain classiﬁcation in a well-deﬁned population of cancer patients
with standardised assessment and relevant outcomeswould benec-
essary further steps towards achieving consensus on an interna-
tional cancer pain classiﬁcation system.
Conﬂict of interest statement
G. Apolone received consultancy and lecture fees from Grunen-
thal and Cephalon Italy. O. Corli received consultancy fees from
Grunenthal and ProStrakan Italy.
Acknowledgements
This study was supported by the EU’s 6th framework, contract
no. 037777 and partially funded by the Floriani Foundation of Mi-
lan and by the Italian Association for Cancer Research (AIRC) (Grant
IG 9347). Grunenthal Italy partially supported the Cancer Pain Out-
come Research study with an educational unrestricted grant. The
Norwegian Cancer Society supports the European Palliative Care
Research Centre. Anne Kari Knudsen received a grant from the Cen-
tral Norway Regional Health Authority.
Appendix A. European Palliative Care Research Collaborative
(EPCRC)
The European Palliative Care Research Collaborative was funded
by the European Commission’s Sixth Framework Programme (con-
tract no LSHC-CT-2006-037777) with the overall aim to improve
treatment of pain, depression, and fatigue through translation re-
search. Core scientiﬁc group/work package leaders: Stein Kaasa (pro-
ject coordinator), Frank Skorpen, Marianne Jensen Hjermstad, and
Jon Håvard Loge, Norwegian University of Science and Technology
(NTNU); Geoffrey Hanks, University of Bristol; Augusto Caraceni
and Franco De Conno, Fondazione IRCCS Istituto Nazionale dei
Tumori, Milan; Irene Higginson, King’s College London; Florian
Strasser, Cantonal Hospital St. Gallen; Lukas Radbruch, RWTH Aa-
chen University; Kenneth Fearon, University of Edinburgh; Hell-
mut Samonigg, Medical University of Graz; Ketil Bø, Trollhetta
AS, Norway; Irene Rech-Weichselbraun, Bender MedSystems
GmbH, Austria; Odd Erik Gundersen, Verdande Technology AS,
Norway. Scientiﬁc advisory group: Neil Aaronson, The Netherlands
Cancer Institute; Vickie Baracos and Robin Fainsinger, University
of Alberta; Patrick C. Stone, St. George’s University of London; Mari
Lloyd-Williams, University of Liverpool. Project management: Stein
Kaasa, Ola Dale, and Dagny F. Haugen, NTNU.
References
[1] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A,
Flechtner H, Fleishman SB, de Haes JC, Kaasa S, Klee M, Osoba D, Razavi D, Rofe
RB, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European Organization for
Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for
use in international clinical trials in oncology. J Natl Cancer Inst
1993;85:365–76.
[2] Apolone G, Bertetto O, Caraceni A, Corli O, De Conno F, Labianca R, Maltoni M,
Nicora M, Torri V, Zucco F. Pain in cancer. An outcome research project to
702 A.K. Knudsen et al. / PAIN

153 (2012) 696–703
evaluate the epidemiology, the quality and the effects of pain treatment in
cancer patients. Health Qual Life Outcomes 2006;4:7.
[3] Apolone G, Corli O, Caraceni A, Negri E, Deandrea S, Montanari M, Greco MT.
Pattern and quality of care of cancer pain management. Results from the
Cancer Pain Outcome Research Study Group. Br J Cancer 2009;100:1566–74.
[4] Banning A, Sjogren P, Henriksen H. Pain causes in 200 patients referred to a
multidisciplinary cancer pain clinic. Pain 1991;45:45–8.
[5] Boisvert M, Cohen SR. Opioid use in advanced malignant disease: why do
different centers use vastly different doses? A plea for standardized reporting. J
Pain Symptom Manage 1995;10:632–8.
[6] Caraceni A, Martini C, Zecca E, Portenoy RK, Ashby MA, Hawson G, Jackson KA,
Lickiss N, Muirden N, Pisasale M, Moulin D, Schulz VN, Rico Pazo MA, Serrano
JA, Andersen H, Henriksen HT, Mejholm I, Sjogren P, Heiskanen T, Kalso E, Pere
P, Poyhia R, Vuorinen E, Tigerstedt I, Ruismaki P, Bertolino M, Larue F, Ranchere
JY, Hege-Scheuing G, Bowdler I, Helbing F, Kostner E, Radbruch L, Kastrinaki K,
Shah S, Vijayaram S, Sharma KS, Devi PS, Jain PN, Ramamani PV, Beny A,
Brunelli C, Maltoni M, Mercadante S, Plancarte R, Schug S, Engstrand P, Ovalle
AF, Wang X, Alves MF, Abrunhosa MR, Sun WZ, Zhang L, Gazizov A, Vaisman M,
Rudoy S, Gomez SM, Vila P, Trelis J, Chaudakshetrin P, Koh ML, Van Dongen RT,
Vielvoye-Kerkmeer A, Boswell MV, Elliott T, Hargus E, Lutz L. Working Group of
an ITFoCP. Breakthrough pain characteristics and syndromes in patients with
cancer pain. An international survey. Palliat Med 2004;18:177–83.
[7] Caraceni A, Mendoza TR, Mencaglia E, Baratella C, Edwards K, Forjaz MJ,
Martini C, Serlin RC, de Conno F, Cleeland CS. A validation study of an Italian
version of the Brief Pain Inventory (Breve Questionario per la Valutazione del
Dolore). Pain 1996;65:87–92.
[8] Caraceni A, Weinstein SM. Classiﬁcation of cancer pain syndromes. Oncology
(Williston Park) 2001;15:1627–40.
[9] Cherny NI, Baselga J, de Conno F, Radbruch L. Formulary availability and
regulatory barriers to accessibility of opioids for cancer pain in Europe: a
report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol
2010;21:615–26.
[10] Daut RL, Cleeland CS, Flanery RC. Development of the Wisconsin Brief Pain
Questionnaire to assess pain in cancer and other diseases. Pain
1983;17:197–210.
[11] Delgado-Guay MO, Wollner D. Managing cancer pain in the elderly. In: Bruera
ED, Portenoy RK, editors. Cancer pain assessment and management. New
York: Cambridge University Press; 2010. p. 444–5.
[12] Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns
RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R,
Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG,
McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP,
Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J,
Witter J. Core outcome measures for chronic pain clinical trials: IMMPACT
recommendations. Pain 2005;113:9–19.
[13] Fainsinger RL, Fairchild A, Nekolaichuk C, Lawlor P, Lowe S, Hanson J. Is pain
intensity a predictor of the complexity of cancer pain management? J Clin
Oncol 2009;27:585–90.
[14] Fainsinger RL, Nekolaichuk C, Lawlor P, Hagen N, Bercovitch M, Fisch M,
Galloway L, Kaye G, Landman W, Spruyt O, Zhukovsky D, Bruera E, Hanson J.
An international multicentre validation study of a pain classiﬁcation system
for cancer patients. Eur J Cancer 2010;46:2896–904.
[15] Fainsinger RL, Nekolaichuk CL, Lawlor PG, Neumann CM, Hanson J, Vigano A. A
multicenter study of the revised Edmonton Staging System for classifying
cancer pain in advanced cancer patients. J Pain Symptom Manage
2005;29:224–37.
[16] Fayers PM. D. Quality of life. The assessment, analysis and interpretation of
patient-reported outcomes. West Sussex, UK: Wiley; 2007.
[17] Foley KM. Pain syndromes in patients with cancer. In: Bonica JJ, Ventafridda V,
editors. Advances in pain research and therapy. New York: Raven Press; 1979.
p. 59–75.
[18] Gagliese L, Jovellanos M, Zimmermann C, Shobbrook C, Warr D, Rodin G. Age-
related patterns in adaptation to cancer pain: a mixed-method study. Pain
Med 2009;10:1050–61.
[19] Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, Cruccu G,
Hansson P, Haythornthwaite JA, Iannetti GD, Jensen TS, Kauppila T, Nurmikko
TJ, Rice AS, Rowbotham M, Serra J, Sommer C, Smith BH, Treede RD. NeuPSIG
guidelines on neuropathic pain assessment. Pain 2011;152:14–27.
[20] Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S. Assessment and
classiﬁcation of cancer breakthrough pain: a systematic literature review. Pain
2010;149:476–82.
[21] Hill JC, Lewis M, Sim J, Hay EM, Dziedzic K. Predictors of poor outcome in
patients with neck pain treated by physical therapy. Clin J Pain
2007;23:683–90.
[22] Hjermstad MJ, Fainsinger R, Kaasa S. Assessment and classiﬁcation of cancer
pain. Curr Opin Support Palliat Care 2009;3:24–30.
[23] Hjermstad MJ, Gibbins J, Haugen DF, Caraceni A, Loge JH, Kaasa S. Pain
assessment tools in palliative care: an urgent need for consensus. Palliat Med
2008;22:895–903.
[24] Holen JC, Hjermstad MJ, Loge JH, Fayers PM, Caraceni A, De CF, Forbes K, Furst
CJ, Radbruch L, Kaasa S. Pain assessment tools: is the content appropriate for
use in palliative care? J Pain Symptom Manage 2006;32:567–80.
[25] Hwang SS, Chang VT, Fairclough DL, Kasimis B. Development of a cancer pain
prognostic scale. J Pain Symptom Manage 2002;24:366–78.
[26] International Union Against Cancer, Sobin LH, Wittekind C, editors. TNM
classiﬁcation of malignant tumours. New York: Wiley-Liss; 2002.
[27] Jacobsen R, Moldrup C, Christrup L, Sjogren P, Hansen OB. Psychological and
behavioural predictors of pain management outcomes in patients with cancer.
Scand J Caring Sci 2010;24:781–90.
[28] Jensen MP, Chen C, Brugger AM. Postsurgical pain outcome assessment. Pain
2002;99:101–9.
[29] Kaasa S, Apolone G, Klepstad P, Loge JH, Hjermstad MJ, Corli O, Strasser F,
Heiskanen T, Costantini M, Zagonel V, Groenvold M, Fainsinger R, Jensen M,
Farrar J, McQuay H, Rothrock N, Cleary J, Deguines C, Caraceni A. Expert
conference on cancer pain assessment and classiﬁcation, the need for
international consensus: working proposals on international standards. BMJ
Support Palliat Care 2011;1:281–7.
[30] Karnofsky DA, Abelmann WH, Craver LF, Burchenal J. The use of nitrogen
mustards in the palliative treatment of carcinoma. Cancer 1948:634–56.
[31] Klepstad P, Kaasa S, Skauge M, Borchgrevink PC. Pain intensity and side effects
during titration of morphine to cancer patients using a ﬁxed schedule dose
escalation. Acta Anaesthesiol Scand 2000;44:656–64.
[32] Knudsen AK, Brunelli C, Kaasa S, Apolone G, Corli O, Montanari M, Fainsinger R,
Aass N, Fayers P, Caraceni A, Klepstad P. Which variables are associated with
pain intensity and treatment response in advanced cancer patients?
Implications for a future classiﬁcation system for cancer pain. Eur J Pain
2011;15:320–7.
[33] Knudsen AK, Aass N, Fainsinger R, Caraceni A, Klepstad P, Jordhoy M,
Hjermstad MJ, Kaasa S. Classiﬁcation of pain in cancer patients—a systematic
literature review. Palliat Med 2009;23:295–308.
[34] Mercadante S, Costanzo BV, Fusco F, Butta V, Vitrano V, Casuccio A.
Breakthrough pain in advanced cancer patients followed at home: a
longitudinal study. J Pain Symptom Manage 2009;38:554–60.
[35] Nekolaichuk CL, Fainsinger RL, Lawlor PG. A validation study of a pain
classiﬁcation system for advanced cancer patients using content experts: the
Edmonton Classiﬁcation System for Cancer Pain. Palliat Med 2005;19:466–76.
[36] O’Connor M, Weir J, Butcher I, Kleiboer A, Murray G, Sharma N,
Thekkumpurath P, Walker J, Fallon M, Storey DJ, Sharpe M. Pain in patients
attending a specialist cancer service. prevalence and association with
emotional distress. J Pain SymptomManage 2011 Jun 14 [Epub ahead of print].
[37] Palesh OG, Roscoe JA, Mustian KM, Roth T, Savard J, Ancoli-Israel S, Heckler C,
Purnell JQ, Janelsins MC, Morrow GR. Prevalence, demographics, and
psychological associations of sleep disruption in patients with cancer:
University of Rochester Cancer Center-Community Clinical Oncology
Program. J Clin Oncol 2010;28:292–8.
[38] Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: signiﬁcance for
the prognostic classiﬁcation of cancer. Cancer 1996;77:834–42.
[39] Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-
controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal
Spray (FPNS) in the treatment of breakthrough cancer pain. Pain
2010;151:617–24.
[40] Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and
impact in patients with cancer pain. Pain 1999;81:129–34.
[41] Raftery MN, Sarma K, Murphy AW, De la Harpe D, Normand C, McGuire BE.
Chronic pain in the Republic of Ireland—community prevalence, psychosocial
proﬁle and predictors of pain-related disability: results from the Prevalence,
Impact and Cost of Chronic Pain (PRIME) study, part 1. Pain
2011;152:1096–103.
[42] Royston P, Sauerbrei W. Stability of multivariable fractional polynomial
models with selection of variables and transformations: a bootstrap
investigation. Stat Med 2003;22:639–59.
[43] Sauerbrei W, Royston P, Binder H. Selection of important variables and
determination of functional form for continuous predictors in multivariable
model building. Stat Med 2007;26:5512–28.
[44] Savard J, Morin CM. Insomnia in the context of cancer: a review of a neglected
problem. J Clin Oncol 2001;19:895–908.
[45] Sloan JA, Frost MH, Berzon R, Dueck A, Guyatt G, Moinpour C, Sprangers M,
Ferrans C, Cella D. The clinical signiﬁcance of quality of life assessments in
oncology: a summary for clinicians. Support Care Cancer 2006;14:988–98.
[46] Tamburini M, Rosso S, Gamba A, Mencaglia E, De Conno F, Ventafridda V. A
therapy impact questionnaire for quality-of-life assessment in advanced
cancer research. Ann Oncol 1992;3:565–70.
[47] Vijayaram S, Ramamani PV, Chandrashekhar NS, Sudharshan R, Heranjal R,
Lobo B, Obedullah D, Bhargava MK. Continuing care for cancer pain relief with
oral morphine solution. One-year experience in a regional cancer center.
Cancer 1990;66:1590–5.
[48] Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the
literature. J Pain Symptom Manage 2002;24:526–42.
A.K. Knudsen et al. / PAIN

153 (2012) 696–703 703
Appendix

Appendix
Contents
1. Search string (paper I) 
2. Edmonton Symptom Assessment System (ESAS)  in Norwegian (paper II) 
3. Edmonton Symptom Assessment System (ESAS)  in German (paper II) 
4. Brief Pain Inventory (BPI) in English (paper III) 
5. European Organization for Research and Treatment of Cancer Core Quality of 
Life Questionnaire-C30 version 3.0 (EORTC-QLQ-C30)  (paper III) 
6. Items from BPI and Therapy Impact Questionnaire (TIQ) in Italian (paper IV) 
7. Karnofsky Performance Status (paper II, III and IV) 
8. Mini Mental Status Exam (MMSE) (paper III) 
9. Mini Mental Status Exam (MMSE) short version (paper II)  
10. Revised Edmonton Staging System (rESS) (paper IV) 
11. Edmonton Classification System for Cancer Pain (ECS-CP) 
Search string used for paper I  
Ovid MEDLINE 15 February 2007 
# Search History 
1 (classif$ adj5 pain).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
2 (Cut point$ adj5 pain).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
3 (Staging adj5 pain).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
4 (Categor$ adj5 pain).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
5  (pain adj5 character$).mp.  [mp=title, original title, abstract, name of substance word, subject heading word] 
6 (grad$ adj5 pain).mp. [mp=title, original title, abstract, name of substance word, subject heading word] 
7 (1 or 2 or 3 or 4 or 5 or 6) and (cancer.mp. or exp Neoplasms/)  Limit to Humans 
St.Olavs Hospital
Hvordan har du det i dag?
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligIngen
Smerte -  i ro
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligIngen
Smerte -  ved bevegelse
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligIngen
Slapphet
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligIngen
Kvalme
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligIngen
Tungpust
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligIngen
Munntørrhet
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligMeget bra
Matlyst
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligIngen
Angst/uro
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligIngen
Trist / deprimert
0 1 2 3 4 5 6 7 8 9 10 Verst tenkeligMeget bra
Alt tatt i betraktning, hvordan har du det i dag?
ESAS (Edmonton Symptom Assessment Scale)
Utfylt av:
Dato
. .
Tidspunkt
Fødselsnr
Navn
Seksjon lindrende behandling, Kreftavdelingen. Sist endret: 18.11.2007
Draft
EPCRC Patients’ experiences with pain and depression-a qualitative study  
EPCRC-CSA German Version (adapted) 
0      1       2       3     4     5     6     7     8     9     10 
0      1       2       3     4     5     6     7    8     9     10 
0      1       2       3     4     5     6     7     8     9     10 
0      1       2       3     4     5     6     7     8     9     10 
0      1       2       3     4     5     6     7     8     9     10 
0      1       2       3     4     5     6     7     8     9     10 
0      1       2       3     4     5     6     7    8     9     10 
0      1       2       3     4     5     6     7     8     9     10 
0      1       2       3     4     5     6     7     8     9     10 
ESAS
                                                                                                                                        
Edmonton Symptom Erfassung: Numerische Skala 
Bitte kreisen Sie die Zahl ein, die Ihre jetzige Sitaution am besten beschreibt: 
Schmerz 
       Keine Schmerzen          Schlimmste Schmerzen
Erschöpfung
          Nicht erschöpft       Völlige Erschöpfung
Übelkeit 
           Keine Übelkeit        Schlimmste Übelkeit
Depression 
          Nicht depressiv       Stärkste Depression
Angst
           Nicht ängstlich       Schlimmste Angst 
Müdigkeit
                Nicht müde Schlimmste Müdigkeit
Appetit
           Bester Appetit Kein Appetit
Wohlbefinden 
                        Bestes             Schlechtestes                                              
            Wohlbefinden         Wohlbefinden 
Luftnot   
            Keine Luftnot Schlimmste Luftnot
Yes No
1. Throughout our lives, most of us have had pain from time to time (such as minor headaches,
      sprains, and toothaches). Have you had pain other than these everyday kinds of pain today?
2. On the diagram, shade in the areas where you feel pain. Put an X on the area that hurts the most.
3. Please rate your pain by circling the one number that best describes your pain at its worst in the last 24
      hours.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
4. Please rate your pain by circling the one number that best describes your pain at its least in the last 24
      hours.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
5. Please rate your pain by circling the one number that best describes your pain on the average.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
Please go to the next page
6. Please rate your pain by circling the one number that tells how much pain you have right now.
0 1 2 3 4 5 6 7 8 9 10
No pain Pain as bad as you can imagine
Right RightLeft Left
CRF no:
 
NTNU         DMF, IKM 
  
Brief Pain Inventory 
New version 
p. 1 of 2 
 
 
 
 
 
Projectno.:      
OPI 03-006      
37414
7. In the last 24 hours, how much relief have pain treatments or medications provided? Please
      circle the one percentage that most shows how much relief you have recieved.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
No Relief Complete Relief
Circle the one number that describes how, during the past 24 hours, pain has interfered with
your:
8. General Activity
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
9. Mood
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
10. Walking Ability
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
11. Normal work (includes both work outside the home and housework)
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
12. Relations with other people
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
13. Sleep
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
14. Enjoyment of  life
0 1 2 3 4 5 6 7 8 9 10
Does not Interfere Completely Interferes
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Projectno.:      
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We are interested in some things about you and your health. Please answer all of these questions
yourself by ticking the alternative that best applies to you. There are no "right" or "wrong" answers. The
information that you provide will remain strictly confidential.
1. Do tou have any trouble doing strenuous activities,
like carrying a heavy shopping bag or a suitcase?
2. Do you have any trouble taking a long walk?
3. Do you have any trouble taking a short walk outside
of the house?
4. Do you need to stay in bed or a chair during the day?
5. Do you need help with eating, dressing, washing
yourself or using the toilet?
During the past week:
6. Were you limited in doing either your work or other
daily activities?
7. Were you limited in pursuing your hobbies or other
leisure time activities?
8. Were you short of breath?
9. Have you had pain?
10. Did you need to rest?
11. Have you had trouble sleeping?
12. Have you felt weak?
13. Have you lacked appetite?
14. Have you felt nauseated?
Not at
all
A
little
Quite
a bit
Very
much
Please go to the next page
CRF nr:
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EORTC QLQ-C30 
(version 3) 
p. 1 of 2 
 
 
 
 
 
Projectno.:      
OPI 03-006      
Not at
all
A
little
Quite
a bit
Very
much
8476
For the following question please tick the number between 1 and 7 that best applies to you.
29. How would you rate your overall health during the past week?
30. How would you rate your overall quality of life during the past week?
1 2 3 4 5 6 7
Versjon 3.0 1995©Copyright EORTC Study Group on Quality of Life. All rights reserved.
   During the past week:
1 2 3 4 5 6 7
Very poor Excellent
Very poor Excellent
15. Have you vomited?
16. Have you been constipated?
17. Have you had diarrhea?
18. Were you tired?
19. Did pain interfere with your daily activities?
20. Have you had difficulty in concentrating on things,
like reading a newspaper or watching TV?
21. Did you feel tense?
22. Did you worry?
23. Did you feel irritable?
24. Did you feel depressed?
25. Have you had difficulty remembering things?
26. Has your physical condition or medical treatment
interferred with your family life?
27. Has your physical condition or medical treatment 
interferred with your social activities?
28. Has your physical condition or medical treatment 
caused you financial difficulties?
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(version 3) 
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Not at
all
A
little
Quite
a bit
Very
much
CRF nr:
8476
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Mini Mental Status Exam short version           Patient number: …………….. 
           Date: …………………………... 
 Question Score      Maximum  
score
1.  What year is it? 1
2.  What is today’s date? 1
3.  Spell WORLD backwards 2 letters correct    = 1 
3 or more correct  = 2 
4.  Copy this design 1
 Total 5
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Appendix
Revised Edmonton Staging System for Cancer Pain
The definitions for each of the categories in the rESS are as follows:
Mechanism of Pain
No – No pain syndrome
Nc – Any nociceptive combination of visceral and/or bone or soft tissue pain
Ne – Neuropathic pain syndrome with or without any combination of nociceptive pain
Nx – Insufficient information to classify pain syndrome
Incidental Pain
Pain can be defined as incidental when it is aggravated suddenly because of movements, swallowing,
defecation, or urination.
Patients should only be defined as having incidental pain if the incidental pain produces discomfort
sufficient to significantly impact on physical and/or psychological function.
I – Used to designate presence of this characteristic
Psychological Distress and Addictive Behavior
Psychological distress is definedas “amajor problemassessed as limiting thepatient’s ability to differen-
tiate physiological and psychological pain accurately, due to the presence of somatization alone or
somatization accompanied by symptoms such as depression, anxiety, hostility or neuroticism severe
enough to jeopardize the success of the analgesic treatment”.
Addictive behavior is defined as “Any lifetime history of alcohol addiction as defined by the CAGE or
a strong clinical history of alcohol abuse provided by other sources, and/or any other lifetime history
of addiction to prescription or non-prescription drugs.”
Po – Psychological distress and addictive behavior not present
Pp – Psychological distress alone present
Pa – Addictive behavior alone present
Ppa – Psychological distress and addictive behavior present
Cognitive Function
Cn – Ability to provide pain history past and present unimpaired (normal cognitive function)
Ci – Sufficient impairment to affect patient’s ability to provide accurate pain history for present
and/or past
Cu – Patient unable to provide any pain history past or present
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
The Edmonton Classification System for Cancer Pain (ECS-CP) Quick User Guide provides a brief 
outline on how to use the ECS-CP.  
An initial pain classification assessment, using the ECS-CP, is generally conducted prior to pain 
management (e.g. on admission to a palliative consultation service). Subsequent assessments 
may be conducted if the patient’s condition changes or as additional information regarding the five 
pain features is obtained. The classification should be used to guide the interdisciplinary team in 
using different pharmacological and non-pharmacological approaches to optimize pain control.  
 
The more detailed and complete Administration manual consists of four key sections: (1) 
Background, (2) Edmonton Classification System for Cancer Pain, (3) Case Studies and (4) 
Frequently Asked Questions. Refer to that resource if you need information beyond what is 
provided in the Quick User Guide. 
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Edmonton Classification System for Cancer Pain 
 
Patient Name:  ______________________________________    Patient ID No:____________ 
 
For each of the following features, circle the response that is most appropriate, based on your 
clinical assessment of the patient.  
 
1. Mechanism of Pain 
No No pain syndrome 
 Nc Any nociceptive combination of visceral and/or bone or soft tissue pain  
 Ne Neuropathic pain syndrome with or without any combination of nociceptive pain 
 Nx Insufficient information to classify  
 
2. Incident Pain 
Io No incident pain 
 Ii Incident pain present 
 Ix Insufficient information to classify 
 
3. Psychological Distress 
Po No psychological distress  
 Pp Psychological distress present 
 Px Insufficient information to classify 
 
4. Addictive Behavior 
Ao No addictive behavior  
 Aa Addictive behavior present 
 Ax Insufficient information to classify 
 
5. Cognitive Function 
Co No impairment. Patient able to provide accurate present and past pain history 
unimpaired  
Ci Partial impairment. Sufficient impairment to affect patient’s ability to provide 
accurate present and/or past pain history 
Cu Total impairment. Patient unresponsive, delirious or demented to the stage of 
being unable to provide any present and past pain history 
Cx Insufficient information to classify 
 
ECS-CP profile:  N__ I__ P__ A__ C__   (combination of the five responses, one for each 
category)  
 
Assessed by: _________________________  Date:  ______________________   
 
Mechanism of Pain 
The ECS-CP classification system is based on a hierarchy of 
mechanism of pain features, in which neuropathic pain 
represents a greater management challenge than nociceptive 
pain. If a patient presents with one or more pains involving 
multiple pain mechanisms, then the default classification would 
be the one with the greatest management challenge. For 
example if a patient presents with two different cancer related 
pains, one of which is neuropathic pain, you would classify the 
mechanism of pain as neuropathic. This is also addressed in 
the descriptor for neuropathic pain (Ne), which refers to 
“neuropathic pain syndrome with or without any combination 
of nociceptive pain.” The assessment of the mechanism is a 
judgment decision made by the clinician, based on history, 
physical examination and available diagnostic imaging. The 
use of screening tools such at the Leeds Assessment of 
Neuropathic Symptoms and Signs (LANSS) may enhance 
accuracy of the classification of the mechanism.      
 
Incident Pain 
Pain can be defined as incident pain when a patient has 
background pain of no more than moderate intensity with 
intermittent episodes of moderate to severe pain, usually 
having a rapid onset and often a known trigger. 
 
Guidelines for Use: There are six key characteristics of 
incident pain, as defined in the ECS-CP: 
° Relationship with background pain: The intensity of 
incident pain is significantly greater than 
background pain. 
° Severity: The intensity of incident pain is moderate 
to severe. 
° Predictability: The trigger is often known, such as 
movement, defecation, urination, swallowing and 
dressing change. However, clinically significant 
episodic pain (i.e. no predictable trigger) can be 
included (e.g. bladder or bowel spasm). 
° Onset: Its onset is rapid, with intensity often 
peaking within 5 minutes. 
° Transiency: Incident pain is transient, and may 
return to baseline shortly after the trigger is 
stopped or removed. 
° Recurrence: It is intermittent, recurring when the 
trigger returns. 
 
Psychological Distress 
Psychological distress, within the context of the pain 
experience, is defined as a patient's inner state of suffering 
resulting from physical, psychological, social, spiritual and/or 
practical factors that may compromise the patient's coping 
ability and complicate the expression of pain and/or other 
symptoms. 
 
Guidelines for Use: There are five key characteristics of 
psychological distress, as defined in the ECS-CP: 
° Relationship with pain: The definition of psychological 
distress is limited to patients who are experiencing 
psychological distress within the context of the pain 
experience and who appear to express their suffering 
through physical symptoms. 
° Relationship with suffering: Psychological distress is 
an expression of suffering, often referred to as total 
pain. 
°   Multidimensional: Psychological distress is 
multidimensional in nature, influencing many spheres of 
a patient's experience, including but not necessarily 
limited to physical, psychological, social, and spiritual 
factors. 
° Relationship with coping: Psychological distress 
may impair a patient's ability to cope with his/her 
illness. 
° Physical symptom expression: Psychological 
distress is often expressed as an exacerbation of 
pain and/or other symptoms, which may be 
conceptualized as a form of somatization. 
 
Assessment of psychological distress may include, but is 
not necessarily limited to, the following: 
° Assessment of patient's experience in 
multidimensional domains 
° Patient's behavioral presentation and symptom 
reporting profile 
° Collateral history from primary caregivers 
 
Addictive Behavior 
Addiction is a primary, chronic, neurobiologic disease, with 
genetic, psychosocial, and environmental factors influencing its 
development and manifestations. It is characterized by 
behaviors that include one or more of the following: impaired 
control over drug use, compulsive use, continued use despite 
harm, and craving. 
 
Guidelines for Use: There are five key characteristics of 
addictive behavior, as defined in the ECS-CP: 
° chronicity: It is a chronic disorder, which may have 
periods of relapse and remission. 
° multidimensional: It is multidimensional in its 
development and expression, including genetic, 
psychosocial and environmental factors. 
° compulsivity 
° persistent use despite harm  
° craving 
 
This definition is limited to the following: 
° A remote history of prior alcohol/substance use may 
not be considered relevant as a complicating factor in 
ongoing pain assessment and management. 
° Substances of abuse include alcohol, prescription 
medications, non prescription medications, and illicit 
drugs.  
° It does not include chronic tobacco use. 
 
Assessment of addictive behavior may include, 
but is not necessarily limited to, the following: 
° Use of CAGE as screening tool for possible alcohol 
abuse 
° Patient's behavioral presentation over a series of 
visits 
° A strong clinical history of substance abuse provided 
by the patient  
° Collateral history from primary caregivers 
 
Cognitive Function 
The assessment of cognition is at the discretion of the clinician 
and is focused on the ability to provide a pain history since the 
ECS-CP is a pain classification system. Other global cognitive 
assessment measures, such as the Mini-Mental Status 
Examination (MMSE), SOMCT/BOMCT, Sweet 16,  or the 
Montreal Cognitive Assessment (MOCA), may also be included 
as part of the screening process, if appropriate. 
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